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Abstract 
 iii 
 
Advances in computing power and metagenomic sequencing have facilitated the 
sourcing of a wealth of evidence to support the long-held belief that the complex 
community of microorganisms inhabiting the human gastrointestinal tract has 
significant influence on the health of the host. Equally, disruption of the composition 
and function of this population has been associated with many disease states. 
Therefore, it stands to reason that selective modulation of the gut microbiota, 
through antimicrobials, probiotics, or diet, presents an attractive therapeutic 
approach to the treatment of these diseases. One category of antimicrobials with this 
potential is the bacteriocins – antimicrobial peptides produced by many lineages of 
bacteria that kill or inhibit the growth of specific competitors. This thesis focuses 
primarily on the first step toward harnessing the bacteriocin-producing capacity of 
the human microbiota to bring about desired changes, i.e., identification of potential 
bacteriocin-producing bacteria using in silico genomic and metagenomic screening 
approaches. It highlights numerous putative bacteriocin-producing bacteria, 
including many from genera either not previously associated with bacteriocin-
production or recently under consideration as the next generation of probiotics. It 
also investigates the relationship between diet, the gut microbiota, and bacteriocin 
gene cluster density in elite athletes and healthy controls, in addition to evaluating 
the effect of probiotic supplementation of the gut microbiota and overall health in a 
diet-induced obesity mouse model. Taken together these results show that there is a 
vast reservoir of putative bacteriocin-producing bacteria in the human microbiota 
with the potential to impact human health in a beneficial manner and highlights diet 
as a major factor in influencing the density and distribution of these putative 
producers.
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Chapter 1 
Beneficial modulation of the gut microbiota 
 
Updated for this thesis since publication in FEBS Letters 
 (doi: 10.1016/j.febslet.2014.03.035) 
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Abstract 
 
The human gut microbiota has a significant effect on many aspects of human 
physiology including metabolism, nutrient absorption and immune function. 
Disruption of this population has been implicated in many conditions and diseases, 
including obesity, inflammatory bowel disease, colorectal cancer and even mental 
health. A logical extension of these observations suggests that manipulation of the gut 
microbiota can be employed to prevent or treat these conditions. This literature review 
highlights a variety of options, including the use of changes in diet (including the use 
of prebiotics), antimicrobial-based intervention (and discovery thereof), probiotics, 
and faecal microbiota transplantation, and discuss their relative merits with respect to 
modulating the intestinal community in a beneficial way. 
  
3 
 
Introduction 
 
Humans are now thought of as “superorganisms” or “holobionts” on the basis of the 
genetic potential encoded within our resident microbial populations in addition to our 
own genome. It is widely accepted that our microbiota develops with us and alters its 
own composition and gene expression in response to changing environmental 
conditions (Ley et al., 2008), but it has also been suggested that our microbiota 
changed in parallel though our evolutionary history in a relationship termed 
“phylosymbiosis” (Brooks et al., 2016). While almost all niches in the human body 
contain their own bespoke microbial communities, the largest and most varied of these 
exists in the gastrointestinal (GI) tract. 
It has been estimated that the human microbiota comprises approximately 100 
trillion bacterial cells, outnumbering our own cells by a factor of 10 or more (Bäckhed 
et al., 2005) and plays an integral role in human health and disease (Clemente et al., 
2012, Flint et al., 2012). A recent publication, however, has argued that the ratio is 
actually more likely to be one-to-one, with the numbers being similar enough that each 
defecation event may alter the ratio to favour human cells over bacteria (Sender et al., 
2016). Regardless of absolute numbers, this community is thought to contain 100–
1,000 phylotypes (Faith et al., 2013, Qin et al., 2010), the most abundant being 
members of the Firmicutes and Bacteroidetes phyla, with smaller numbers 
representing the Proteobacteria, Fusobacteria, Cyanobacteria, Verrucomicrobia and 
Actinobacteria, amongst others (Qin et al., 2010), and exhibit robust temporal stability 
(Belstrøm et al., 2016, Jeffery et al., 2016). Of greater consequence than bacterial 
numbers, however, is the collection of genes encoded in this metagenome, thought to 
be approximately 150 times larger than that of the human genome, with a functional 
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potential far broader than that of its host (Qin et al., 2010). It has been noted that, 
although there is great inter-individual variation in the composition of the gut 
microbiota, this functional potential is highly conserved between individuals, 
suggesting that it is the functionality of the microbiota, rather than its composition, 
that is of greatest importance to the host. The functions and pathways encoded in this 
“core microbiome” are thought to confer the greatest benefit to the host and are 
probably essential for the correct functioning of the gut.  Some well-studied benefits 
include protection against potential pathogens, digestion of polysaccharides, 
production of essential vitamins, stimulation of angiogenesis, regulation of fat storage 
and modulation of the host’s immune system (Sekirov et al., 2010). Recent studies 
have also shown that the gut microbiota influences the gut-brain axis and shapes stress-
related symptoms such as anxiety and pain tolerance (Cryan and O'Mahony, 2011). In 
addition, bacteriophage are present in the gut microbiota and may be involved in 
controlling its composition and functionality, although these studies are relatively 
recent and the community is not as well characterised as its bacterial counterpart 
(Manrique et al., 2016). 
Advances in high throughput sequencing technologies (HTS) and tools 
enabling comparative analysis of the large amount of data that are generated by these 
technologies have led to a better understanding of what constitutes a ‘healthy” gut 
microbiota. One of the most interesting observations drawn from the data generated is 
that the resident microbiota encodes > 100 fold more genes than the human genome 
(The Human Microbiome Project Consortium, 2012). The genes present in the 
microbiome are responsible for many functions essential to host survival but which 
are not encoded within the human genome. Due to the range and importance of the 
5 
 
metabolic and biochemical processes carried out by the microbiome it has been 
referred to as “our hidden organ” (O'Hara and Shanahan, 2006).  
While the “healthy” gut microbiota is seen to be a stable community (Jeffery 
et al., 2016), there are stages within the life cycle of humans during which there can 
be dramatic alterations in the structure and function of this population. These “natural” 
changes begin with initial colonisation immediately following birth and subsequent 
development of the microbiota over the first two years of life. The earliest colonizers 
are usually members of the enterococci and enterobacteria followed by strict anaerobes 
such as Bifidobacterium, Clostridium and Bacteroides spp. once the initial oxygen 
supply present has been depleted (Adlerberth and Wold, 2009). Despite this general 
pattern, it is important to appreciate that the method of delivery and subsequent 
feeding type have a profound effect on the initial populations (Dominguez-Bello et al., 
2010). Once the infant reaches two years of age the microbiota has already begun to 
transform into its adult form, which is thought to be relatively stable before it 
undergoes a final shift when entering old age (Palmer et al., 2007). Indeed, with 
respect to the latter phenomenon, a study by Claesson and colleagues that compared 
the gut microbiota of individuals ages 65 or older to 9 younger control subjects has 
highlighted significant changes in community structure associated with ageing, 
specifically an increase in the abundance of Bacteroides spp. and distinct shifts within 
the Clostridium genus (Claesson et al., 2011). It has been hypothesised that alterations 
in the elderly microbiota are due to physiological changes in the elderly 
gastrointestinal tract such as chronic low-grade inflammation, in addition to dietary 
habits and antibiotic use (Franceschi, 2007, Jeffery et al., 2016). 
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An interesting recent development is that exercise also has a significant 
influence on the composition and function of the gut microbiota. It was noted that 
physical activity, as measured through plasma creatine kinase levels, impacted the use 
of dietary nutrients by the gut microbiota beyond the changes that would be expected 
by a simple change in diet (Barton et al., 2017, Clarke et al., 2014). 
It has been well established that the human gut microbiota is integral to human 
health, and, as will be discussed below, it also plays an important role in 
gastrointestinal disease. It is therefore reasonable to assume that modulation of the gut 
microbiota can be used as a therapeutic approach to treating chronic gastrointestinal 
diseases. Thus, this review is focussed primarily on the methods that can be employed 
to modulate the gut microbiota, some of which are illustrated in Figure 1, while 
highlighting the benefit of guiding community structure towards a more desirable 
state. 
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Figure 1. Potential strategies for manipulation of the gut microbiota. 
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Role of the Gut Microbiota in Health and Disease 
 
There are a growing number of gastrointestinal conditions that have been linked with 
alterations in the gut microbiota. To properly implement strategies to modulate the gut 
microbiota as a therapeutic tool, it is first necessary to understand the role of the gut 
microbiome in specific GI, and other, diseases.  Given the recent rapid expansion in 
the number of disease states that have been linked with alterations in the gut 
microbiota, it is not possible to address the issue in depth, so a number of relevant and 
well-studied examples were selected to highlight these links. 
 
Inflammatory Bowel Disease 
 
Inflammatory Bowel Disease (IBD) is a relapsing disorder characterized by 
chronic inflammation of the GI tract, and of the colon in particular. The two major 
types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC).  Evidence suggests 
that IBD is a complex disease arising from a combination of genetic and environmental 
factors. From a genetic perspective, genome-wide association studies (GWAS) and 
subsequent meta-analyses have identified a total of 240 genetic risk loci for IBD 
(Anderson et al., 2011, Franke et al., 2010, Jostins et al., 2012, de Lange et al., 2017). 
A German twin cohort study confirmed the strong genetic element to IBD by 
observing that monozygotic twins are significantly more likely to be concordant for 
the disease than dizygotic twins (Spehlmann et al., 2008). However, concordance rates 
between monozygotic twins are nonetheless low (35% for CD and 16% for UC), 
highlighting that environmental triggers do indeed play an important role in both 
diseases, and in UC in particular. A similar study of Norwegian siblings reported a 
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higher risk of CD concordance in dizygotic twins than in ordinary siblings, suggesting 
the importance of a shared environment in utero or in childhood (Bengtson et al., 
2010). 
It is notable that murine studies have revealed that the presence of commensal 
enteric bacteria is necessary for the development of spontaneous colitis and immune 
system activation (Sellon et al., 1998) and, indeed, transferring colitogenic gut 
microbiota into healthy mice can induce spontaneous colitis (Garrett et al., 2010). 
Similarly, it has consistently been observed that patients suffering from IBD harbour 
an altered gut microbiota (Frank et al., 2007, Sokol and Seksik, 2010), specifically 
reduced bacterial diversity and changes within the Firmicutes phylum (Elson and 
Cong, 2012). The changes in microbiota composition appear to be somewhat different 
between UC and CD. For example, decreased abundance of the butyrate-producing 
bacteria Roseburia hominis and Faecalibacterium prausnitzii have been observed in 
UC patients relative to controls (Machiels et al., 2013), while the opposite has been 
observed in CD patients who possessed increased F. prausnitzii levels in addition to a 
reduced overall diversity (Hansen et al., 2012). Although these microbial changes 
could be a result of increased inflammation, evidence suggests that it is more likely 
that shifts in the microbiota are involved in the disease’s pathogenesis, either due to 
an intolerance to a specific group of commensals or due to an imbalance between 
protective and harmful members of the population (Frank et al., 2007, Lepage et al., 
2011, Elson and Cong, 2012).  
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Irritable Bowel Syndrome 
 
Irritable Bowel Syndrome (IBS) is a chronic GI disorder that presents with 
symptoms including abdominal pain, bloating and altered bowel function. IBS is 
divided into several subtypes based on stool characteristics; diarrhoea, constipated or 
mixed. Its cause, as of yet, is not fully known and although the aetiology is thought to 
be a combination of a number of factors, it is hypothesised that perturbations in the 
normal microbial microbiota play a role in the syndrome’s characteristic low-grade 
inflammation (Ohman and Simren, 2013). Indeed, Rajiić-Stojanović et al. used qPCR 
and phylogenetic microarrays to show that the gut microbiota of IBS patients differed 
significantly from healthy controls, with IBS sufferers having a 2-fold higher 
Firmicutes to Bacteroidetes ratio and correlation analysis implicating several groups 
of Firmicutes and Proteobacteria in IBS pathogenesis (Rajilic-Stojanovic et al., 2011). 
Contrastingly, Jalanka-Tuovinen and colleagues observed that the faeces of diarrhoea-
predominant IBS sufferers harboured 12-fold higher levels of several Bacteroidetes 
members. This group also noted that healthy controls have 35-fold higher numbers of 
uncultured clostridia (Jalanka-Tuovinen et al., 2013). Interestingly, these alterations 
in the microbiota correlated with changes in expression of host genes involved in 
amino acid synthesis, cell junction integrity and inﬂammatory response, suggesting 
impaired epithelial barrier function in IBS patients. An interesting note is that patients 
suffering from IBS exhibit greater temporal instability with respect to their microbiota 
than their healthy counterparts, suggesting that the varying symptoms of this disease 
may result from fluctuations (Mättö et al., 2005). Small intestinal bacterial overgrowth 
(SIBO), which is characterized by excessive bacteria in the small intestine, has also 
been put forward as a possible factor in IBS aetiology (Lin, 2004). Bacterial 
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overgrowth can result in overproduction of gas in the small intestine by degradation 
of carbohydrates, contributing to the symptoms of IBS (Riordan and Kim, 2006). The 
most commonly isolated bacteria from SIBO patients are Escherichia coli, 
Streptococcus, Lactobacillus, Bacteroides and Enterococcus species (Bouhnik et al., 
1999). However it is not fully understood if any of these microorganisms play a 
specific role in IBS progression. It should also be recognised that differences between 
studies may be due to the causative microorganisms or imbalances differing between 
IBS subtypes. Regardless, a bacterial role in IBS onset would seem to be clear, as 
further evidenced by the disease’s response to antibiotic therapy (Pimentel et al., 2011) 
and differential expression levels of Toll-like receptors in colonic biopsies of patients 
with IBS (Brint et al., 2011).  
 
Obesity 
 
Obesity is a complex disease resulting from a prolonged imbalance of energy input 
and energy expenditure. Modern dietary and exercise habits are major contributing 
factors but it is now understood that the composition and function of the gut 
microbiome plays an important role through a variety of mechanisms (Backhed et al., 
2004). A number of comprehensive reviews focussing on the association between the 
microbiota and obesity have been published (Cani, 2013, Clarke et al., 2012, Khan et 
al., 2016). Differences in the gut microbiota between obese and lean individuals have 
been the subject of great scrutiny. A range of different murine models have been used 
to this end, including genetically obese (Ley et al., 2005, Turnbaugh et al., 2006), diet-
induced obese (Turnbaugh et al., 2008) and humanized (Turnbaugh et al., 2009) mice. 
Although a number of studies have reported an increased ratio of Firmicutes to 
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Bacteroidetes in obese mice compared to their lean counterparts, these findings 
continue to be the subject of much debate in relation to human studies, which have 
revealed a number of microbial populations that have been associated with obesity 
(Clarke et al., 2012). Recently, it has become apparent that diversity of the microbiota 
is of greater relevance to obesity than specific compositional profiles with a less 
diverse gut microbiota observed in obesity (Turnbaugh et al., 2009), as well as diseases 
such as type 1 diabetes (Patterson et al., 2015) and rheumatoid arthritis (Chen et al., 
2016). Notably, transplanting the faecal microbiota of obese humans into germ-free 
mice brought about significant increases in the fat-mass of, and obesity-related 
metabolic phenotypes in, these mice relative to those which occurred when the 
corresponding faecal microbiota from lean monozygotic twins was transplanted 
(Ridaura et al., 2013). Furthermore, a second trial showed that cohousing mice 
harbouring these two microbial communities prevented development of the obese 
phenotype, a trend correlating with invasion of specific Bacteroidetes members from 
lean to obese microbiota (Ridaura et al., 2013). A bacterium gaining a lot of attention 
in the areas of obesity and type 2 diabetes is the mucin-degrader Akkermansia 
muciniphila. A. muciniphila abundance was decreased in obese and type 2 diabetic 
mice and normalised by prebiotic feeding, which in turn correlated with an improved 
metabolic profile. Orally administered A. muciniphila also reversed high-fat diet 
induced metabolic disorders in these mice (Everard et al., 2013). Recently, it was 
reported that pasteurized A. muciniphila, that was initially grown in a synthetic 
medium safe for human consumption, possessed the ability to reduce fat mass 
development, insulin resistance, and dyslipidemia in mice (Plovier et al., 2017). The 
results of these, and other studies, make it apparent that the microbiota plays a role in 
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obesity but the specific changes associated with the phenotype are complex and remain 
unclear. 
 
Type 2 Diabetes 
 
Type 2 diabetes (T2D) is a metabolic disorder with both genetic and 
environmental influences. It is a major health concern throughout the western world, 
arising particularly as a result of increasing obesity-related insulin resistance 
(Wellcome Trust Case Control Consortium, 2007, Scott et al., 2007). It is evident from 
a number of studies that the gut microbiome is altered in patients suffering from T2D 
(Larsen et al., 2010, Musso et al., 2011, Qin et al., 2012), although, as with many 
obesity-related associations, it is not clear whether these changes are a cause or simply 
a consequence of the disorder. Nonetheless, it was an interesting development when, 
in 2010 it was reported that the proportions of Firmicutes, and in particular species of 
clostridia, were significantly reduced in T2D sufferers compared to healthy 
individuals (Larsen et al., 2010). A subsequent, and much larger, metagenome-wide 
association study of 345 Chinese individuals showed that the gut microbiota of 
patients with T2D was characterized by a moderate degree of microbial dysbiosis, 
lower levels of butyrate-producing bacteria and an enrichment of microbial functions 
relating to sulphate reduction and resistance to oxidative stress (Qin et al., 2012). 
Almost all of the microbial genes enriched in T2D patients were from opportunistic 
pathogens, including genes from several Clostridium spp. as well as Bacteroides 
caccae (Qin et al., 2012). These results provided a number of markers that were 
assessed to determine if they could successfully identify patients with T2D on the basis 
of an analysis of faecal samples. Notably, this method successfully identified the T2D 
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disease state with 81% accuracy (Qin et al., 2012), i.e. a greater success rate than using 
a combination of clinical risk factors and genetic information (Lyssenko et al., 2008). 
Another notable study using microbiome data, in addition to clinical measurements, 
allowed a machine-learning algorithm to design personalized diets which significantly 
lowered postprandial blood glucose levels in type 2 diabetics (Zeevi et al., 2015). 
 
Colorectal Cancer 
 
Colorectal cancer (CRC) is the third most common cause of cancer mortality 
in the world (Jemal et al., 2011). It is becoming apparent that, even though a single 
causative microorganism has not been explicitly identified, the gut microbiota plays a 
role in CRC (Arthur et al., 2012, Plottel and Blaser, 2011). Wang and colleagues noted 
that there was a clear segregation between the microbiota of CRC patients and healthy 
volunteers, particularly, as was the case for T2D, a decrease in the abundance of 
butyrate producers and an increase in the incidence of opportunistic pathogens in CRC 
patients (Wang et al., 2012b). Increased intake of dietary fibre appears to play a key 
role in decreasing CRC risk via the ‘fibre-microbiota-butyrate axis’ whereby it is 
fermented by colonic bacteria into butyrate, a potent histone deacetylate inhibitor, that 
upregulates tumour-supressing genes in CRC cells and anti-inflammatory genes in 
immune cells (Bultman, 2017, Bultman and Jobin, 2014). Dietary fibre also speeds 
colonic transit, thereby limiting the exposure of colonic epithelial cells to potential 
carcinogens. Members of the Fusobacterium genus have also been recently identified 
as potential causative agents after it was observed that they were enriched in colorectal 
carcinomas (Kostic et al., 2012), a pattern also noted in other studies (Wang et al., 
2012b, Castellarin et al., 2012, McCoy et al., 2013, Tahara et al., 2014). The authors 
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hypothesised that Fusobacterium spp. may contribute to tumourigenesis by an 
inflammatory-mediated mechanism, a hypothesis supported by a follow-up study 
which showed that members of fusobacteria could generate a proinflammatory 
microenvironment through the recruitment of tumour-infiltrating immune cells 
(Kostic et al., 2013). E. coli has also been linked with CRC in a number of studies. 
Arthur et al. observed that E. coli levels were ~100-fold higher in the microbiota of 
the colitis-susceptible IL10 -/- mouse strain compared to the wild type (Arthur et al., 
2012). They went on to show that E. coli NC101 mono-association significantly 
promoted development of invasive mucinous adenocarcinomas in azoxymethane 
treated, IL10 -/- mice and that deletion of the polyketide synthase (pks) genotoxic island 
from this E. coli strain decreased tumour multiplicity and invasion (Arthur et al., 
2012). While further investigations are required, these results suggest that colitis 
promotes tumourigenesis in mice by altering the composition of the gut microbiota 
and selecting for members with genotoxic capabilities. 
Ultimately, identification of microorganisms, microbial populations or 
microbial functionalities involved in GI disease is fundamental to developing novel 
therapies. It is evident that the gut microbiota plays a large role in intestinal health and 
disease, and therefore manipulation or modulation of this community, is a clinical 
option that merits serious consideration.  
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Modulation of the Gut Microbiota 
 
Modulation by Diet 
 
Environmental factors, including dietary intake, can shape the composition of 
the intestinal microbial community.  Indeed, a number of recent studies have 
highlighted the links between diet and distinct microbial profiles and, in turn, overall 
gut health (Bäckhed et al., 2005, Claesson et al., 2012, David et al., 2013, Turnbaugh 
et al., 2008, Wu et al., 2011, Duncan et al., 2007). Having an understanding of how 
diet influences microbial communities will be of critical importance with respect to 
employing food to beneficially alter the gut microbiota.  
The amount, type and balance of the three main dietary components, i.e. 
protein, carbohydrates and fat, have a profound impact on the gut microbiota. Short-
chain fatty acids (SCFAs), primarily butyrate, propionate and acetate, are the major 
end products from the microbial degradation of carbohydrates and protein in the gut. 
SCFAs have a diverse range of physiological effects on the host, with perhaps the most 
important being their oxidation by mucosal cells to provide energy. An excellent 
review of the benefits of SCFAs on the host has been published by Macfarlane & 
Macfarlane (Macfarlane and Macfarlane, 2012) and a study involving native Africans 
and African Americans illustrated that a relatively short two-week dietary intervention 
had a profound impact on the gut microbiota and metabolites including butyrate and 
mucosal biomarkers of cancer risk (O’Keefe et al., 2015). The majority of microbial 
protein degradation occurs in the distal colon where the pH is neutral and conditions 
are favourable for the growth of proteolytic bacteria such as Bacteroides spp., 
Propionibacterium spp. and Clostridium perfringens (Walker et al., 2005, Macfarlane 
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et al., 1986). The main pathway of protein degradation by this population is 
deamination of amino acids to the aforementioned SCFAs and ammonia (Cummings 
and Macfarlane, 1991), high concentrations of the latter have been shown to act as 
tumour promoters in rats (Clinton et al., 1988). The range of end products generated 
by protein digestion is broader than that of carbohydrates (see below) and also includes 
branched-chain amino acids, phenols, indoles and amines (Hamer et al., 2012). The 
majority of studies examining the effect of dietary protein on the gut microbiota have 
focussed primarily on the detection of altered fermentation products in the cecum 
(Lhoste et al., 1998) and faeces (Magee et al., 2000). However, the effects of whey 
protein isolate on the microbiota have been the topic of some scrutiny in recent years 
as it has been indicated that dairy products can alleviate several disorders relating to 
metabolic syndrome (Elwood et al., 2008). One such study noted significantly 
increased counts of bifidobacteria and lactobacilli in the faeces of rats whose diets 
included cheese whey protein isolate or casein supplemented with either threonine or 
cysteine (Sprong et al., 2010). Whey protein isolate (WPI) has also been observed to 
alter the composition of the gut microbiota of mice in a dose-dependent manner 
(McAllan et al., 2014). All mice whose high fat diet was supplemented with WPI had 
significantly increased proportions of Lactobacillaceae and significantly decreased 
proportions of Clostridiaceae compared to high-fat fed controls, and increasing the 
amount of total energy derived from WPI caused a more profound shift in the 
microbiota (McAllan et al., 2014). Certain components of the normal human dietary 
intake of carbohydrates cannot by digested directly by the host and act as the major 
diet-derived energy source for microorganisms in the gut (Cummings and Englyst, 
1991). This fraction, comprised largely of resistant starches and non-starch 
polysaccharides, is degraded by microbial fermentation to a mixture of gasses and the 
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aforementioned SCFAs. Many such carbohydrates are also referred to as prebiotics. 
The term prebiotic was introduced by Gibson and Roberfroid in 1995 (Gibson and 
Roberfroid, 1995) and are defined as “selectively fermented ingredients that allow 
specific changes, both in the composition and/or activity in the gastrointestinal 
microflora that confer benefits upon host well-being and health” (Gibson et al., 2004). 
Prebiotics have most frequently been employed with a view to stimulating the growth 
of either lactobacilli or bifidobacteria, with many studies focussing on inulin 
(Costabile et al., 2010, Koleva et al., 2012, Ramnani et al., 2010), oligofructose (Lewis 
et al., 2005, Waligora-Dupriet et al., 2007) or fructooligosaccharides (Bouhnik et al., 
2004, Respondek et al., 2008). There is a substantial body of evidence linking prebiotic 
consumption to human health benefits through modulation of the gut microbiota, with 
research in this area having been the subject of  a number of recent reviews (Slavin, 
2013, Roberfroid et al., 2010, Vieira et al., 2013). In one particularly notable recent 
study, it was observed that supplementing the murine diet with SCFAs or 
fructooligosaccharides caused a shift in microbiota composition which strongly 
correlated with beneficial changes in body weight, adiposity and glucose control. 
These physiological changes were brought about via butyrate- and propionate-
mediated activation of intestinal gluconeogenesis (De Vadder et al., 2014). 
The majority of dietary fat is absorbed in the human small intestine but it has 
been shown that a substantial amount survives digestion and can be recovered in faeces 
(Gabert et al., 2011). The undigested portion passes through the colon where it can 
have a profound effect on the intestinal microbiota. Murphy et al. observed that high-
fat feeding caused a greater compositional change in the gut microbiota than 
genetically induced obesity (Murphy et al., 2010), in accordance with a previous study 
which showed that, when fed a high-fat diet, RELMβ knockout mice showed a 
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significantly altered gut community while staying lean. RELMβ knockout mice were 
employed as they are known to stay relatively lean when fed a high-fat diet. The 
authors could therefore conclude that the change in diet, as opposed to the obese state, 
was responsible for the observed changes in the microbiota (Hildebrandt et al., 2009). 
Many studies have established that mice fed a high-fat diet have significantly 
dissimilar microbial populations in the gut compared to mice fed on normal chow (Ley 
et al., 2005, Turnbaugh et al., 2008, Daniel et al., 2013).  
However, life-long calorie restriction significantly alters the gut microbiota in 
mice fed on both high-fat and low-fat diets (Zhang et al., 2013). This implies that not 
only the fat content of the diet, but also the number of calories consumed, has the 
potential to influence the bacterial communities present in the GI tract. The study also 
linked changes in the gut microbiota to claims that calorie restriction promotes 
healthy-ageing and increases lifespan in various animal models as the healthiest and 
longest living mice were those that were fed a low fat diet with calorie restriction 
(Zhang et al., 2013). Interestingly, another investigation involving calorie restriction, 
this time in humans, suggested that increased levels of A. muciniphila were associated 
with a healthier metabolic status pre-restriction and better clinical outcomes post-
restriction (Dao et al., 2016), implying that the gut microbiota may play a role in the 
success of dietary interventions. 
This specific combination of dietary components can vary according to 
geographic location, food availability, cultural practices and age and can have a 
profound impact on the conditions within the gut and the requirements of the 
microbiota (Table 1 highlights some studies which have investigated this impact). In 
one instance, the faecal microbiota of European children and children from an African  
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Diet Effect on microbiota Effect on host 
Rich in plant-derived polysaccharides (De 
Filippo et al., 2010, Wu et al., 2011). 
Increased Bacteroidetes, decreased Firmicutes (De 
Filippo et al., 2010). Associated with Prevotella-rich 
enterotype (Wu et al., 2011). 
Faster gut transit time compared to high 
protein and animal fat diet (Wu et al., 
2011). 
Omnivorous compared to vegetarian and lacto-
vegetarian (Kabeerdoss et al., 2012, Liszt et al., 
2009, Matijasic et al., 2013). 
Increased Clostridium clusters IV and XIVa 
(Kabeerdoss et al., 2012, Liszt et al., 2009, Matijasic 
et al., 2013). 
Not reported 
High-fat, simple carbohydrate “Western” diet 
(Ley et al., 2005, Turnbaugh et al., 2008). 
Increased Firmicutes, decreased Bacteroidetes (Ley 
et al., 2005, Turnbaugh et al., 2008). 
Diet-induced obesity. 
Subsequent transplantation of obese 
microbiota to germ free mice increased 
adiposity (Turnbaugh et al., 2008). 
Reduced carbohydrate intake (Duncan et al., 
2007). 
Reduced Bifidobacterium, Roseburia spp. and 
Eubacterium rectale (Duncan et al., 2007). 
Not reported 
Animal product-based (David et al., 2013). 
High protein and animal fat (Wu et al., 2011). 
Increased β-diversity and bile-tolerant bacteria, 
including Bacteroides, decreased Firmicutes (David 
et al., 2013). 
Associated with Bacteroides-rich enterotype (Wu et 
al., 2011). 
Decreased weight independent of 
calories consumed (David et al., 2013). 
Less fruit, vegetables and fish (Cotillard et al., 
2013). 
Reduced microbial gene richness (Cotillard et al., 
2013). 
Increased insulin resistance, fasting 
serum triglyceride levels, LDL 
cholesterol and inflammation (Cotillard 
et al., 2013). 
Reduced variety due to long-stay care (Claesson 
et al., 2012). 
Increased Bacteroidetes and reduced overall diversity 
(Claesson et al., 2012). 
Increased frailty and poorer general 
health (Claesson et al., 2012). 
Changed from a vegetarian diet to an animal-
based diet (David et al., 2013). 
Decreased Prevotella, increased Bacteroides (David 
et al., 2013). 
Not reported 
Table 1. Some examples of studies assessing the influence of diet on the microbiota and health of the host. 
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village in Burkina Faso, whose diets differed considerably, was investigated. The 
diet of the African children was predominately vegetarian; high in starch, fibre and 
plant polysaccharides and low in fat and animal protein. This diet correlated with a 
significant increase in the Bacteroidetes:Firmicutes ratio in addition to an abundance 
of Prevotella and Xylanibacter when compared to the microbiota of the children 
consuming a carbohydrate-rich European diet (De Filippo et al., 2010). The 
Xylanibacter genus, which was absent in European children, is known to contain 
genes for xylan and cellulose hydrolysis and so it was hypothesised that the gut 
microbiota coevolved with the polysaccharide-rich diet of the Burkina Faso children, 
allowing them to increase the energy extracted from dietary fibre while also 
conferring protection from inflammation and non-infectious colonic disease (De 
Filippo et al., 2010). The comparatively high abundance of Prevotella in the faecal 
microbiota of the African children and the fact that it coincides with a carbohydrate-
rich diet is consistent with the observations of Wu et al. who found that the overall 
composition of the microbiota was strongly associated with long-term diet (Wu et 
al., 2011).  Specifically, a diet rich in protein and animal fat was associated with 
higher proportions of Bacteroides while Prevotella were more abundant when the 
diet was enriched with plant-derived carbohydrates (Wu et al., 2011). A recent study 
by De Filippo et al. took these investigations a step further by focussing specifically 
on the effect of diets composed entirely of animal or plants products on the gut 
microbiota (David et al., 2013). It revealed that an animal-based diet increased the 
numbers of bile-tolerant microorganisms present and decreased the numbers of plant 
polysaccharide degrading Firmicutes. Interestingly, the respective diets brought 
about a transcriptional response among the gut microbiota that was consistent with 
previously reported differences in gene abundances between herbivorous and 
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carnivorous animals (David et al., 2013). In other studies, members of the 
Clostridium clusters IV and XIVa have been found to be enriched in the faeces of 
omnivores compared to vegetarians and lacto-vegetarians, who generally consume 
higher proportions of carbohydrates as part of their diet (Liszt et al., 2009, 
Kabeerdoss et al., 2012, Matijasic et al., 2013). These clusters of bacteria are noted 
for their ability to convert dietary fibre to SCFAs. 
The overall dietary patterns in the De Filippo study above are similar to a study 
in mice where  conventionalised mice were switched from a low-fat diet rich in 
complex plant polysaccharides (CHO) to an obesity-inducing high-fat/simple 
carbohydrate “Western” diet (Turnbaugh et al., 2008).  Mice fed on the “Western” diet 
had a significantly lower level of bacterial diversity, a characteristic seen to be an 
indicator of an unhealthy microbiota (Bäckhed et al., 2005). These mice possessed a 
significantly higher relative proportion of Firmicutes and lower relative proportions 
of Bacteroidetes compared to littermates which remained on the CHO diet. This 
population shift is similar to what is seen in the ob/ob mouse model of obesity (Ley et 
al., 2005) but differs in that the Firmicutes shift in the genetically-induced obesity 
model is division-wide whereas the dietary intervention above caused a bloom in a 
single uncultured clade within the Mollicutes class. A subsequent microbiota 
transplantation from these diet-induced obese mice into germ-free recipients promoted 
greater adiposity than transplants from lean donor (Ley et al., 2005). A further study 
by the same group showed that this response of the microbiome to dietary intervention 
is rapid and can occur within 24 hours (Turnbaugh et al., 2009), a phenomenon also 
observed by Wu et al., (Wu et al., 2011).  
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 A gut microbiota with decreased diversity has been linked with increased 
frailty and poorer general health in elderly subjects (Claesson et al., 2012). In this 
study, clustering of subjects by diet, residence location and by microbial groupings 
was apparent. Ultimately, it was evident that subjects that were living in the 
community had a healthier and more varied diet than subjects in long-term residential 
care, which gave rise to a more diverse gut microbiota with significant changes being 
noted at phylum and family levels. Differences were also apparent at the genus level 
with long-stay subjects possessing higher levels of Parabacteroides, Eubacterium, 
Anaerotructus, Lactonifactor and Coprobacillus, while Coprococcus and Roseburia 
(both members of the Lachnospiraceae family) were more abundant in community-
dwelling subjects (Claesson et al., 2012). The data also linked microbiota composition 
to the duration spent in long-stay care. The longer the subject stayed in residential care 
(and consumed a less varied diet), the more dissimilar their microbiota became to the 
microbiota of healthy community-dwelling subjects (Claesson et al., 2012). Another 
study investigating the temporal relationship between food intake, gut microbiota and 
metabolic and inflammatory phenotypes reported that individuals with reduced 
microbial gene richness present more pronounced dys-metabolism and low-grade 
inflammation than their richer counterparts (Cotillard et al., 2013). This microbiota-
associated phenotype was suggested to be a result of long-term dietary habits as it was 
noted that these subjects seemed to consume less fruits, vegetables and fish than their 
high gene richness equivalents, i.e. a pattern consistent with that reported by Claesson 
et al (Claesson et al., 2012). More specifically, the initial sampling of the cohort (49 
obese or overweight subjects) showed that subjects with lower gene richness in the gut 
microbiota presented with increased obesity-associated phenotypes such as higher 
insulin resistance and increased levels of fasting serum triglyceride, LDL cholesterol 
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and inflammation. Dietary intervention (6 week energy-restricted high-protein diet) 
increased gene richness significantly in individuals that originally had a low gene 
count. This increased gene richness remained after the subjects were switched to a 6 
week weight-maintenance diet suggesting that dietary intervention as the potential to, 
at least partially, correct a loss of richness in the microbiota (Cotillard et al., 2013). 
Given the complexity of the relationship between diet and the gut microbiota, 
there would seem to be merit in developing and utilising models that allow one to 
elucidate the specific relationship between specific dietary components and 
microorganisms. An elegant strategy to facilitate this was provided by Faith et al. 
when they introduced a model community of ten human gut bacteria into gnotobiotic 
mice and developed a relatively simple statistical model which predicted over 60% of 
the species variations that occurred in response to changes in diet (Faith et al., 2011). 
The amount of casein in the diet was observed to be significantly associated with the 
abundances of all 10 microbial species and highly correlated with the total biomass of 
the community. Interestingly, E. coli and Clostridium symbosium were the only two 
species that had a second dietary variable significantly associated with their 
abundance, sucrose and starch respectively. The statistical model was subsequently 
able to determine 61% of the variation of the community members when the host was 
fed a new, previously unseen diet (Faith et al., 2011). These results represent a 
significant step towards tailoring diet to address chronic microbiota-associated 
illnesses and a potential evolution of research within the field. 
It is clear that microbial composition varies between groups living on different 
long-term diets. Recent investigations that suggest that short-term dietary changes can 
also alter the composition, and result in changes to the metabolic activity of the 
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microbiome as a whole, are noteworthy but further investigations are required to 
determine how best to take advantage of these observations.  
 
Modulation by Antimicrobials 
 
The manipulation of the gut microbiota by antimicrobials is emerging as an 
attractive therapeutic strategy (Table 2). The success of this approach is likely to 
ultimately depend on the target specificity of the antimicrobials in question, especially 
as the undesirable consequences of the overuse of broad-spectrum antimicrobials have 
become ever more apparent in recent years. For quite some time broad-spectrum 
antibiotics have been commonly used by clinicians as they can be used in the treatment 
of a wide range of infections or when the causative bacterium has not been formally 
identified. However, due to the frequent use of these antibiotics, the spread of 
antibiotic resistance is now posing a serious problem in health care settings.  In 
addition, antibiotic therapies not only affect the target microorganism but can also 
perturb the host gut microbial communities. The extent of this damage has recently 
become more evident through the application of high throughput DNA-based 
sequencing technologies to assess the composition of gut microbial populations (for 
review see Cotter et al. 2012) (Cotter et al., 2012). Here we provide just a few 
examples of the negative consequences of the use of broad-spectrum antibiotics on the 
gut microbiota and, in turn, health. 
The widespread use of broad-spectrum antibiotics, such as amoxicillin, to treat 
childhood infections has been linked to a dramatic decrease in Helicobacter pylori 
carriage (Blaser, 2011). However, studies indicate that those who did not acquire H.  
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Antimicrobial Effect on Microbiota Physiological effect on host 
Thuricin CD Eliminated C. difficile without impacting overall 
microbiota composition (Rea et al., 2011). 
Not examined – distal colon model 
Abp118 Protection against Listeria monocytogenes 
infection (Corr et al., 2007). 
Increased Bacteroidetes and Proteobacteria, 
decreased Actinobacteria (Walsh et al., 2008). 
Temporarily reduced weight gain in pigs (Corr et al., 2007). 
Vancomycin Decreased Firmicutes and Bacteroidetes, 
increased Proteobacteria (Murphy et al., 2013). 
Decrease in weight gain, fasting blood glucose, plasma TNFα and 
triglyceride levels in DIO mice (Murphy et al., 2013). 
Sub-therapeutic antibiotic 
therapy* 
Increased Firmicutes, especially 
Lachnospiraceae, relative to Bacteroidetes (Cho 
et al., 2012). 
Increased adiposity and bone mineral density in mice (Cho et al., 2012). 
5 strain probiotic 
mixture** 
Reduced shedding of Samonella enterica 
serovar Typhimurium in pigs(Casey et al., 
2007). 
Reduced incidence, severity and duration of diarrhoea in pigs. 
Also increased weight gain (Casey et al., 2007). 
Lactobacillus gasseri 
SBT2055, producer of 
gassericin T bacteriocin 
Not reported Decreased abdominal adiposity, body weight, BMI, waist 
circumference and hip circumference in human adults (Kadooka et al., 
2010). 
Lower triglyceride levels and reduced expression of lipogenic and pro-
inflammatory genes in DIO mice (Miyoshi et al., 2013). 
* Penicillin, vancomycin, penicillin plus vancomycin, and chlortetracycline 
** Lactobacillus murinus DPC6002, Lactobacillus murinus DPC6003, Lactobacillus pentosus DPC6004, Lactobacillus salivarius DPC6005, and 
Pediococcus pentosaceus DPC6006 
Table 2. Some examples of studies assessing the influence of antimicrobials on the gut microbiota and, where relevant, the host. 
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pylori in childhood were more likely to subsequently develop asthma, hay fever and 
skin allergies (Chen and Blaser, 2007), while other investigations suggest that H. 
pylori infection has a protective effect with respect to the development of allergic 
asthma in mouse models (Arnold et al., 2011). The use of some broad-spectrum 
antibiotics, including clindamycin, ampicillin, amoxicillin, cephalosporins and 
flouroquinolones, can also result in Clostridium difficile overgrowth by impacting the 
resident gut microbiota, followed by antibiotic-associated diarrhoea, 
pseudomembranous colitis and, potentially, life-threatening complications such as 
toxic megacolon (Rea et al., 2010, Warren and Guerrant, 2011). Low doses of 
antibiotics have also been used as growth promoters in agriculture since the 1950’s 
despite an unclear understanding of the mechanisms at work. A recent investigation 
into this effect revealed subtherapeutic antibiotic treatment (STAT) of various 
antibiotics increased adiposity and hormones related to metabolism in young mice 
compared to untreated controls (Cho et al., 2012). Analysis of the composition and 
function of the gut microbiota of these animals made it apparent that STAT exposure 
selected for microbial species that were able to extract more calories from dietary 
complex carbohydrates that were otherwise indigestible in the control group (Cho et 
al., 2012). 
When considering these results, it is important to be aware that different broad-
spectrum antibiotics differ with respect to their impact on the gut microbiota. Changes 
to the gut microbiota can also be either long- or short-term. In one instance this was 
highlighted through murine studies which established that mice treated with a cocktail 
of amoxicillin, metronidazole and bismuth [3.0 mg, 0.69 mg and 0.185 mg, 
respectively] daily for 10 days had largely recovered their baseline microbial 
community structure 2 weeks post-treatment but that treatment with cefoperazone [0.5 
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mg/ml of drinking water] had long-term effects on community structure and reduced 
overall diversity (Antonopoulos et al., 2009). The effect of an antibiotic on the gut 
microbiota is influenced by several factors including its antimicrobial effect 
(bactericidal or bacteriostatic), its mode of action, the structure of the microbiota and 
the distribution of antibiotic resistance genes among this population (Perez-Cobas et 
al., 2013). 
In light of this greater appreciation of the impact of broad spectrum 
antimicrobials on the gut microbiota, it is apparent that there is value in utilising 
antimicrobials with a narrow spectrum of inhibition. In addition to existing repositories 
of narrow spectrum antimicrobials that were not previously commercialised, it is worth 
noting that the gut microbiota is considered a rich, but yet relatively, underutilised 
source of antimicrobial-producing, and in particular bacteriocin-producing, bacteria. 
Bacteriocins are ribosomally synthesised peptides to which the producer has a specific 
immunity gene and can have either a narrow or broad spectrum of activity (Cotter et 
al., 2005a). Many bacteriocins have a number of desirable traits, including low 
toxicity, high potency and, in the case of gut associated strains, the possibility of in 
situ antimicrobial. production This combination of traits makes them attractive 
alternatives to traditional antibiotic therapies. Despite being, as stated above, a 
relatively underutilised source of antimicrobials, a number of bacteriocins have 
previously been isolated from mammalian gut microbes (O'Shea et al., 2009, Rea et 
al., 2011, Casey et al., 2004, Lakshminarayanan et al., 2013). Indeed, for example, 
screening of faecal samples from 266 elderly Irish subjects identified 13 bacteriocin 
producing strains (Lakshminarayanan et al., 2013) while a further study lead to the 
isolation of 23 distinct bacteriocin-producing strains from a range of mammalian 
gastrointestinal sources (O'Shea et al., 2009). Given that, for a bacteriocin to be 
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produced and be active in the gut, the producer needs to be able to survive in and 
colonize the human gut and the associated antimicrobial needs to be active in the gut 
environment, it has been argued that the gut is an ideal source of bacteriocin producers 
with the potential to alter the gut microbiota (Saarela et al., 2000). There have already 
been a number of studies which have highlighted the merits of employing gut-
associated bacteriocins, several of which we refer to here. In a distal colon model, the 
narrow spectrum bacteriocin thuricin CD has been observed to inhibit the growth of 
C. difficile without having any significant additional impact on the other components 
of the gut microbiota (Rea et al., 2011). This contrasted with the significant shift in the 
relative proportions of the dominant bacterial populations that were observed when the 
broad-spectrum antimicrobials lacticin 3147, metronidazole and vancomycin, 
respectively, were employed. Notably, thuricin CD also exhibited a potency 
comparable to that of the control antimicrobials (Rea et al., 2011), thereby establishing 
that thuricin CD has potential as an alternative to the conventional antimicrobial 
strategies employed to treat C. difficile infection, especially as it is less likely to impact 
negatively on the commensal gut microbiota and, thus, is more likely to prevent 
recurrent C. difficile infections. While, in the above example, thuricin CD, rather than 
the associated Bacillus thuringiensis producer (Rea et al., 2010), was employed, there 
are other examples that have highlighted the merits of using the bacteriocin-producing 
strain itself. In one such instance, ingestion of the bacteriocin producing probiotic 
strain Lactobacillus salivarius UCC118 provided significant protection against 
infection by Listeria monocytogenes in mice (Corr et al., 2007). Production of the 
Abp118 bacteriocin by UCC118, which has previously been shown to be capable of 
altering the intestinal microbiota of pigs and mice (Riboulet-Bisson et al., 2012), 
proved to be the key protective factor as a non-bacteriocin producing mutant failed to 
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confer the same protection. This protective effect was also lost when infection was 
with a bacteriocin-immune L. monocytogenes mutant, thereby confirming that the 
mode of action was direct antagonism by Abp118 rather than via some other indirect 
effect (Corr et al., 2007). In another instance a combination of 5 probiotic strains were 
employed to control Salmonella Typhimurium-induced diarrhoea in pigs (Casey et al., 
2007). It was subsequently established that the only bacteriocin-producing strain, L. 
salivarius DPC6005, was the dominant member of the cocktail in both the ileum 
digesta and in the mucosa. It could not be established, however, if bacteriocin 
production was directly responsible for anti-Salmonella activity (Walsh et al., 2008). 
In addition to the control of pathogens, antimicrobials have also been 
investigated with a view to altering metabolic health in diet-induced obese mice 
(Murphy et al., 2013). Supplementation of a high-fat diet with vancomycin caused a 
significant decrease in Firmicutes and Bacteroidetes populations with a corresponding 
increase in Proteobacteria. This compositional shift was accompanied by a marked 
decrease in weight gain, fasting blood glucose, plasma TNFα and triglyceride levels 
compared to the diet-induced obese controls. Although supplementation of the high-
fat diet with the bacteriocin-producing probiotic L. salivarius UCC118 did not produce 
any significant changes in the metabolic profiles of the mice, it did result in an increase 
in relative proportions of Bacteroidetes and Proteobacteria with a corresponding 
decrease in Actinobacteria. The authors concluded that antimicrobial strategies have 
the potential to alter both the composition of the gut microbiota and the metabolic 
health of the host. However, it was noted that care must be taken when choosing the 
antimicrobial to be used so as to bring about extended beneficial impacts on metabolic 
health. 
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As with diet, the vast majority of work concerning modulation of the 
microbiota by antimicrobials has taken place in mouse models. Nevertheless, the 
results are encouraging and suggest that carefully selected antimicrobials represent a 
viable option with respect to intelligently altering the bacterial populations within the 
human gut. The first step, however, is identifying antimicrobials with this potential. 
 
Identification of antimicrobials with the potential to modulate the gut 
microbiota 
 
Almost all classes of life are known to produce antimicrobial peptides as a feature of 
their natural defence (De Smet and Contreras, 2005, Bishop et al., 2017, Bahar and 
Ren, 2013). The variety of strategies to identify novel antimicrobial producing bacteria 
can be broadly divided into traditional, culture-based approaches and modern, in 
silico-based strategies. Culture-based approaches, particularly those focused on the 
mammalian gastrointestinal tract, have identified a large number of antimicrobials 
with potential importance for both the food and healthcare industries (Rea et al., 2010, 
Lakshminarayanan et al., 2013, O'Shea et al., 2009, Drissi et al., 2015, Mullane et al., 
2014). One such example is bactofencin A, a bacteriocin showing much potential to 
subtly modulate the gut microbiota (Guinane et al., 2016), which was originally 
isolated from the porcine gastrointestinal tract (O'Shea et al., 2013). 
Culture-based techniques have the limitation however of only selecting easy-to-
cultivate microbes and therefore the antimicrobial-producing activity of all of the 
components of the community are not sampled. To overcome this, culture-independent 
techniques have been developed. The first advance to address this was functional 
metagenomics, whereby total DNA from an environment is expressed in a suitable 
host and this clonal bank is then screened for the desirable trait. Many novel antibiotics 
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and antibacterial peptides have been identified by these methods (Banik and Brady, 
2010) but also has drawbacks such as insert sizes which may be too small to encompass 
some of the larger bacteriocin gene clusters or the non-expression of the gene clusters 
in specific hosts. 
In silico mining overcomes the challenges associated with culture-dependent 
approaches, taking advantage of the continually growing volume of data generated by 
genome and metagenome sequencing projects and exploiting the highly conserved 
nature of many features of bacteriocin gene clusters. Sequencing consortiums, 
particularly those centred on the human microbiome, such as the Human Microbiome 
Project and MetaHIT (The Human Microbiome Project Consortium, 2012, Qin et al., 
2010) have provided large quantities of sequencing data from which novel 
antimicrobial gene clusters can be identified. The robust temporal stability and mean-
reverting behaviour of the microbiota (Belstrøm et al., 2016, Jeffery et al., 2016, 
Gibbons et al., 2017) is perhaps due, in part, to the protection against invading bacteria 
conferred by bacteriocins and other antimicrobials produced in situ (Corr et al., 2007, 
Moroni et al., 2006, Rea et al., 2011). It, therefore, stands to reason that the mining of 
the human microbiome merits consideration with respect to the production of a new 
generation of therapeutics for diseases such as obesity and type 2 diabetes (Walsh et 
al., 2014). 
Until relatively recently, sequence-homology based approaches, such as BLAST, were 
the primary method of identifying novel putative bacteriocin-encoding gene clusters 
(PBGCs) and were used with great success (Marsh et al., 2010, Murphy et al., 2011, 
Singh and Sareen, 2014). For example, the two-peptide lantibiotic, lichenicindin, was 
originally identified by mining the NCBI bacterial genome database for sequences 
similar to the lacticin 3147-associated modification protein LtnM1 (Begley et al., 
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2009). However, an abundance of tools and algorithms have, in recent years, become 
available for mining genomic and metagenomic data for bacteriocins and other 
biosynthetic gene clusters. BAGEL and antiSMASH are two such tools whose user-
friendly, online applications are routinely used to identify bacteriocins, antibiotics, and 
other secondary metabolic biosynthetic gene clusters in genome sequence data (van 
Heel et al., 2013, Weber et al., 2015). An approach combining both of these tools 
identified 1814 putative antimicrobial gene clusters from 328 members of the 
Bacillales order, including bacteriocins, non-ribosomal synthesised peptides and 
polyketides (Zhao and Kuipers, 2016). One aspect of BAGEL3’s functionality is a 
sequence similarity approach using a manually curated database of bacteriocin 
prepeptide protein sequences. This database was utilized by Zheng and colleagues to 
identify PBGCs in genomic and metagenomic data representative of the human 
gastrointestinal microbiota (Zheng et al., 2014). However, the true power of BAGEL 
comes from indirect mining for bacteriocin-associated genes, a tactic particularly 
useful for identifying peptides which undergo significant post-translational 
modification such as lantibiotics and sactibiotics, as seen in Chapter 2 of this thesis 
(Walsh et al., 2015).  
As mentioned previously, the conserved nature of bacteriocin gene clusters make them 
ideal candidates for in silico mining. The posttranslational modification enzymes, 
which provide many bacteriocins with structures beyond those possible by ribosomal 
translation alone, are particularly important in this regard. These modifications are 
typically key to the peptide’s functionality, stability and target recognition and so, 
unlike bacteriocin prepeptides which show substantial heterogeneity even within the 
same subclass, these modification proteins possess highly conserved functional 
domains which have been exploited to identify many novel lantibiotic (Begley et al., 
34 
 
2009, Lawton et al., 2007, Marsh et al., 2010, Singh and Sareen, 2014, McClerren et 
al., 2006) and sactibiotic (Murphy et al., 2011) gene clusters.  
To date, the greatest proportion of bacteriocin mining efforts appear to focus on 
lantibiotics, as they are particularly well-characterised, possess highly conserved 
biosynthetic machinery, and are produced by many food-grade bacteria (van Kraaij et 
al., 1999). The vast majority of lantibiotics are produced by members of the Firmicutes 
phylum (Li and O'Sullivan, 2012), a pattern also reflected by investigations of their 
distribution in the gut microbiota (Walsh et al., 2015, Zheng et al., 2014, Drissi et al., 
2015, Walsh et al., 2017). A similar trend is also apparent in the recently characterised 
sactibiotic class (Murphy et al., 2011). In silico mining is not limited to these classes 
however, as exploration of genomes representative of the human microbiota using the 
ClusterFinder algorithm led to the discovery and characterisation of a thiopeptide 
produced by a Lactobacillus gasseri vaginal isolate (Donia et al., 2014). This was the 
first thiopeptide of human origin to be experimentally characterised, although a 
semisynthetic member of this class of antimicrobial peptides, LFF571, is already 
showing promise for the treatment of Clostridium difficile infections in human trials 
with outcomes comparable to vancomycin (Mullane et al., 2014). This is an example 
of overcoming the second major hurdle in in silico mining for antimicrobials, i.e., 
confirmation and characterisation of production in vitro. There are many factors 
influencing bacteriocin production (Guinane et al., 2015), and as production of these 
compounds is costly in terms of energy and resources, it is ulinkely that all bacteriocins 
are expressed in pure culture where antimicrobial production is not advantageous. 
However, haloduracin (McClerren et al., 2006) and lichenicidin (Begley et al., 2009), 
in addition to the thiopeptide mentioned above, are examples of in silico-identified 
antimirobals which have been characterised in vitro. 
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Taken together, these results are encouraging from a public health viewpoint as they 
suggest intelligent mining of the human microbiota’s extensive bioactive potential 
may be the first step in relieving the pressure on antibiotics and overcoming the 
persistent threat of resistance. 
 
Modulation by Probiotics 
 
The World Health Organization defines probiotics as “live microorganisms which 
when administered in adequate amounts confer a health benefit on the host” (Pineiro 
and Stanton, 2007). Probiotics are becoming increasingly popular and are generally 
marketed as functional foods or dietary supplements. As it has been recognised that 
changes in the gut microbiota play a role in GI disease then it is not surprising that 
probiotics are an attractive option with respect to modulation of the gut microbiome. 
For a probiotic to successfully exert its benefit on the host’s gut microbiota it should 
be able to remain viable during storage and also be capable of surviving, and 
potentially colonizing, the host’s intestinal environment (Vyas and Ranganathan, 
2012). The majority of probiotics currently used are members of lactic acid bacteria 
(LAB) and, more specifically, strains from the genera Lactobacillus and 
Bifidobacterium are most commonly used in commercial probiotics. Mixtures of these 
strains are becoming increasingly popular as researchers gain a deeper understanding 
of increasing efficacy via possible additive or synergistic effects (Chapman et al., 
2011). Rijkers et al. categorised the benefit of probiotics into three levels based on 
location and method; 1) interference with the growth or survival of pathogenic 
microorganisms in the gut lumen, 2) improvement of mucosal barrier function or 
mucosal immune system and 3) influence beyond the gut through the systemic immune 
system and other organs (Rijkers et al., 2010). A study undertaken by Park et al. found 
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that DIO mice treated with the probiotic strains Lactobacillus curvatus HY7601 and 
Lactobacillus plantarum KY1032 experienced reduced body weight gain and fat 
accumulation in addition to lowered plasma insulin, leptin, total-cholesterol and liver 
toxicity biomarkers compared to a group on the same diet supplemented with a placebo 
(Park et al., 2013). Supplementation with these probiotic strains also resulted in down-
regulation of pro-inflammatory genes in adipose tissue, up-regulation of fatty acid 
oxidation-related genes in the liver and significant alterations in the diversity and 
function of the gut microbiota. Similar results were observed by Yadav et al., who 
found that administration of the probiotic VSL#3 prevented and treated obesity and 
diabetes in a number of different murine models through modulation of the gut 
microbiota. In particular, an increase in the number of butyrate-producing bacteria was 
linked with enhanced secretion of the hunger-reducing hormone GLP-1 as well as 
upregulation of genesinvolved in GLP-1 synthesis and excretion (Yadav et al., 2013). 
McNulty et al. observed that, in gnotobiotic mice harbouring a 15-member model 
human gut microbial community, introduction of 5 probiotic strains isolated from a 
fermented milk product did not significantly alter the composition of the intestinal 
microbiota but instead increased the expression of microbial genes involved in 
carbohydrate and nucleotide metabolism while decreasing expression of genes 
involved in the metabolism of lipids and amino acids (McNulty et al., 2011). These 
metatranscriptomic changes were also apparent in the microbiota of human 
monozygotic twins when fed the same fermented milk product, primarily upregulation 
of genes involved in carbohydrate metabolism. In addition to their investigation with 
a view to contributing to the prevention/treatment of obesity and T2D, it should be 
noted that probiotics are thought to have the potential to treat a wide range of other 
conditions such as IBS, allergies, C. difficile infection, IBD and others by modulation 
37 
 
of the gut microbiota as highlighted in a number of recent manuscripts (Andreasen et 
al., 2010, Aronsson et al., 2010, Kadooka et al., 2010, Dai et al., 2013, Fitzpatrick, 
2013, Veerappan et al., 2012, Miyoshi et al., 2013). As improvements in metagenome 
sequencing and computational biology permit us to learn more about other gut 
microbes and their role in human health, there are indications that the future may lie 
in the development and application of next-generation probiotics such as Akkermansia 
muciniphila, Faecalibacterium prausnitzii, and members of the Bacteroides (O’Toole 
et al., 2017). 
 
Modulation by Faecal Microbiota Transplantation 
 
Following on from the probiotics principle, but on a community rather than strain 
level, faecal microbiota transplantation (FMT) is the process of transplanting faecal 
bacterial communities from a healthy individual to a recipient whose microbiota has 
been disrupted or altered. Although still somewhat in its infancy, FMT is becoming 
more commonly used as an approach to replenish the gut microbiota in order to 
alleviate the symptoms of disease. To date, FMT has most commonly been used to 
treat recurrent C. difficile infection (CDI) by replacing populations of commensal 
bacteria which have been wiped out by antibiotic therapy. Khoruts and colleagues used 
terminal-restriction fragment length polymorphism and 16S rRNA approaches to 
compare the bacterial component of a CDI patient’s microbiota before and after FMT 
intervention (Khoruts et al., 2010) and found that, before intervention, the microbiota 
was deficient in both Bacteroidetes and Firmicutes but 14 days post-transplantation 
the microbiota was changed to closely resemble the donor’s microbiota and was 
dominated by Bacteroides spp. (Khoruts et al., 2010). These results are similar to 
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findings by Tvede and Rask-Madsen who reported Bacteroides spp. were absent in 
CDI patients but were replenished after FMT intervention (Tvede and Rask-Madsen, 
1989). The composition of the donor’s microbiota is the key factor in determining the 
efficacy of this treatment, as shown by Grehan et al. who collected faecal samples from 
patients undergoing FMT at 4 time points; pre-treatment and at intervals of 4, 8 and 
24 weeks post-treatment to determine the effect of FMT on its microbial content 
(Tvede and Rask-Madsen, 1989). Using a molecular approach they found that the 
microbiota was altered by FMT intervention and that at 4, 8 and 24 weeks the 
community of the recipient was composed predominately of bacteria derived from the 
healthy donor’s samples. Crucially, in addition to bringing about desirable microbiota-
related changes, FMT has in a high frequency of cases been successful in controlling 
CDI. In one such study it was revealed that only 1 of 16 patients treated with FMT 
experienced a recurrence of colitis during the 90 day follow-up period (Aas et al., 
2003). Indeed, when many such studies were combined in a systematic literature 
review by Gough et al., i.e. to examine the effect of FMT on 317 CDI patients across 
27 case studies, it was revealed that disease was resolved in 92% of cases (Gough et 
al., 2011). An interesting development in the application of FMT is the use of synthetic 
microbial communities in place of undefined mixtures from donors (for review see de 
Vos et al (de Vos, 2013)). The synthetic mixtures have the advantage of being 
controlled, tested extensively for the presence of viruses or pathogens and have the 
potential to be reproducibly manufactured. Petrof et al. showed that a defined mixture 
of 33 isolates, when administered during a colonoscopy, cured the CDI of 2 patients 
who had previously failed to respond to antibiotic treatment (Petrof et al., 2013). 16S 
rRNA analysis showed that taxa found in the stool substitute were rare in the patient’s 
gut microbiota before intervention, however following treatment these taxa accounted 
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for over 25% of sequences recovered from the gut microbiota. The current consensus 
supports FMT for use in CDI as a safe, well-tolerated, effective treatment with few 
adverse events (Kelly et al., 2015) and such is the effectiveness of FMT that a 
technique known as autologous restoration of gastrointestinal flora (ARGF) proposes 
that an individual’s healthy gut microbiota should be encapsulated and stored 
indefinitely so that their original microbiota can be reintroduced in the event of 
disruption by antibiotic treatment (Martin, 2009). Although FMT has been most 
extensively studied with a view to CDI treatment, it has, however, also been 
investigated as a potential treatment option for a range of microbiota-associated 
diseases including IBD, IBS, obesity, idiopathic thrombocytopaenic purpura and even 
multiple sclerosis. A recently published review by Gupta et al. summarises the current 
state of research and possible future directions of the technique (Gupta et al., 2016).  
 
Concluding Remarks 
 
It is well established that the gut microbiota influences host metabolism, 
nutrient absorption and immune function, and that disruption of this balanced 
community can have very serious health implications. As we gain a deeper 
understanding of the specific relationships between the gut microbiota and disease, we 
expose potential therapeutic targets. Intelligent modulation of the intestinal 
community is a topic that had gained considerable interest and has the possibility to be 
extremely beneficial for human health, particularly as advances in metagenomic 
sequencing and computational analysis permit the identification of novel 
antimicrobials and probiotics with targeted therapeutic potential.
40 
 
References 
 
AAS, J., GESSERT, C. E. & BAKKEN, J. S. 2003. Recurrent Clostridium difficile 
colitis: case series involving 18 patients treated with donor stool administered 
via a nasogastric tube. Clin Infect Dis, 36, 580-5. 
ADLERBERTH, I. & WOLD, A. E. 2009. Establishment of the gut microbiota in 
Western infants. Acta Paediatr, 98, 229-38. 
ANDERSON, C. A., BOUCHER, G., LEES, C. W., FRANKE, A., D'AMATO, M., 
TAYLOR, K. D., LEE, J. C., GOYETTE, P., IMIELINSKI, M. & LATIANO, 
A. 2011. Meta-analysis identifies 29 additional ulcerative colitis risk loci, 
increasing the number of confirmed associations to 47. Nature genetics, 43, 
246-252. 
ANDREASEN, A. S., LARSEN, N., PEDERSEN-SKOVSGAARD, T., BERG, R. 
M., MOLLER, K., SVENDSEN, K. D., JAKOBSEN, M. & PEDERSEN, B. 
K. 2010. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and 
the systemic inflammatory response in human subjects. Br J Nutr, 104, 1831-
8. 
ANTONOPOULOS, D. A., HUSE, S. M., MORRISON, H. G., SCHMIDT, T. M., 
SOGIN, M. L. & YOUNG, V. B. 2009. Reproducible Community Dynamics 
of the Gastrointestinal Microbiota following Antibiotic Perturbation. Infection 
and Immunity, 77, 2367-2375. 
ARNOLD, I. C., DEHZAD, N., REUTER, S., MARTIN, H., BECHER, B., TAUBE, 
C., XFC & LLER, A. 2011. Helicobacter pylori infection prevents allergic 
asthma in mouse models through the induction of regulatory T cells. The 
Journal of Clinical Investigation, 121, 3088-3093. 
41 
 
ARONSSON, L., HUANG, Y., PARINI, P., KORACH-ANDRE, M., HAKANSSON, 
J., GUSTAFSSON, J. A., PETTERSSON, S., ARULAMPALAM, V. & 
RAFTER, J. 2010. Decreased fat storage by Lactobacillus paracasei is 
associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). 
PLoS One, 5. 
ARTHUR, J. C., PEREZ-CHANONA, E., MUHLBAUER, M., TOMKOVICH, S., 
URONIS, J. M., FAN, T. J., CAMPBELL, B. J., ABUJAMEL, T., DOGAN, 
B., ROGERS, A. B., RHODES, J. M., STINTZI, A., SIMPSON, K. W., 
HANSEN, J. J., KEKU, T. O., FODOR, A. A. & JOBIN, C. 2012. Intestinal 
inflammation targets cancer-inducing activity of the microbiota. Science, 338, 
120-3. 
BACKHED, F., DING, H., WANG, T., HOOPER, L. V., KOH, G. Y., NAGY, A., 
SEMENKOVICH, C. F. & GORDON, J. I. 2004. The gut microbiota as an 
environmental factor that regulates fat storage. Proc Natl Acad Sci U S A, 101, 
15718-23. 
BÄCKHED, F., LEY, R. E., SONNENBURG, J. L., PETERSON, D. A. & GORDON, 
J. I. 2005. Host-Bacterial Mutualism in the Human Intestine. Science, 307, 
1915-1920. 
BAHAR, A. A. & REN, D. 2013. Antimicrobial Peptides. Pharmaceuticals, 6, 1543-
1575. 
BANIK, J. J. & BRADY, S. F. 2010. Recent application of metagenomic approaches 
toward the discovery of antimicrobials and other bioactive small molecules. 
Curr Opin Microbiol, 13, 603-9. 
BARTON, W., PENNEY, N. C., CRONIN, O., GARCIA-PEREZ, I., MOLLOY, M. 
G., HOLMES, E., SHANAHAN, F., COTTER, P. D. & O'SULLIVAN, O. 
42 
 
2017. The microbiome of professional athletes differs from that of more 
sedentary subjects in composition and particularly at the functional metabolic 
level. Gut. 
BEGLEY, M., COTTER, P. D., HILL, C. & ROSS, R. P. 2009. Identification of a 
novel two-peptide lantibiotic, lichenicidin, following rational genome mining 
for LanM proteins. Appl Environ Microbiol, 75, 5451-60. 
BELSTRØM, D., HOLMSTRUP, P., BARDOW, A., KOKARAS, A., FIEHN, N.-E. 
& PASTER, B. J. 2016. Temporal Stability of the Salivary Microbiota in Oral 
Health. PLoS ONE, 11, e0147472. 
BENGTSON, M. B., AAMODT, G., VATN, M. H. & HARRIS, J. R. 2010. 
Concordance for IBD among twins compared to ordinary siblings--a 
Norwegian population-based study. J Crohns Colitis, 4, 312-8. 
BISHOP, B. M., JUBA, M. L., RUSSO, P. S., DEVINE, M., BARKSDALE, S. M., 
SCOTT, S., SETTLAGE, R., MICHALAK, P., GUPTA, K., VLIET, K., 
SCHNUR, J. M. & VAN HOEK, M. L. 2017. Discovery of Novel 
Antimicrobial Peptides from Varanus komodoensis (Komodo Dragon) by 
Large-Scale Analyses and De-Novo-Assisted Sequencing Using Electron-
Transfer Dissociation Mass Spectrometry. J Proteome Res. 
BLASER, M. 2011. Antibiotic overuse: Stop the killing of beneficial bacteria. Nature, 
476, 393-394. 
BOUHNIK, Y., ALAIN, S., ATTAR, A., FLOURIE, B., RASKINE, L., SANSON-
LE PORS, M. J. & RAMBAUD, J. C. 1999. Bacterial populations 
contaminating the upper gut in patients with small intestinal bacterial 
overgrowth syndrome. Am J Gastroenterol, 94, 1327-31. 
43 
 
BOUHNIK, Y., RASKINE, L., SIMONEAU, G., VICAUT, E., NEUT, C., FLOURIÉ, 
B., BROUNS, F. & BORNET, F. R. 2004. The capacity of nondigestible 
carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-
blind, randomized, placebo-controlled, parallel-group, dose-response relation 
study. The American journal of clinical nutrition, 80, 1658-1664. 
BRINT, E. K., MACSHARRY, J., FANNING, A., SHANAHAN, F. & QUIGLEY, E. 
M. 2011. Differential expression of toll-like receptors in patients with irritable 
bowel syndrome. Am J Gastroenterol, 106, 329-36. 
BROOKS, A. W., KOHL, K. D., BRUCKER, R. M., VAN OPSTAL, E. J. & 
BORDENSTEIN, S. R. 2016. Phylosymbiosis: Relationships and Functional 
Effects of Microbial Communities across Host Evolutionary History. PLOS 
Biology, 14, e2000225. 
BULTMAN, S. J. 2017. Interplay between diet, gut microbiota, epigenetic events, and 
colorectal cancer. Molecular Nutrition & Food Research, 61, 1500902-n/a. 
BULTMAN, S. J. & JOBIN, C. 2014. Microbial-derived butyrate: an oncometabolite 
or tumor-suppressive metabolite? Cell Host Microbe, 16, 143-5. 
CANI, P. D. 2013. Gut microbiota and obesity: lessons from the microbiome. Brief 
Funct Genomics, 12, 381-7. 
CASEY, P. G., CASEY, G. D., GARDINER, G. E., TANGNEY, M., STANTON, C., 
ROSS, R. P., HILL, C. & FITZGERALD, G. F. 2004. Isolation and 
characterization of anti-Salmonella lactic acid bacteria from the porcine 
gastrointestinal tract. Letters in Applied Microbiology, 39, 431-438. 
CASEY, P. G., GARDINER, G. E., CASEY, G., BRADSHAW, B., LAWLOR, P. G., 
LYNCH, P. B., LEONARD, F. C., STANTON, C., ROSS, R. P. & 
FITZGERALD, G. F. 2007. A five-strain probiotic combination reduces 
44 
 
pathogen shedding and alleviates disease signs in pigs challenged with 
Salmonella enterica serovar Typhimurium. Applied and Environmental 
Microbiology, 73, 1858-1863. 
CASTELLARIN, M., WARREN, R. L., FREEMAN, J. D., DREOLINI, L., 
KRZYWINSKI, M., STRAUSS, J., BARNES, R., WATSON, P., ALLEN-
VERCOE, E., MOORE, R. A. & HOLT, R. A. 2012. Fusobacterium nucleatum 
infection is prevalent in human colorectal carcinoma. Genome Res, 22, 299-
306. 
CHAPMAN, C., GIBSON, G. & ROWLAND, I. 2011. Health benefits of probiotics: 
are mixtures more effective than single strains? European journal of nutrition, 
50, 1-17. 
CHEN, J., WRIGHT, K., DAVIS, J. M., JERALDO, P., MARIETTA, E. V., 
MURRAY, J., NELSON, H., MATTESON, E. L. & TANEJA, V. 2016. An 
expansion of rare lineage intestinal microbes characterizes rheumatoid 
arthritis. Genome Medicine, 8, 43. 
CHEN, Y. & BLASER, M. J. 2007. Inverse associations of helicobacter pylori with 
asthma and allergy. Archives of Internal Medicine, 167, 821-827. 
CHO, I., YAMANISHI, S., COX, L., METHE, B. A., ZAVADIL, J., LI, K., GAO, Z., 
MAHANA, D., RAJU, K., TEITLER, I., LI, H., ALEKSEYENKO, A. V. & 
BLASER, M. J. 2012. Antibiotics in early life alter the murine colonic 
microbiome and adiposity. Nature, 488, 621-6. 
CLAESSON, M. J., CUSACK, S., O'SULLIVAN, O., GREENE-DINIZ, R., DE 
WEERD, H., FLANNERY, E., MARCHESI, J. R., FALUSH, D., DINAN, T., 
FITZGERALD, G., STANTON, C., VAN SINDEREN, D., O'CONNOR, M., 
HARNEDY, N., O'CONNOR, K., HENRY, C., O'MAHONY, D., 
45 
 
FITZGERALD, A. P., SHANAHAN, F., TWOMEY, C., HILL, C., ROSS, R. 
P. & O'TOOLE, P. W. 2011. Composition, variability, and temporal stability 
of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A, 108 Suppl 
1, 4586-91. 
CLAESSON, M. J., JEFFERY, I. B., CONDE, S., POWER, S. E., O/'CONNOR, E. 
M., CUSACK, S., HARRIS, H. M. B., COAKLEY, M., 
LAKSHMINARAYANAN, B., O/'SULLIVAN, O., FITZGERALD, G. F., 
DEANE, J., O/'CONNOR, M., HARNEDY, N., O/'CONNOR, K., 
O/'MAHONY, D., VAN SINDEREN, D., WALLACE, M., BRENNAN, L., 
STANTON, C., MARCHESI, J. R., FITZGERALD, A. P., SHANAHAN, F., 
HILL, C., ROSS, R. P. & O/'TOOLE, P. W. 2012. Gut microbiota composition 
correlates with diet and health in the elderly. Nature, 488, 178-184. 
CLARKE, S. F., MURPHY, E. F., NILAWEERA, K., ROSS, P. R., SHANAHAN, F., 
O'TOOLE, P. W. & COTTER, P. D. 2012. The gut microbiota and its 
relationship to diet and obesity: new insights. Gut Microbes, 3, 186-202. 
CLARKE, S. F., MURPHY, E. F., O'SULLIVAN, O., LUCEY, A. J., HUMPHREYS, 
M., HOGAN, A., HAYES, P., O'REILLY, M., JEFFERY, I. B., WOOD-
MARTIN, R., KERINS, D. M., QUIGLEY, E., ROSS, R. P., O'TOOLE, P. 
W., MOLLOY, M. G., FALVEY, E., SHANAHAN, F. & COTTER, P. D. 
2014. Exercise and associated dietary extremes impact on gut microbial 
diversity. Gut. 
CLEMENTE, JOSE C., URSELL, LUKE K., PARFREY, LAURA W. & KNIGHT, 
R. 2012. The Impact of the Gut Microbiota on Human Health: An Integrative 
View. Cell, 148, 1258-1270. 
46 
 
CLINTON, S. K., BOSTWICK, D. G., OLSON, L. M., MANGIAN, H. J. & VISEK, 
W. J. 1988. Effects of ammonium acetate and sodium cholate on N-methyl-N′-
nitro-N-nitrosoguanidine-induced colon carcinogenesis of rats. Cancer 
research, 48, 3035-3039. 
CORR, S. C., LI, Y., RIEDEL, C. U., O'TOOLE, P. W., HILL, C. & GAHAN, C. G. 
M. 2007. Bacteriocin production as a mechanism for the antiinfective activity 
of Lactobacillus salivarius UCC118. Proceedings of the National Academy of 
Sciences, 104, 7617-7621. 
COSTABILE, A., KOLIDA, S., KLINDER, A., GIETL, E., BÄUERLEIN, M., 
FROHBERG, C., LANDSCHÜTZE, V. & GIBSON, G. R. 2010. A double-
blind, placebo-controlled, cross-over study to establish the bifidogenic effect 
of a very-long-chain inulin extracted from globe artichoke (Cynara scolymus) 
in healthy human subjects. British Journal of Nutrition, 104, 1007. 
COTILLARD, A., KENNEDY, S. P., KONG, L. C., PRIFTI, E., PONS, N., LE 
CHATELIER, E., ALMEIDA, M., QUINQUIS, B., LEVENEZ, F., 
GALLERON, N., GOUGIS, S., RIZKALLA, S., BATTO, J.-M., RENAULT, 
P., CONSORTIUM, A. N. R. M., DORE, J., ZUCKER, J.-D., CLEMENT, K., 
EHRLICH, S. D. & MEMBERS, A. N. R. M. C. 2013. Dietary intervention 
impact on gut microbial gene richness. Nature, 500, 585-588. 
COTTER, P. D., HILL, C. & ROSS, R. P. 2005. Bacteriocins: developing innate 
immunity for food. Nat Rev Microbiol, 3, 777-88. 
COTTER, P. D., STANTON, C., ROSS, R. P. & HILL, C. 2012. The impact of 
antibiotics on the gut microbiota as revealed by high throughput DNA 
sequencing. Discovery medicine, 13, 193. 
47 
 
CRYAN, J. F. & O'MAHONY, S. M. 2011. The microbiome-gut-brain axis: from 
bowel to behavior. Neurogastroenterol Motil, 23, 187-92. 
CUMMINGS, J. & MACFARLANE, G. 1991. The control and consequences of 
bacterial fermentation in the human colon. Journal of Applied Microbiology, 
70, 443-459. 
CUMMINGS, J. H. & ENGLYST, H. N. 1991. What is dietary fibre? Trends in Food 
Science & Technology, 2, 99-103. 
DAI, C., ZHENG, C. Q., JIANG, M., MA, X. Y. & JIANG, L. J. 2013. Probiotics and 
irritable bowel syndrome. World J Gastroenterol, 19, 5973-80. 
DANIEL, H., GHOLAMI, A. M., BERRY, D., DESMARCHELIER, C., HAHNE, H., 
LOH, G., MONDOT, S., LEPAGE, P., ROTHBALLER, M., WALKER, A., 
BOHM, C., WENNING, M., WAGNER, M., BLAUT, M., SCHMITT-
KOPPLIN, P., KUSTER, B., HALLER, D. & CLAVEL, T. 2013. High-fat diet 
alters gut microbiota physiology in mice. ISME J. 
DAO, M. C., EVERARD, A., ARON-WISNEWSKY, J., SOKOLOVSKA, N., 
PRIFTI, E., VERGER, E. O., KAYSER, B. D., LEVENEZ, F., CHILLOUX, 
J., HOYLES, L., DUMAS, M. E., RIZKALLA, S. W., DORE, J., CANI, P. D. 
& CLEMENT, K. 2016. Akkermansia muciniphila and improved metabolic 
health during a dietary intervention in obesity: relationship with gut 
microbiome richness and ecology. Gut, 65, 426-36. 
DAVID, L. A., MAURICE, C. F., CARMODY, R. N., GOOTENBERG, D. B., 
BUTTON, J. E., WOLFE, B. E., LING, A. V., DEVLIN, A. S., VARMA, Y. 
& FISCHBACH, M. A. 2013. Diet rapidly and reproducibly alters the human 
gut microbiome. Nature. 
48 
 
DE FILIPPO, C., CAVALIERI, D., DI PAOLA, M., RAMAZZOTTI, M., POULLET, 
J. B., MASSART, S., COLLINI, S., PIERACCINI, G. & LIONETTI, P. 2010. 
Impact of diet in shaping gut microbiota revealed by a comparative study in 
children from Europe and rural Africa. Proceedings of the National Academy 
of Sciences, 107, 14691-14696. 
DE LANGE, K. M., MOUTSIANAS, L., LEE, J. C., LAMB, C. A., LUO, Y., 
KENNEDY, N. A., JOSTINS, L., RICE, D. L., GUTIERREZ-ACHURY, J., 
JI, S.-G., HEAP, G., NIMMO, E. R., EDWARDS, C., HENDERSON, P., 
MOWAT, C., SANDERSON, J., SATSANGI, J., SIMMONS, A., WILSON, 
D. C., TREMELLING, M., HART, A., MATHEW, C. G., NEWMAN, W. G., 
PARKES, M., LEES, C. W., UHLIG, H., HAWKEY, C., PRESCOTT, N. J., 
AHMAD, T., MANSFIELD, J. C., ANDERSON, C. A. & BARRETT, J. C. 
2017. Genome-wide association study implicates immune activation of 
multiple integrin genes in inflammatory bowel disease. Nat Genet, 49, 256-
261. 
DE SMET, K. & CONTRERAS, R. 2005. Human antimicrobial peptides: defensins, 
cathelicidins and histatins. Biotechnol Lett, 27, 1337-47. 
DE VOS, W. M. 2013. Fame and future of faecal transplantations--developing next-
generation therapies with synthetic microbiomes. Microb Biotechnol, 6, 316-
25. 
DE VADDER, F., KOVATCHEVA-DATCHARY, P., GONCALVES, D., VINERA, 
J., ZITOUN, C., DUCHAMPT, A., BÄCKHED, F. & MITHIEUX, G. 2014. 
Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain 
Neural Circuits. Cell, 156, 84-96. 
49 
 
DOMINGUEZ-BELLO, M. G., COSTELLO, E. K. & KNIGHT, R. 2010. Reply to 
Putignani et al.: Vagina as a major source of natural inoculum for the newborn. 
Proceedings of the National Academy of Sciences, 107, E160. 
DRISSI, F., BUFFET, S., RAOULT, D. & MERHEJ, V. 2015. Common occurrence 
of antibacterial agents in human intestinal microbiota. Frontiers in 
Microbiology, 6. 
DUNCAN, S. H., BELENGUER, A., HOLTROP, G., JOHNSTONE, A. M., FLINT, 
H. J. & LOBLEY, G. E. 2007. Reduced dietary intake of carbohydrates by 
obese subjects results in decreased concentrations of butyrate and butyrate-
producing bacteria in feces. Applied and environmental microbiology, 73, 
1073-1078. 
ELSON, C. O. & CONG, Y. 2012. Host-microbiota interactions in inflammatory 
bowel disease. Gut Microbes, 3, 332-44. 
ELWOOD, P. C., GIVENS, D. I., BESWICK, A. D., FEHILY, A. M., PICKERING, 
J. E. & GALLACHER, J. 2008. The survival advantage of milk and dairy 
consumption: an overview of evidence from cohort studies of vascular 
diseases, diabetes and cancer. J Am Coll Nutr, 27, 723s-34s. 
EVERARD, A., BELZER, C., GEURTS, L., OUWERKERK, J. P., DRUART, C., 
BINDELS, L. B., GUIOT, Y., DERRIEN, M., MUCCIOLI, G. G., 
DELZENNE, N. M., DE VOS, W. M. & CANI, P. D. 2013. Cross-talk between 
Akkermansia muciniphila and intestinal epithelium controls diet-induced 
obesity. Proc Natl Acad Sci U S A, 110, 9066-71. 
FAITH, J. J., GURUGE, J. L., CHARBONNEAU, M., SUBRAMANIAN, S., 
SEEDORF, H., GOODMAN, A. L., CLEMENTE, J. C., KNIGHT, R., 
50 
 
HEATH, A. C., LEIBEL, R. L., ROSENBAUM, M. & GORDON, J. I. 2013. 
The Long-Term Stability of the Human Gut Microbiota. Science, 341. 
FAITH, J. J., MCNULTY, N. P., REY, F. E. & GORDON, J. I. 2011. Predicting a 
human gut microbiota’s response to diet in gnotobiotic mice. Science, 333, 
101-104. 
FITZPATRICK, L. R. 2013. Probiotics for the treatment of Clostridium difficile 
associated disease. World J Gastrointest Pathophysiol, 4, 47-52. 
FLINT, H. J., SCOTT, K. P., LOUIS, P. & DUNCAN, S. H. 2012. The role of the gut 
microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol, 9, 577-589. 
FRANCESCHI, C. 2007. Inflammaging as a major characteristic of old people: can it 
be prevented or cured? Nutr Rev, 65, S173-6. 
FRANK, D. N., AMAND, A. L. S., FELDMAN, R. A., BOEDEKER, E. C., 
HARPAZ, N. & PACE, N. R. 2007. Molecular-phylogenetic characterization 
of microbial community imbalances in human inflammatory bowel diseases. 
Proceedings of the National Academy of Sciences, 104, 13780-13785. 
FRANKE, A., MCGOVERN, D. P., BARRETT, J. C., WANG, K., RADFORD-
SMITH, G. L., AHMAD, T., LEES, C. W., BALSCHUN, T., LEE, J., 
ROBERTS, R., ANDERSON, C. A., BIS, J. C., BUMPSTEAD, S., 
ELLINGHAUS, D., FESTEN, E. M., GEORGES, M., GREEN, T., 
HARITUNIANS, T., JOSTINS, L., LATIANO, A., MATHEW, C. G., 
MONTGOMERY, G. W., PRESCOTT, N. J., RAYCHAUDHURI, S., 
ROTTER, J. I., SCHUMM, P., SHARMA, Y., SIMMS, L. A., TAYLOR, K. 
D., WHITEMAN, D., WIJMENGA, C., BALDASSANO, R. N., BARCLAY, 
M., BAYLESS, T. M., BRAND, S., BUNING, C., COHEN, A., COLOMBEL, 
J. F., COTTONE, M., STRONATI, L., DENSON, T., DE VOS, M., D'INCA, 
51 
 
R., DUBINSKY, M., EDWARDS, C., FLORIN, T., FRANCHIMONT, D., 
GEARRY, R., GLAS, J., VAN GOSSUM, A., GUTHERY, S. L., 
HALFVARSON, J., VERSPAGET, H. W., HUGOT, J. P., KARBAN, A., 
LAUKENS, D., LAWRANCE, I., LEMANN, M., LEVINE, A., LIBIOULLE, 
C., LOUIS, E., MOWAT, C., NEWMAN, W., PANES, J., PHILLIPS, A., 
PROCTOR, D. D., REGUEIRO, M., RUSSELL, R., RUTGEERTS, P., 
SANDERSON, J., SANS, M., SEIBOLD, F., STEINHART, A. H., 
STOKKERS, P. C., TORKVIST, L., KULLAK-UBLICK, G., WILSON, D., 
WALTERS, T., TARGAN, S. R., BRANT, S. R., RIOUX, J. D., D'AMATO, 
M., WEERSMA, R. K., KUGATHASAN, S., GRIFFITHS, A. M., 
MANSFIELD, J. C., VERMEIRE, S., DUERR, R. H., SILVERBERG, M. S., 
SATSANGI, J., SCHREIBER, S., CHO, J. H., ANNESE, V., 
HAKONARSON, H., DALY, M. J. & PARKES, M. 2010. Genome-wide 
meta-analysis increases to 71 the number of confirmed Crohn's disease 
susceptibility loci. Nat Genet, 42, 1118-25. 
GABERT, L., VORS, C., LOUCHE‐PÉLISSIER, C., SAUVINET, V., LAMBERT‐
PORCHERON, S., DRAI, J., LAVILLE, M., DÉSAGE, M. & MICHALSKI, 
M. C. 2011. 13C tracer recovery in human stools after digestion of a fat‐rich 
meal labelled with [1, 1, 1‐13C3] tripalmitin and [1, 1, 1‐13C3] triolein. Rapid 
Communications in Mass Spectrometry, 25, 2697-2703. 
GARRETT, W. S., GALLINI, C. A., YATSUNENKO, T., MICHAUD, M., DUBOIS, 
A., DELANEY, M. L., PUNIT, S., KARLSSON, M., BRY, L., GLICKMAN, 
J. N., GORDON, J. I., ONDERDONK, A. B. & GLIMCHER, L. H. 2010. 
Enterobacteriaceae Act in Concert with the Gut Microbiota to Induce 
52 
 
Spontaneous and Maternally Transmitted Colitis. Cell Host & Microbe, 8, 292-
300. 
GIBBONS, S. M., KEARNEY, S. M., SMILLIE, C. S. & ALM, E. J. 2017. Two 
dynamic regimes in the human gut microbiome. PLOS Computational Biology, 
13, e1005364. 
GIBSON, G. R., PROBERT, H. M., VAN LOO, J., RASTALL, R. A. & 
ROBERFROID, M. B. 2004. Dietary modulation of the human colonic 
microbiota: updating the concept of prebiotics. Nutr Res Rev, 17, 259-275. 
GIBSON, G. R. & ROBERFROID, M. B. 1995. Dietary modulation of the human 
colonic microbiota: introducing the concept of prebiotics. J Nutr, 125, 1401-
12. 
GOUGH, E., SHAIKH, H. & MANGES, A. R. 2011. Systematic review of intestinal 
microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium 
difficile infection. Clin Infect Dis, 53, 994-1002. 
GUINANE, C. M., LAWTON, E. M., O'CONNOR, P. M., O'SULLIVAN, O., HILL, 
C., ROSS, R. P. & COTTER, P. D. 2016. The bacteriocin bactofencin A subtly 
modulates gut microbial populations. Anaerobe, 40, 41-9. 
GUINANE, C. M., PIPER, C., DRAPER, L. A., O'CONNOR, P. M., HILL, C., ROSS, 
R. P. & COTTER, P. D. 2015. Impact of Environmental Factors on Bacteriocin 
Promoter Activity in Gut-Derived Lactobacillus salivarius. Applied and 
Environmental Microbiology, 81, 7851-7859. 
GUPTA, S., ALLEN-VERCOE, E. & PETROF, E. O. 2016. Fecal microbiota 
transplantation: in perspective. Therap Adv Gastroenterol, 9, 229-39. 
53 
 
HAMER, H. M., DE PRETER, V., WINDEY, K. & VERBEKE, K. 2012. Functional 
analysis of colonic bacterial metabolism: relevant to health? American Journal 
of Physiology-Gastrointestinal and Liver Physiology, 302, G1-G9. 
HANSEN, R., RUSSELL, R. K., REIFF, C., LOUIS, P., MCINTOSH, F., BERRY, S. 
H., MUKHOPADHYA, I., BISSET, W. M., BARCLAY, A. R., BISHOP, J., 
FLYNN, D. M., MCGROGAN, P., LOGANATHAN, S., MAHDI, G., FLINT, 
H. J., EL-OMAR, E. M. & HOLD, G. L. 2012. Microbiota of De-Novo 
Pediatric IBD: Increased Faecalibacterium Prausnitzii and Reduced Bacterial 
Diversity in Crohn's But Not in Ulcerative Colitis. Am J Gastroenterol, 107, 
1913-1922. 
HILDEBRANDT, M. A., HOFFMANN, C., SHERRILL–MIX, S. A., KEILBAUGH, 
S. A., HAMADY, M., CHEN, Y. Y., KNIGHT, R., AHIMA, R. S., 
BUSHMAN, F. & WU, G. D. 2009. High-Fat Diet Determines the 
Composition of the Murine Gut Microbiome Independently of Obesity. 
Gastroenterology, 137, 1716-1724.e2. 
JALANKA-TUOVINEN, J., SALOJÄRVI, J., SALONEN, A., IMMONEN, O., 
GARSED, K., KELLY, F. M., ZAITOUN, A., PALVA, A., SPILLER, R. C. 
& DE VOS, W. M. 2013. Faecal microbiota composition and host–microbe 
cross-talk following gastroenteritis and in postinfectious irritable bowel 
syndrome. Gut. 
JEFFERY, I. B., LYNCH, D. B. & O'TOOLE, P. W. 2016. Composition and temporal 
stability of the gut microbiota in older persons. ISME J, 10, 170-182. 
JEMAL, A., BRAY, F., CENTER, M. M., FERLAY, J., WARD, E. & FORMAN, D. 
2011. Global cancer statistics. CA Cancer J Clin, 61, 69-90. 
54 
 
JOSTINS, L., RIPKE, S., WEERSMA, R. K., DUERR, R. H., MCGOVERN, D. P., 
HUI, K. Y., LEE, J. C., PHILIP SCHUMM, L., SHARMA, Y., ANDERSON, 
C. A., ESSERS, J., MITROVIC, M., NING, K., CLEYNEN, I., THEATRE, 
E., SPAIN, S. L., RAYCHAUDHURI, S., GOYETTE, P., WEI, Z., 
ABRAHAM, C., ACHKAR, J.-P., AHMAD, T., AMININEJAD, L., 
ANANTHAKRISHNAN, A. N., ANDERSEN, V., ANDREWS, J. M., 
BAIDOO, L., BALSCHUN, T., BAMPTON, P. A., BITTON, A., BOUCHER, 
G., BRAND, S., BUNING, C., COHAIN, A., CICHON, S., D/'AMATO, M., 
DE JONG, D., DEVANEY, K. L., DUBINSKY, M., EDWARDS, C., 
ELLINGHAUS, D., FERGUSON, L. R., FRANCHIMONT, D., FRANSEN, 
K., GEARRY, R., GEORGES, M., GIEGER, C., GLAS, J., HARITUNIANS, 
T., HART, A., HAWKEY, C., HEDL, M., HU, X., KARLSEN, T. H., 
KUPCINSKAS, L., KUGATHASAN, S., LATIANO, A., LAUKENS, D., 
LAWRANCE, I. C., LEES, C. W., LOUIS, E., MAHY, G., MANSFIELD, J., 
MORGAN, A. R., MOWAT, C., NEWMAN, W., PALMIERI, O., 
PONSIOEN, C. Y., POTOCNIK, U., PRESCOTT, N. J., REGUEIRO, M., 
ROTTER, J. I., RUSSELL, R. K., SANDERSON, J. D., SANS, M., 
SATSANGI, J., SCHREIBER, S., SIMMS, L. A., SVENTORAITYTE, J., 
TARGAN, S. R., TAYLOR, K. D., TREMELLING, M., VERSPAGET, H. 
W., DE VOS, M., WIJMENGA, C., WILSON, D. C., WINKELMANN, J., 
XAVIER, R. J., ZEISSIG, S., ZHANG, B., ZHANG, C. K., ZHAO, H., 
SILVERBERG, M. S., ANNESE, V., HAKONARSON, H., BRANT, S. R., 
RADFORD-SMITH, G., MATHEW, C. G., RIOUX, J. D., SCHADT, E. E., 
et al. 2012. Host-microbe interactions have shaped the genetic architecture of 
inflammatory bowel disease. Nature, 491, 119-124. 
55 
 
KABEERDOSS, J., DEVI, R. S., MARY, R. R. & RAMAKRISHNA, B. S. 2012. 
Faecal microbiota composition in vegetarians: comparison with omnivores in 
a cohort of young women in southern India. Br J Nutr, 108, 953-7. 
KADOOKA, Y., SATO, M., IMAIZUMI, K., OGAWA, A., IKUYAMA, K., AKAI, 
Y., OKANO, M., KAGOSHIMA, M. & TSUCHIDA, T. 2010. Regulation of 
abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults 
with obese tendencies in a randomized controlled trial. Eur J Clin Nutr, 64, 
636-43. 
KELLY, C. R., KAHN, S., KASHYAP, P., LAINE, L., RUBIN, D., ATREJA, A., 
MOORE, T. & WU, G. 2015. Update on Fecal Microbiota Transplantation 
2015: Indications, Methodologies, Mechanisms, and Outlook. 
Gastroenterology, 149, 223-37. 
KHAN, M. J., GERASIMIDIS, K., EDWARDS, C. A. & SHAIKH, M. G. 2016. Role 
of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and 
Review of the Literature. Journal of Obesity, 2016, 27. 
KHORUTS, A., DICKSVED, J., JANSSON, J. K. & SADOWSKY, M. J. 2010. 
Changes in the composition of the human fecal microbiome after 
bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin 
Gastroenterol, 44, 354-60. 
KOLEVA, P. T., VALCHEVA, R. S., SUN, X., GÄNZLE, M. G. & DIELEMAN, L. 
A. 2012. Inulin and fructo-oligosaccharides have divergent effects on colitis 
and commensal microbiota in HLA-B27 transgenic rats. British Journal of 
Nutrition, 108, 1633-1643. 
KOSTIC, A. D., CHUN, E., ROBERTSON, L., GLICKMAN, J. N., GALLINI, C. A., 
MICHAUD, M., CLANCY, T. E., CHUNG, D. C., LOCHHEAD, P., HOLD, 
56 
 
G. L., EL-OMAR, E. M., BRENNER, D., FUCHS, C. S., MEYERSON, M. & 
GARRETT, W. S. 2013. Fusobacterium nucleatum potentiates intestinal 
tumorigenesis and modulates the tumor-immune microenvironment. Cell Host 
Microbe, 14, 207-15. 
KOSTIC, A. D., GEVERS, D., PEDAMALLU, C. S., MICHAUD, M., DUKE, F., 
EARL, A. M., OJESINA, A. I., JUNG, J., BASS, A. J., TABERNERO, J., 
BASELGA, J., LIU, C., SHIVDASANI, R. A., OGINO, S., BIRREN, B. W., 
HUTTENHOWER, C., GARRETT, W. S. & MEYERSON, M. 2012. 
Genomic analysis identifies association of Fusobacterium with colorectal 
carcinoma. Genome Res, 22, 292-8. 
LAKSHMINARAYANAN, B., GUINANE, C. M., O'CONNOR, P. M., COAKLEY, 
M., HILL, C., STANTON, C., O'TOOLE, P. W. & ROSS, R. P. 2013. Isolation 
and characterization of bacteriocin-producing bacteria from the intestinal 
microbiota of elderly Irish subjects. Journal of Applied Microbiology, 114, 
886-898. 
LARSEN, N., VOGENSEN, F. K., VAN DEN BERG, F. W., NIELSEN, D. S., 
ANDREASEN, A. S., PEDERSEN, B. K., AL-SOUD, W. A., SORENSEN, 
S. J., HANSEN, L. H. & JAKOBSEN, M. 2010. Gut microbiota in human 
adults with type 2 diabetes differs from non-diabetic adults. PLoS One, 5, 
e9085. 
LAWTON, E. M., COTTER, P. D., HILL, C. & ROSS, R. P. 2007. Identification of a 
novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile 
Bacillus halodurans C-125. FEMS Microbiol Lett, 267, 64-71. 
LEPAGE, P., HÄSLER, R., SPEHLMANN, M. E., REHMAN, A., ZVIRBLIENE, 
A., BEGUN, A., OTT, S., KUPCINSKAS, L., DORÉ, J. & RAEDLER, A. 
57 
 
2011. Twin study indicates loss of interaction between microbiota and mucosa 
of patients with ulcerative colitis. Gastroenterology, 141, 227-236. 
LEWIS, S., BRAZIER, J., BEARD, D., NAZEM, N. & PROCTOR, D. 2005. Effects 
of metronidazole and oligofructose on faecal concentrations of sulphate-
reducing bacteria and their activity in human volunteers. Scandinavian journal 
of gastroenterology, 40, 1296-1303. 
LEY, R. E., BÄCKHED, F., TURNBAUGH, P., LOZUPONE, C. A., KNIGHT, R. D. 
& GORDON, J. I. 2005. Obesity alters gut microbial ecology. Proceedings of 
the National Academy of Sciences of the United States of America, 102, 11070-
11075. 
LEY, R. E., HAMADY, M., LOZUPONE, C., TURNBAUGH, P. J., RAMEY, R. R., 
BIRCHER, J. S., SCHLEGEL, M. L., TUCKER, T. A., SCHRENZEL, M. D. 
& KNIGHT, R. 2008. Evolution of mammals and their gut microbes. Science, 
320, 1647-1651. 
LHOSTE, E. F., MOUZON, B., ANDRIEUX, C., GUEUGNEAU, A.-M., 
FISZLEWICZ, M., LE, E., CORRING, T. & SZYLIT, O. 1998. Physiological 
effects of a pea protein isolate in gnotobiotic rats: comparison with a soybean 
isolate and meat. Annals of nutrition and metabolism, 42, 44-54. 
LI, X. & O'SULLIVAN, D. J. 2012. Contribution of the Actinobacteria to the growing 
diversity of lantibiotics. Biotechnol Lett, 34, 2133-45. 
LIN, H. C. 2004. Small intestinal bacterial overgrowth: a framework for understanding 
irritable bowel syndrome. Jama, 292, 852-8. 
LISZT, K., ZWIELEHNER, J., HANDSCHUR, M., HIPPE, B., THALER, R. & 
HASLBERGER, A. G. 2009. Characterization of bacteria, clostridia and 
58 
 
Bacteroides in faeces of vegetarians using qPCR and PCR-DGGE 
fingerprinting. Ann Nutr Metab, 54, 253-7. 
LYSSENKO, V., JONSSON, A., ALMGREN, P., PULIZZI, N., ISOMAA, B., 
TUOMI, T., BERGLUND, G., ALTSHULER, D., NILSSON, P. & GROOP, 
L. 2008. Clinical risk factors, DNA variants, and the development of type 2 
diabetes. N Engl J Med, 359, 2220-32. 
MACFARLANE, G., CUMMINGS, J. & ALLISON, C. 1986. Protein degradation by 
human intestinal bacteria. Journal of general microbiology, 132, 1647-1656. 
MACFARLANE, G. T. & MACFARLANE, S. 2012. Bacteria, colonic fermentation, 
and gastrointestinal health. Journal of AOAC International, 95, 50-60. 
MACHIELS, K., JOOSSENS, M., SABINO, J., DE PRETER, V., ARIJS, I., 
EECKHAUT, V., BALLET, V., CLAES, K., VAN IMMERSEEL, F., 
VERBEKE, K., FERRANTE, M., VERHAEGEN, J., RUTGEERTS, P. & 
VERMEIRE, S. 2013. A decrease of the butyrate-producing species Roseburia 
hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with 
ulcerative colitis. Gut. 
MAGEE, E. A., RICHARDSON, C. J., HUGHES, R. & CUMMINGS, J. H. 2000. 
Contribution of dietary protein to sulfide production in the large intestine: an 
in vitro and a controlled feeding study in humans. The American journal of 
clinical nutrition, 72, 1488-1494. 
MANRIQUE, P., BOLDUC, B., WALK, S. T., VAN DER OOST, J., DE VOS, W. 
M. & YOUNG, M. J. 2016. Healthy human gut phageome. Proceedings of the 
National Academy of Sciences, 113, 10400-10405. 
59 
 
MARSH, A. J., O'SULLIVAN, O., ROSS, R. P., COTTER, P. D. & HILL, C. 2010. 
In silico analysis highlights the frequency and diversity of type 1 lantibiotic 
gene clusters in genome sequenced bacteria. BMC Genomics, 11, 679. 
MARTIN, W. 2009. Encapsulated Medicines for Iatrogenic Diseases. British Patent 
Application: GB0916335, 3. 
MATIJASIC, B. B., OBERMAJER, T., LIPOGLAVSEK, L., GRABNAR, I., 
AVGUSTIN, G. & ROGELJ, I. 2013. Association of dietary type with fecal 
microbiota in vegetarians and omnivores in Slovenia. Eur J Nutr. 
MÄTTÖ, J., MAUNUKSELA, L., KAJANDER, K., PALVA, A., KORPELA, R., 
KASSINEN, A. & SAARELA, M. 2005. Composition and temporal stability 
of gastrointestinal microbiota in irritable bowel syndrome – a longitudinal 
study in IBS and control subjects. FEMS Immunology & Medical 
Microbiology, 43, 213-222. 
MCALLAN, L., SKUSE, P., COTTER, P. D., O’ CONNOR, P., CRYAN, J. F., 
ROSS, R. P., FITZGERALD, G., ROCHE, H. M. & NILAWEERA, K. N. 
2014. Whey protein isolate at varying doses differentially influences energy 
balance and the composition of the gut microbiota in high-fat fed mice. PLoS 
One, (in print). 
MCCLERREN, A. L., COOPER, L. E., QUAN, C., THOMAS, P. M., KELLEHER, 
N. L. & VAN DER DONK, W. A. 2006. Discovery and in vitro biosynthesis 
of haloduracin, a two-component lantibiotic. Proceedings of the National 
Academy of Sciences of the United States of America, 103, 17243-17248. 
MCCOY, A. N., ARAUJO-PEREZ, F., AZCARATE-PERIL, A., YEH, J. J., 
SANDLER, R. S. & KEKU, T. O. 2013. Fusobacterium is associated with 
colorectal adenomas. PLoS One, 8, e53653. 
60 
 
MCNULTY, N. P., YATSUNENKO, T., HSIAO, A., FAITH, J. J., MUEGGE, B. D., 
GOODMAN, A. L., HENRISSAT, B., OOZEER, R., COOLS-PORTIER, S., 
GOBERT, G., CHERVAUX, C., KNIGHTS, D., LOZUPONE, C. A., 
KNIGHT, R., DUNCAN, A. E., BAIN, J. R., MUEHLBAUER, M. J., 
NEWGARD, C. B., HEATH, A. C. & GORDON, J. I. 2011. The impact of a 
consortium of fermented milk strains on the gut microbiome of gnotobiotic 
mice and monozygotic twins. Sci Transl Med, 3, 106ra106. 
MIYOSHI, M., OGAWA, A., HIGURASHI, S. & KADOOKA, Y. 2013. Anti-obesity 
effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-
inflammatory gene expression in the visceral adipose tissue in diet-induced 
obese mice. Eur J Nutr. 
MORONI, O., KHEADR, E., BOUTIN, Y., LACROIX, C. & FLISS, I. 2006. 
Inactivation of Adhesion and Invasion of Food-Borne Listeria monocytogenes 
by Bacteriocin-Producing Bifidobacterium Strains of Human Origin. Applied 
and Environmental Microbiology, 72, 6894-6901. 
MULLANE, K., LEE, C., BRESSLER, A., BUITRAGO, M., WEISS, K., DABOVIC, 
K., PRAESTGAARD, J., LEEDS, J. A., BLAIS, J. & PERTEL, P. 2014. A 
multi-center, randomized clinical trial to compare the safety and efficacy of 
LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial 
Agents and Chemotherapy. 
MURPHY, E. F., COTTER, P. D., HEALY, S., MARQUES, T. M., O'SULLIVAN, 
O., FOUHY, F., CLARKE, S. F., O'TOOLE, P. W., QUIGLEY, E. M., 
STANTON, C., ROSS, P. R., O'DOHERTY, R. M. & SHANAHAN, F. 2010. 
Composition and energy harvesting capacity of the gut microbiota: 
relationship to diet, obesity and time in mouse models. Gut, 59, 1635-1642. 
61 
 
MURPHY, E. F., COTTER, P. D., HOGAN, A., O'SULLIVAN, O., JOYCE, A., 
FOUHY, F., CLARKE, S. F., MARQUES, T. M., O'TOOLE, P. W., 
STANTON, C., QUIGLEY, E. M. M., DALY, C., ROSS, P. R., O'DOHERTY, 
R. M. & SHANAHAN, F. 2013. Divergent metabolic outcomes arising from 
targeted manipulation of the gut microbiota in diet-induced obesity. Gut, 62, 
220-226. 
MURPHY, K., O'SULLIVAN, O., REA, M. C., COTTER, P. D., ROSS, R. P. & 
HILL, C. 2011. Genome Mining for Radical SAM Protein Determinants 
Reveals Multiple Sactibiotic-Like Gene Clusters. PLoS ONE, 6, e20852. 
MUSSO, G., GAMBINO, R. & CASSADER, M. 2011. Interactions between gut 
microbiota and host metabolism predisposing to obesity and diabetes. Annu 
Rev Med, 62, 361-80. 
O'HARA, A. M. & SHANAHAN, F. 2006. The gut flora as a forgotten organ. EMBO 
Rep, 7, 688-93. 
O'SHEA, E. F., GARDINER, G. E., O'CONNOR, P. M., MILLS, S., ROSS, R. P. & 
HILL, C. 2009. Characterization of enterocin- and salivaricin-producing lactic 
acid bacteria from the mammalian gastrointestinal tract. FEMS Microbiology 
Letters, 291, 24-34. 
O'SHEA, E. F., O'CONNOR, P. M., O'SULLIVAN, O., COTTER, P. D., ROSS, R. P. 
& HILL, C. 2013. Bactofencin A, a New Type of Cationic Bacteriocin with 
Unusual Immunity. mBio, 4. 
O’KEEFE, S. J. D., LI, J. V., LAHTI, L., OU, J., CARBONERO, F., MOHAMMED, 
K., POSMA, J. M., KINROSS, J., WAHL, E., RUDER, E., VIPPERLA, K., 
NAIDOO, V., MTSHALI, L., TIMS, S., PUYLAERT, P. G. B., DELANY, J., 
KRASINSKAS, A., BENEFIEL, A. C., KASEB, H. O., NEWTON, K., 
62 
 
NICHOLSON, J. K., DE VOS, W. M., GASKINS, H. R. & ZOETENDAL, E. 
G. 2015. Fat, fibre and cancer risk in African Americans and rural Africans. 
Nature Communications, 6, 6342. 
O’TOOLE, P. W., MARCHESI, J. R. & HILL, C. 2017. Next-generation probiotics: 
the spectrum from probiotics to live biotherapeutics. Nature Microbiology, 2, 
17057. 
OHMAN, L. & SIMREN, M. 2013. Intestinal microbiota and its role in irritable bowel 
syndrome (IBS). Curr Gastroenterol Rep, 15, 323. 
PALMER, C., BIK, E. M., DIGIULIO, D. B., RELMAN, D. A. & BROWN, P. O. 
2007. Development of the human infant intestinal microbiota. PLoS Biol, 5, 
e177. 
PARK, D. Y., AHN, Y. T., PARK, S. H., HUH, C. S., YOO, S. R., YU, R., SUNG, 
M. K., MCGREGOR, R. A. & CHOI, M. S. 2013. Supplementation of 
Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 in diet-
induced obese mice is associated with gut microbial changes and reduction in 
obesity. PLoS One, 8, e59470. 
PATTERSON, E., MARQUES, T. M., O’SULLIVAN, O., FITZGERALD, P., 
FITZGERALD, G. F., COTTER, P. D., DINAN, T. G., CRYAN, J. F., 
STANTON, C. & ROSS, R. P. 2015. Streptozotocin-induced type-1-diabetes 
disease onset in Sprague–Dawley rats is associated with an altered intestinal 
microbiota composition and decreased diversity. Microbiology, 161, 182-193. 
PEREZ-COBAS, A. E., ARTACHO, A., KNECHT, H., FERRUS, M. L., 
FRIEDRICHS, A., OTT, S. J., MOYA, A., LATORRE, A. & GOSALBES, M. 
J. 2013. Differential effects of antibiotic therapy on the structure and function 
of human gut microbiota. PLoS One, 8, e80201. 
63 
 
PETROF, E. O., GLOOR, G. B., VANNER, S. J., WEESE, S. J., CARTER, D., 
DAIGNEAULT, M. C., BROWN, E. M., SCHROETER, K. & ALLEN-
VERCOE, E. 2013. Stool substitute transplant therapy for the eradication of 
Clostridium difficile infection:‘RePOOPulating’the gut. Microbiome, 1, 1-12. 
PIMENTEL, M., LEMBO, A., CHEY, W. D., ZAKKO, S., RINGEL, Y., YU, J., 
MAREYA, S. M., SHAW, A. L., BORTEY, E. & FORBES, W. P. 2011. 
Rifaximin therapy for patients with irritable bowel syndrome without 
constipation. N Engl J Med, 364, 22-32. 
PINEIRO, M. & STANTON, C. 2007. Probiotic Bacteria: Legislative Framework— 
Requirements to Evidence Basis. The Journal of Nutrition, 137, 850S-853S. 
PLOTTEL, C. S. & BLASER, M. J. 2011. Microbiome and malignancy. Cell Host 
Microbe, 10, 324-35. 
PLOVIER, H., EVERARD, A., DRUART, C., DEPOMMIER, C., VAN HUL, M., 
GEURTS, L., CHILLOUX, J., OTTMAN, N., DUPARC, T., 
LICHTENSTEIN, L., MYRIDAKIS, A., DELZENNE, N. M., KLIEVINK, J., 
BHATTACHARJEE, A., VAN DER ARK, K. C. H., AALVINK, S., 
MARTINEZ, L. O., DUMAS, M.-E., MAITER, D., LOUMAYE, A., 
HERMANS, M. P., THISSEN, J.-P., BELZER, C., DE VOS, W. M. & CANI, 
P. D. 2017. A purified membrane protein from Akkermansia muciniphila or 
the pasteurized bacterium improves metabolism in obese and diabetic mice. 
Nat Med, 23, 107-113. 
QIN, J., LI, R., RAES, J., ARUMUGAM, M., BURGDORF, K. S., MANICHANH, 
C., NIELSEN, T., PONS, N., LEVENEZ, F., YAMADA, T., MENDE, D. R., 
LI, J., XU, J., LI, S., LI, D., CAO, J., WANG, B., LIANG, H., ZHENG, H., 
XIE, Y., TAP, J., LEPAGE, P., BERTALAN, M., BATTO, J.-M., HANSEN, 
64 
 
T., LE PASLIER, D., LINNEBERG, A., NIELSEN, H. B., PELLETIER, E., 
RENAULT, P., SICHERITZ-PONTEN, T., TURNER, K., ZHU, H., YU, C., 
LI, S., JIAN, M., ZHOU, Y., LI, Y., ZHANG, X., LI, S., QIN, N., YANG, H., 
WANG, J., BRUNAK, S., DORE, J., GUARNER, F., KRISTIANSEN, K., 
PEDERSEN, O., PARKHILL, J., WEISSENBACH, J., BORK, P., EHRLICH, 
S. D. & WANG, J. 2010. A human gut microbial gene catalogue established 
by metagenomic sequencing. Nature, 464, 59-65. 
QIN, J., LI, Y., CAI, Z., LI, S., ZHU, J., ZHANG, F., LIANG, S., ZHANG, W., 
GUAN, Y., SHEN, D., PENG, Y., ZHANG, D., JIE, Z., WU, W., QIN, Y., 
XUE, W., LI, J., HAN, L., LU, D., WU, P., DAI, Y., SUN, X., LI, Z., TANG, 
A., ZHONG, S., LI, X., CHEN, W., XU, R., WANG, M., FENG, Q., GONG, 
M., YU, J., ZHANG, Y., ZHANG, M., HANSEN, T., SANCHEZ, G., RAES, 
J., FALONY, G., OKUDA, S., ALMEIDA, M., LECHATELIER, E., 
RENAULT, P., PONS, N., BATTO, J. M., ZHANG, Z., CHEN, H., YANG, 
R., ZHENG, W., LI, S., YANG, H., WANG, J., EHRLICH, S. D., NIELSEN, 
R., PEDERSEN, O., KRISTIANSEN, K. & WANG, J. 2012. A metagenome-
wide association study of gut microbiota in type 2 diabetes. Nature, 490, 55-
60. 
RAJILIC-STOJANOVIC, M., BIAGI, E., HEILIG, H. G., KAJANDER, K., 
KEKKONEN, R. A., TIMS, S. & DE VOS, W. M. 2011. Global and deep 
molecular analysis of microbiota signatures in fecal samples from patients with 
irritable bowel syndrome. Gastroenterology, 141, 1792-801. 
RAMNANI, P., GAUDIER, E., BINGHAM, M., VAN BRUGGEN, P., TUOHY, K. 
M. & GIBSON, G. R. 2010. Prebiotic effect of fruit and vegetable shots 
65 
 
containing Jerusalem artichoke inulin: a human intervention study. Br J Nutr, 
104, 233-240. 
REA, M. C., DOBSON, A., O'SULLIVAN, O., CRISPIE, F., FOUHY, F., COTTER, 
P. D., SHANAHAN, F., KIELY, B., HILL, C. & ROSS, R. P. 2011. Effect of 
broad- and narrow-spectrum antimicrobials on Clostridium difficile and 
microbial diversity in a model of the distal colon. Proceedings of the National 
Academy of Sciences, 108, 4639-4644. 
REA, M. C., SIT, C. S., CLAYTON, E., O'CONNOR, P. M., WHITTAL, R. M., 
ZHENG, J., VEDERAS, J. C., ROSS, R. P. & HILL, C. 2010. Thuricin CD, a 
posttranslationally modified bacteriocin with a narrow spectrum of activity 
against Clostridium difficile. Proceedings of the National Academy of 
Sciences, 107, 9352-9357. 
RESPONDEK, F., SWANSON, K. S., BELSITO, K. R., VESTER, B. M., WAGNER, 
A., ISTASSE, L. & DIEZ, M. 2008. Short-chain fructooligosaccharides 
influence insulin sensitivity and gene expression of fat tissue in obese dogs. 
The Journal of nutrition, 138, 1712-1718. 
RIBOULET-BISSON, E., STURME, M. H. J., JEFFERY, I. B., O'DONNELL, M. 
M., NEVILLE, B. A., FORDE, B. M., CLAESSON, M. J., HARRIS, H., 
GARDINER, G. E., CASEY, P. G., LAWLOR, P. G., O'TOOLE, P. W. & 
ROSS, R. P. 2012. Effect of Lactobacillus salivarius Bacteriocin Abp118 on 
the Mouse and Pig Intestinal Microbiota. PLoS ONE, 7, e31113. 
RIDAURA, V. K., FAITH, J. J., REY, F. E., CHENG, J., DUNCAN, A. E., KAU, A. 
L., GRIFFIN, N. W., LOMBARD, V., HENRISSAT, B., BAIN, J. R., 
MUEHLBAUER, M. J., ILKAYEVA, O., SEMENKOVICH, C. F., FUNAI, 
K., HAYASHI, D. K., LYLE, B. J., MARTINI, M. C., URSELL, L. K., 
66 
 
CLEMENTE, J. C., VAN TREUREN, W., WALTERS, W. A., KNIGHT, R., 
NEWGARD, C. B., HEATH, A. C. & GORDON, J. I. 2013. Gut microbiota 
from twins discordant for obesity modulate metabolism in mice. Science, 341, 
1241214. 
RIJKERS, G. T., BENGMARK, S., ENCK, P., HALLER, D., HERZ, U., 
KALLIOMAKI, M., KUDO, S., LENOIR-WIJNKOOP, I., MERCENIER, A., 
MYLLYLUOMA, E., RABOT, S., RAFTER, J., SZAJEWSKA, H., WATZL, 
B., WELLS, J., WOLVERS, D. & ANTOINE, J. M. 2010. Guidance for 
substantiating the evidence for beneficial effects of probiotics: current status 
and recommendations for future research. J Nutr, 140, 671s-6s. 
RIORDAN, S. M. & KIM, R. 2006. Bacterial overgrowth as a cause of irritable bowel 
syndrome. Curr Opin Gastroenterol, 22, 669-73. 
ROBERFROID, M., GIBSON, G. R., HOYLES, L., MCCARTNEY, A. L., 
RASTALL, R., ROWLAND, I., WOLVERS, D., WATZL, B., SZAJEWSKA, 
H., STAHL, B., GUARNER, F., RESPONDEK, F., WHELAN, K., COXAM, 
V., DAVICCO, M. J., LEOTOING, L., WITTRANT, Y., DELZENNE, N. M., 
CANI, P. D., NEYRINCK, A. M. & MEHEUST, A. 2010. Prebiotic effects: 
metabolic and health benefits. Br J Nutr, 104 Suppl 2, S1-63. 
SAARELA, M., MOGENSEN, G., FONDÉN, R., MÄTTÖ, J. & MATTILA-
SANDHOLM, T. 2000. Probiotic bacteria: safety, functional and 
technological properties. Journal of Biotechnology, 84, 197-215. 
SCOTT, L. J., MOHLKE, K. L., BONNYCASTLE, L. L., WILLER, C. J., LI, Y., 
DUREN, W. L., ERDOS, M. R., STRINGHAM, H. M., CHINES, P. S., 
JACKSON, A. U., PROKUNINA-OLSSON, L., DING, C. J., SWIFT, A. J., 
NARISU, N., HU, T., PRUIM, R., XIAO, R., LI, X. Y., CONNEELY, K. N., 
67 
 
RIEBOW, N. L., SPRAU, A. G., TONG, M., WHITE, P. P., HETRICK, K. 
N., BARNHART, M. W., BARK, C. W., GOLDSTEIN, J. L., WATKINS, L., 
XIANG, F., SARAMIES, J., BUCHANAN, T. A., WATANABE, R. M., 
VALLE, T. T., KINNUNEN, L., ABECASIS, G. R., PUGH, E. W., 
DOHENY, K. F., BERGMAN, R. N., TUOMILEHTO, J., COLLINS, F. S. & 
BOEHNKE, M. 2007. A genome-wide association study of type 2 diabetes in 
Finns detects multiple susceptibility variants. Science, 316, 1341-5. 
SEKIROV, I., RUSSELL, S. L., ANTUNES, L. C. M. & FINLAY, B. B. 2010. Gut 
Microbiota in Health and Disease. Physiological Reviews, 90, 859-904. 
SELLON, R. K., TONKONOGY, S., SCHULTZ, M., DIELEMAN, L. A., 
GRENTHER, W., BALISH, E., RENNICK, D. M. & SARTOR, R. B. 1998. 
Resident enteric bacteria are necessary for development of spontaneous colitis 
and immune system activation in interleukin-10-deficient mice. Infection and 
immunity, 66, 5224-5231. 
SENDER, R., FUCHS, S. & MILO, R. 2016. Revised estimates for the number of 
human and bacteria cells in the body. bioRxiv. 
SINGH, M. & SAREEN, D. 2014. Novel LanT associated lantibiotic clusters 
identified by genome database mining. PLoS One, 9, e91352. 
SLAVIN, J. 2013. Fiber and Prebiotics: Mechanisms and Health Benefits. Nutrients, 
5, 1417-1435. 
SOKOL, H. & SEKSIK, P. 2010. The intestinal microbiota in inflammatory bowel 
diseases: time to connect with the host. Curr Opin Gastroenterol, 26, 327-31. 
SPEHLMANN, M. E., BEGUN, A. Z., BURGHARDT, J., LEPAGE, P., RAEDLER, 
A. & SCHREIBER, S. 2008. Epidemiology of inflammatory bowel disease in 
68 
 
a German twin cohort: results of a nationwide study. Inflammatory Bowel 
Diseases, 14, 968-976. 
SPRONG, R., SCHONEWILLE, A. & VAN DER MEER, R. 2010. Dietary cheese 
whey protein protects rats against mild dextran sulfate sodium–induced colitis: 
Role of mucin and microbiota. Journal of dairy science, 93, 1364-1371. 
TAHARA, T., YAMAMOTO, E., SUZUKI, H., MARUYAMA, R., CHUNG, W., 
GARRIGA, J., JELINEK, J., YAMANO, H. O., SUGAI, T., AN, B., 
SHUREIQI, I., TOYOTA, M., KONDO, Y., ESTECIO, M. R. & ISSA, J. P. 
2014. Fusobacterium in colonic flora and molecular features of colorectal 
carcinoma. Cancer Res. 
THE HUMAN MICROBIOME PROJECT CONSORTIUM 2012. Structure, function 
and diversity of the healthy human microbiome. Nature, 486, 207-14. 
TURNBAUGH, P. J., BÄCKHED, F., FULTON, L. & GORDON, J. I. 2008. Diet-
Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse 
Distal Gut Microbiome. Cell Host & Microbe, 3, 213-223. 
TURNBAUGH, P. J., LEY, R. E., MAHOWALD, M. A., MAGRINI, V., MARDIS, 
E. R. & GORDON, J. I. 2006. An obesity-associated gut microbiome with 
increased capacity for energy harvest. Nature, 444, 1027-31. 
TURNBAUGH, P. J., RIDAURA, V. K., FAITH, J. J., REY, F. E., KNIGHT, R. & 
GORDON, J. I. 2009. The Effect of Diet on the Human Gut Microbiome: A 
Metagenomic Analysis in Humanized Gnotobiotic Mice. Science 
Translational Medicine, 1, 6ra14. 
TVEDE, M. & RASK-MADSEN, J. 1989. Bacteriotherapy for chronic relapsing 
Clostridium difficile diarrhoea in six patients. Lancet, 1, 1156-60. 
69 
 
VAN HEEL, A. J., DE JONG, A., MONTALBAN-LOPEZ, M., KOK, J. & 
KUIPERS, O. P. 2013. BAGEL3: Automated identification of genes encoding 
bacteriocins and (non-)bactericidal posttranslationally modified peptides. 
Nucleic Acids Res, 41, W448-53. 
VAN KRAAIJ, C., M. DE VOS, W., J. SIEZEN, R. & P. KUIPERS, O. 1999. 
Lantibiotics: biosynthesis, mode of action and applications. Natural Product 
Reports, 16, 575-587. 
VEERAPPAN, G. R., BETTERIDGE, J. & YOUNG, P. E. 2012. Probiotics for the 
treatment of inflammatory bowel disease. Curr Gastroenterol Rep, 14, 324-
33. 
VIEIRA, A. T., TEIXEIRA, M. M. & MARTINS, F. S. 2013. The Role of Probiotics 
and Prebiotics in Inducing Gut Immunity. Front Immunol, 4, 445. 
VYAS, U. & RANGANATHAN, N. 2012. Probiotics, prebiotics, and synbiotics: gut 
and beyond. Gastroenterol Res Pract, 2012, 872716. 
WALIGORA-DUPRIET, A.-J., CAMPEOTTO, F., NICOLIS, I., BONET, A., 
SOULAINES, P., DUPONT, C. & BUTEL, M.-J. 2007. Effect of oligofructose 
supplementation on gut microflora and well-being in young children attending 
a day care centre. International journal of food microbiology, 113, 108-113. 
WALKER, A. W., DUNCAN, S. H., LEITCH, E. C. M., CHILD, M. W. & FLINT, 
H. J. 2005. pH and peptide supply can radically alter bacterial populations and 
short-chain fatty acid ratios within microbial communities from the human 
colon. Applied and environmental microbiology, 71, 3692-3700. 
WALSH, C. J., GUINANE, C. M., HILL, C., ROSS, R. P., O’TOOLE, P. W. & 
COTTER, P. D. 2015. In silico identification of bacteriocin gene clusters in 
70 
 
the gastrointestinal tract, based on the Human Microbiome Project’s reference 
genome database. BMC Microbiology, 15, 183. 
WALSH, C. J., GUINANE, C. M., O'TOOLE, P. W. & COTTER, P. D. 2014. 
Beneficial modulation of the gut microbiota. FEBS Lett, 588, 4120-30. 
WALSH, C. J., GUINANE, C. M., PW, O. T. & COTTER, P. D. 2017. A Profile 
Hidden Markov Model to investigate the distribution and frequency of LanB-
encoding lantibiotic modification genes in the human oral and gut microbiome. 
PeerJ, 5, e3254. 
WALSH, M. C., GARDINER, G. E., HART, O. M., LAWLOR, P. G., DALY, M., 
LYNCH, B., RICHERT, B. T., RADCLIFFE, S., GIBLIN, L. & HILL, C. 
2008. Predominance of a bacteriocin‐producing Lactobacillus salivarius 
component of a five‐strain probiotic in the porcine ileum and effects on host 
immune phenotype. FEMS microbiology ecology, 64, 317-327. 
WANG, T., CAI, G., QIU, Y., FEI, N., ZHANG, M., PANG, X., JIA, W., CAI, S. & 
ZHAO, L. 2012. Structural segregation of gut microbiota between colorectal 
cancer patients and healthy volunteers. Isme j, 6, 320-9. 
WARREN, C. A. & GUERRANT, R. L. 2011. Pathogenic C difficile is here (and 
everywhere) to stay. The Lancet, 377, 8-9. 
WEBER, T., BLIN, K., DUDDELA, S., KRUG, D., KIM, H. U., BRUCCOLERI, R., 
LEE, S. Y., FISCHBACH, M. A., MÜLLER, R., WOHLLEBEN, W., 
BREITLING, R., TAKANO, E. & MEDEMA, M. H. 2015. antiSMASH 3.0—
a comprehensive resource for the genome mining of biosynthetic gene clusters. 
Nucleic Acids Research, 43, W237-W243. 
71 
 
WELLCOME TRUST CASE CONTROL CONSORTIUM 2007. Genome-wide 
association study of 14,000 cases of seven common diseases and 3,000 shared 
controls. Nature, 447, 661-78. 
WU, G. D., CHEN, J., HOFFMANN, C., BITTINGER, K., CHEN, Y.-Y., 
KEILBAUGH, S. A., BEWTRA, M., KNIGHTS, D., WALTERS, W. A., 
KNIGHT, R., SINHA, R., GILROY, E., GUPTA, K., BALDASSANO, R., 
NESSEL, L., LI, H., BUSHMAN, F. D. & LEWIS, J. D. 2011. Linking Long-
Term Dietary Patterns with Gut Microbial Enterotypes. Science, 334, 105-108. 
YADAV, H., LEE, J. H., LLOYD, J., WALTER, P. & RANE, S. G. 2013. Beneficial 
metabolic effects of a probiotic via butyrate-induced GLP-1 hormone 
secretion. J Biol Chem, 288, 25088-97. 
ZEEVI, D., KOREM, T., ZMORA, N., ISRAELI, D., ROTHSCHILD, D., 
WEINBERGER, A., BEN-YACOV, O., LADOR, D., AVNIT-SAGI, T., 
LOTAN-POMPAN, M., SUEZ, J., MAHDI, J. A., MATOT, E., MALKA, G., 
KOSOWER, N., REIN, M., ZILBERMAN-SCHAPIRA, G., DOHNALOVA, 
L., PEVSNER-FISCHER, M., BIKOVSKY, R., HALPERN, Z., ELINAV, E. 
& SEGAL, E. 2015. Personalized Nutrition by Prediction of Glycemic 
Responses. Cell, 163, 1079-94. 
ZHANG, C., LI, S., YANG, L., HUANG, P., LI, W., WANG, S., ZHAO, G., ZHANG, 
M., PANG, X., YAN, Z., LIU, Y. & ZHAO, L. 2013. Structural modulation of 
gut microbiota in life-long calorie-restricted mice. Nat Commun, 4. 
ZHAO, X. & KUIPERS, O. P. 2016. Identification and classification of known and 
putative antimicrobial compounds produced by a wide variety of Bacillales 
species. BMC Genomics, 17, 882. 
72 
 
ZHENG, J., GÄNZLE, M. G., LIN, X. B., RUAN, L. & SUN, M. 2014. Diversity and 
dynamics of bacteriocins from human microbiome. Environmental 
Microbiology, 2133–2143. 
 
 
  
73 
 
Chapter 2 
In silico identification of bacteriocin gene clusters in the 
gastrointestinal tract, based on the Human Microbiome Project’s 
reference genome database 
Included as published in BMC Microbiology (doi: 10.1186/s12866-015-0515-4) 
 
 
 
74 
 
Abstract 
 
The human gut microbiota comprises approximately 100 trillion microbial cells which 
significantly impact many aspects of human physiology - including metabolism, 
nutrient absorption and immune function. Disturbances in this population have been 
implicated in many conditions and diseases, including obesity, type-2 diabetes and 
inflammatory bowel disease. This suggests that targeted manipulation or shaping of 
the gut microbiota has potential as a therapeutic tool for the prevention or treatment 
of these conditions. The gut is a rich source of antimicrobial/bacteriocin-producers 
with the potential to alter the intestinal communities in a beneficial way for human 
health. With this in mind, several studies have used traditional culture-dependent 
approaches to successfully identify bacteriocin-producers from the mammalian gut. In 
silico-based approaches to identify novel gene clusters are now also being utilised to 
take advantage of the vast amount of data currently being generated by next generation 
sequencing technologies. In this study, we employed an in silico screening approach 
to mine potential bacteriocin clusters in genome-sequenced isolates from the 
gastrointestinal tract (GIT). More specifically, the bacteriocin genome-mining tool 
BAGEL3 was used to identify potential bacteriocin producers in the genomes of the 
GIT subset of the Human Microbiome Project’s reference genome database. Each of 
the identified gene clusters were manually annotated and potential bacteriocin-
associated genes were evaluated. 
We identified 74 clusters of note from 59 unique members of the Firmicutes, 
Bacteroidetes, Actinobacteria, Fusobacteria and Synergistetes. The most commonly 
identified class of bacteriocin was the >10 kDa class, formerly known as 
bacteriolysins, followed by lantibiotics and sactipeptides.  
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Multiple bacteriocin gene clusters were identified in a dataset representative of the 
human gut microbiota. Interestingly, many of these were associated with species and 
genera which are not typically associated with bacteriocin production. 
 
Introduction 
 
Bacteriocins are ribosomally synthesized antimicrobial peptides produced by 
bacteria that are active against other bacteria, either within the same species (narrow 
spectrum) or across genera (broad spectrum), and to which the producing organism is 
immune by a specific immunity protein(s) (Cotter et al., 2005a). Some bacteriocins, 
most notably nisin, have a long history of use as preservatives in the food industry 
(Deegan et al., 2006) and these antimicrobials are also receiving increased attention 
as potential alternatives to antibiotics (Piper et al., 2009). 
The intestinal microbiota comprises a dynamic community with 100-1000 
phylotypes (Qin et al., 2010, Faith et al., 2013) playing an integral role in 
gastrointestinal (GI) health and disease (Clemente et al., 2012, Flint et al., 2012). As 
a consequence of advances in DNA sequencing technologies, there is now a clearer 
understanding of the composition of the GI microbiota and of associations between 
specific taxa with health and disease (Clemente et al., 2012, Karlsson et al., 2013). 
This knowledge can potentially be utilised through the modulation of the gut 
microbiota to address certain GI disorders (Kadooka et al., 2010, Xiao et al., 2014). 
Bacteriocins are ideal candidates with respect to the targeting of undesirable 
populations due to their generally low toxicity, high potency and, particularly in the 
case of gut-associated isolates, the possibility of in situ production (Cotter et al., 2013). 
There have been some notable proof of concept studies, such as the use of a 
representative of the sactibiotic group of bacteriocins, thuricin CD, to specifically 
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inhibit Clostridium difficile in a distal colon model, without significantly impacting 
on other members of the microbiota (Rea et al., 2011). Similarly, bacteriocin 
production by the probiotic Lactobacillus salivarius UCC118 was shown to be directly 
responsible for significantly protecting mice against Listeria monocytogenes infection 
(Corr et al., 2007). Bacteriocin production has also been investigated to assess the 
extent to which it can control weight gain as a consequence of changing the 
composition of the gut microbiota (Murphy et al., 2013, Riboulet-Bisson et al., 2012).  
There are a variety of strategies by which novel bacteriocin producers can be identified 
(Marsh et al., 2010). These can be broadly divided into traditional, culture-based 
approaches and newer, in silico-based, strategies. The latter take advantage of the vast 
amount of data generated by genome and metagenome sequencing projects and the 
fact that many features of bacteriocin gene clusters, and especially bacteriocin 
modification genes, are highly conserved. These modification genes encode enzymes 
responsible for the post-translational modification of Class 1 bacteriocins into their 
active forms. Other features common to bacteriocin gene clusters include specific 
immunity genes, ABC transporters for bacteriocin export, and leader cleavage 
peptidases for removing the leader sequence from the structural prepeptide (for a 
review  see Arnison et al. (Arnison et al., 2013)). To date, in silico bacteriocin 
screening strategies have led to the identification of many novel lantibiotic (Begley et 
al., 2009, Lawton et al., 2007, Marsh et al., 2010, Singh and Sareen, 2014, McClerren 
et al., 2006), microcin (Scholz et al., 2011) and sactibiotic (Murphy et al., 2011) gene 
clusters of interest. While in a number of instances standard BLAST-based approaches 
have been employed to identify such clusters, the BAGEL web-based bacteriocin 
mining tool (http://bagel.molgenrug.nl/) has been a particularly valuable resource (van 
Heel et al., 2013). BAGEL combines direct mining for the structural gene with indirect 
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mining for bacteriocin-associated genes. The latter is particularly useful for 
identifying peptides which undergo significant post-translational modification such as 
those observed in lantibiotics. The most recent iteration of this tool, BAGEL3 (van 
Heel et al., 2013), was recently used to evaluate the density and diversity of 
bacteriocins in the human microbiome (Zheng et al., 2014). A previous version of this 
software was, for example, used in the identification of the novel, two-peptide 
lantibiotic lichenicidin (Begley et al., 2009) and 24 putative novel lantibiotics from 
genomic data (Singh and Sareen, 2014). BAGEL3 classifies clusters in a manner 
consistent with the generally accepted approach of dividing bacteriocins on the basis 
of whether they are modified (class I) or unmodified/minimally modified (class II) 
(Cotter et al., 2005a, Cotter et al., 2013). The former can be sub-divided into a number 
of subclasses including the lantibiotics, sactibiotics, some microcins, bottromycins, 
and linear azol(in)e-containing peptides (LAPs) (Cotter et al., 2013, Arnison et al., 
2013). In addition, it also identifies antimicrobial proteins larger than 10 kDa in size 
(i.e. bacteriolysins, previously referred to as Class III).  
Among the large databases of microbiota data that can be screened using in 
silico approaches are those generated by the Human Microbiome Project (HMP). The 
HMP was established with the goals of characterising the human microbiome, 
elucidating its role in health and disease, and developing new tools and databases to 
aid researchers. Among the data generated by the HMP is a reference genome 
database, which is a collection of genome-sequences from species/strains isolated 
from a variety of human body sites (http://www.hmpdacc.org/). The gastrointestinal 
tract (GIT) subset of this reference genome database was chosen as the focus of this 
study, which aimed to find bacteriocin-producers with the potential to alter the 
composition of the gut microbiota in situ. Indeed, previous culture-based approaches 
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have shown the human gut is a rich reservoir of bacteriocin-producers (Rea et al., 
2010, Lakshminarayanan et al., 2013, O'Shea et al., 2009). Here we employ the 
bacteriocin genome-mining tool BAGEL3 to screen the GIT subset of the HMP 
reference genome database and identify 74 putative bacteriocin-encoding gene 
clusters (PBGCs) from 59 unique producers. 
 
Methods 
 
Initial screening of reference genomes for bacteriocin gene clusters 
 
The GIT subset (382 available sequences as of 20/11/2014) of the HMP’s reference 
genome database (http://www.hmpdacc.org/HMRGD/) was downloaded in multi-
FASTA format and both complete and draft genomes were screened for putative 
bacteriocin gene clusters using the web-version of BAGEL3 
(http://bagel2.molgenrug.nl/index.php/bagel3). 
 
Further investigation of individual gene clusters 
 
Approximately 20 kb of sequence data containing the gene/genes identified as being 
of potential interest by BAGEL3 were extracted and the sequences were manually 
annotated using the Artemis software (Rutherford et al., 2000). Predicted coding 
regions were analysed using the BlastP web server on NCBI 
(http://www.ncbi.nlm.nih/BLAST) and the nr database. The coding regions were also 
analysed for the presence of conserved domains and, where applicable, compared to 
previously described gene clusters using the Artemis Comparison Tool (ACT) (Carver 
et al., 2005). 
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Results and Discussion 
 
In silico screen for putative bacteriocin-encoding gene clusters 
 
The GIT subset of the HMP reference genome database contained 382 fully 
sequenced genomes. The bacteriocin mining software tool BAGEL3 initially 
identified 217 areas of interest (AOIs) from 130 unique putative producers (Table 1). 
Subsequent manual annotation and Blast analysis determined that 74 of these were 
PBGCs (Table 2). The remaining AOIs were eliminated following manual annotation 
due to the absence of key bacteriocin associated genes. However, we accept the 
possibility that these gene products may work in concert with other novel bacteriocin-
related genes encoded elsewhere on the genome. Selection of the 74 PBGCs was 
achieved based on the presence of bacteriocin-associated genes, arrangement of those 
genes in the AOI, and by overall similarity to previously described gene clusters. An 
overall breakdown of the 74 PBGCs according to phylum and predicted bacteriocin 
type can be seen in Figures 1A and 1B, respectively. The vast majority of PBGCs 
belonged to members of the Firmicutes and Proteobacteria phyla, and, in the latter 
case, Escherichia coli strains in particular. PBGCs were also identified in the 
Bacteroidetes, Actinobacteria, Fusobacteria and Synergistetes phyla. The most 
commonly identified clusters were > 10 kDa bacteriolysins followed by lantibiotics 
and sactipeptides (Figure 1). 
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Producer 
Bifidobacterium longum subsp. infantis JCM 1222 
Bifidobacterium sp. 12 1 47BFAA 
Collinsella stercoris DSM 13279 
Eggerthella sp. HGA1 
Propionibacterium sp. 5 U 42AFAA 
Bacteroides dorei DSM 17855 
Bacteroides fragilis 3 1 12 
Bacteroides sp. 2 1 16 
Bacteroides sp. 2 1 56FAA 
Bacteroides sp. 9 1 42FAA 
Bacteroides uniformis ATCC 8492 
Odoribacter laneus YIT 12061 
Anaerofustis stercorihominis DSM 17244 
Anaerotruncus colihominis DSM 17241 
Bacillus sp. 7 6 55CFAA CT2 
Blautia hansenii DSM 20583 
Butyrivibrio crossotus DSM 2876 
Catenibacterium mitsuokai DSM 15897 
Clostridiales sp. SSC 2 
Coprobacillus sp. 29 1 
Coprobacillus sp. 8 2 54BFAA 
Coprobacillus sp. D6 
Coprococcus catus GD 7 
Desulfitobacterium hafniense DP7 
Dorea formicigenerans 4 6 53AFAA 
Dorea longicatena DSM 13814 
Enterococcus faecalis PC1.1 
Enterococcus faecalis TX0104 
Enterococcus faecalis TX1302 
Enterococcus faecalis TX1341 
Enterococcus faecalis TX1342 
Enterococcus faecalis TX1346 
Enterococcus faecalis TX1467 
Enterococcus faecalis TX2134 
Enterococcus faecalis TX2137 
Enterococcus faecalis TX4244 
Enterococcus faecium PC41 
Enterococcus faecium TX1330 
Erysipelotrichaceae bacterium 3 1 53 
Erysipelotrichaceae bacterium 5 2 54FAA 
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Erysipelotrichaceae bacterium 6 1 45 
Eubacterium hallii DSM 3353 
Eubacterium siraeum DSM 15702 
Flavonifractor plautii ATCC 29863 
Holdemania filiformis DSM 12042 
Lachnospiraceae bacterium 2 1 46FAA 
Lachnospiraceae bacterium 2 1 58FAA 
Lachnospiraceae bacterium 3 1 57FAA CT1 
Lachnospiraceae bacterium 5 1 63FAA 
Lachnospiraceae bacterium 7 1 58FAA 
Lactobacillus acidophilus ATCC 4796 
Lactobacillus antri DSM 16041 
Lactobacillus brevis subsp. gravesensis ATCC 27305 
Lactobacillus delbrueckii subsp. lactis DSM 20072 
Lactobacillus helveticus DSM 20075 
Lactobacillus plantarum subsp. plantarum ATCC 14917 
Lactobacillus reuteri CF48 3A 
Lactobacillus reuteri JCM 1112 
Lactobacillus reuteri MM2 3 
Lactobacillus reuteri MM4 1A 
Lactobacillus reuteri SD2112 
Lactobacillus rhamnosus ATCC 21052 
Lactobacillus ultunensis DSM 16047 
Listeria innocua ATCC 33091 
Marvinbryantia formatexigens DSM 14469 
Paenibacillus sp. HGF7 contig00140 
Paenibacillus sp. HGF7 contig00161 
Paenibacillus sp. HGF7 contig00230 
Parvimonas micra ATCC 33270 
Pediococcus acidilactici 7 4 
Roseburia intestinalis L1 82 
Ruminococcus obeum A2 162 
Ruminococcus obeum ATCC 29174 
Ruminococcus sp. 5 1 39B FAA 
Ruminococcus sp. SR1 5 
Streptococcus anginosus 1 2 62CV 
Streptococcus infantarius subsp. infantarius ATCC BAA 102 
Streptococcus sp. 2 1 36FAA 
Fusobacterium sp. D12 
Fusobacterium ulcerans ATCC 49185 
Fusobacterium varium ATCC 27725 
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Arcobacter butzleri JV22 
Campylobacter upsaliensis JV21 
Citrobacter freundii 4 7 47CFAA 
Citrobacter sp. 30 2 
Citrobacter youngae ATCC 29220 
Desulfovibrio sp. 3 1 syn3 
Desulfovibrio sp. 6 1 46AFAA 
Edwardsiella tarda ATCC 23685 
Enterobacter cancerogenus ATCC 35316 
Enterobacter cloacae subsp. cloacae NCTC 9394 
Enterobacteriaceae bacterium 9 2 54FAA 
Escherichia coli 4 1 47FAA 
Escherichia coli MS 107 1 
Escherichia coli MS 110 3 
Escherichia coli MS 115 1 
Escherichia coli MS 116 1 
Escherichia coli MS 117 3 
Escherichia coli MS 119 7 
Escherichia coli MS 124 1 
Escherichia coli MS 146 1 
Escherichia coli MS 153 1 
Escherichia coli MS 16 3 
Escherichia coli MS 175 1 
Escherichia coli MS 185 1 
Escherichia coli MS 187 1 
Escherichia coli MS 196 1 
Escherichia coli MS 198 1 
Escherichia coli MS 200 1 
Escherichia coli MS 21 1 
Escherichia coli MS 45 1 
Escherichia coli MS 57 2 
Escherichia coli MS 69 1 
Escherichia coli MS 78 1 
Escherichia coli MS 79 10 
Escherichia coli MS 85 1 
Escherichia coli SE11 
Escherichia sp. 1 1 43 
Escherichia sp. 3 2 53FAA 
Escherichia sp. 4 1 40B 
Helicobacter bilis ATCC 43879 
Klebsiella sp. MS 92 3 
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Oxalobacter formigenes OXCC13 
Proteus penneri ATCC 35198 
Providencia alcalifaciens DSM 30120 
Providencia rettgeri DSM 1131 
Providencia rustigianii DSM 4541 
Yokenella regensburgei ATCC 43003 
Anaerobaculum hydrogeniformans ATCC BAA 1850 
Synergistes sp. 3 1 syn1 
 
Table 1. 130 unique putative producers identified by BAGEL3. 
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Potential Producer Phylum Class 
BAGEL3 
prediction 
Bifidobacterium longum subsp. infantis JCM 1222 Actinobacteria Lantibiotic Context 
Bifidobacterium sp. 12 1 47BFAA Actinobacteria Lantibiotic BLD_1648 
Eggerthella sp. HGA1 Actinobacteria >10 kDa Linocin M18 
Bacteroides dorei DSM 17855 Bacteroidetes Sactipeptide Context 
Bacteroides fragilis 3 1 12 Bacteroidetes Sactipeptide Context 
Bacteroides sp. 2 1 16 Bacteroidetes Lantibiotic Manual 
Bacteroides sp. 2 1 56FAA Bacteroidetes Unmodified Manual 
Bacteroides sp. 9 1 42FAA Bacteroidetes Sactipeptide Context 
Bacteroides uniformis ATCC 8492 Bacteroidetes Sactipeptide Context 
Anaerofustis stercorihominis DSM 17244 Firmicutes >10 kDa Linocin M18 
Bacillus sp. 7 6 55CFAA CT2 Firmicutes >10 kDa Colicin E9 
Bacillus sp. 7 6 55CFAA CT2 Firmicutes Lantibiotic Haloduracin 
Dorea formicigenerans 4 6 53AFAA Firmicutes Sactipeptide Context 
Enterococcus faecalis PC1.1 Firmicutes >10 kDa Enterolysin A 
Enterococcus faecalis TX1302 Firmicutes >10 kDa Enterolysin A 
Enterococcus faecalis TX1302 Firmicutes Lantibiotic Context 
Enterococcus faecalis TX1341 Firmicutes >10 kDa Enterolysin A 
Enterococcus faecalis TX1342 Firmicutes >10 kDa Enterolysin A 
Enterococcus faecalis TX1342 Firmicutes Lantibiotic Context 
Enterococcus faecalis TX1467 Firmicutes >10 kDa Enterolysin A 
Enterococcus faecalis TX1467 Firmicutes Lantibiotic Context 
Enterococcus faecalis TX2137 Firmicutes >10 kDa Enterolysin A 
Enterococcus faecalis TX2137 Firmicutes Lantibiotic Context 
Enterococcus faecalis TX4244 Firmicutes >10 kDa Enterolysin A 
Enterococcus faecalis TX4244 Firmicutes >10 kDa Enterolysin A 
Holdemania filiformis DSM 12042 Firmicutes >10 kDa Linocin M18 
Lactobacillus acidophilus ATCC 4796 Firmicutes >10 kDa Enterolysin A 
Lactobacillus acidophilus ATCC 4796 Firmicutes >10 kDa Helveticin J 
Lactobacillus antri DSM 16041 Firmicutes >10 kDa Enterolysin A 
Lactobacillus brevis subsp. gravesensis ATCC 27305 Firmicutes Unmodified Plantaricin NC8 
Lactobacillus delbrueckii subsp. lactis DSM 20072 Firmicutes >10 kDa Enterolysin A 
Lactobacillus helveticus DSM 20075 Firmicutes >10 kDa Helveticin J 
Lactobacillus helveticus DSM 20075 Firmicutes >10 kDa Helveticin J 
Lactobacillus ultunensis DSM 16047 Firmicutes >10 kDa Helveticin J 
Lactobacillus ultunensis DSM 16047 Firmicutes >10 kDa Enterolysin A 
Lactobacillus ultunensis DSM 16047 Firmicutes >10 kDa Helveticin J 
Listeria innocua ATCC 33091 Firmicutes LAP Context 
Marvinbryantia formatexigens DSM 14469 Firmicutes Sactipeptide Context 
Roseburia intestinalis L1 82 Firmicutes Sactipeptide Context 
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Ruminococcus obeum A2 162 Firmicutes Lantibiotic Context 
Ruminococcus sp. 5 1 39B FAA Firmicutes Lantibiotic Context 
Streptococcus anginosus 1 2 62CV Firmicutes Unmodified Multiple 
Streptococcus infantarius subsp. infantarius ATCC BAA 
102 Firmicutes Unmodified Multiple 
Streptococcus sp. 2 1 36FAA Firmicutes Class IIc Context 
Fusobacterium ulcerans ATCC 49185 Fusobacteria >10 kDa Linocin M18 
Fusobacterium varium ATCC 27725 Fusobacteria >10 kDa Linocin M18 
Arcobacter butzleri JV22 Proteobacteria >10 kDa Colicin E9 
Escherichia coli MS 110 3 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 110 3 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 119 7 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 124 1 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 146 1 Proteobacteria >10 kDa Linocin M18 
Escherichia coli MS 153 1 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 16 3 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 16 3 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 16 3 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 185 1 Proteobacteria >10 kDa Colicin E9 
Escherichia coli MS 196 1 Proteobacteria >10 kDa Colicin-10 
Escherichia coli MS 200 1 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 21 1 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 45 1 Proteobacteria Microcin Microcin H47 
Escherichia coli MS 45 1 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 57 2 Proteobacteria >10 kDa Colicin E9 
Escherichia coli MS 78 1 Proteobacteria >10 kDa Colicin 
Escherichia coli MS 85 1 Proteobacteria >10 kDa Colicin E9 
Escherichia coli SE11 Proteobacteria >10 kDa Colicin 
Escherichia sp. 3 2 53FAA Proteobacteria >10 kDa Colicin 
Klebsiella sp. MS 92 3 Proteobacteria >10 kDa Klebicin B 
Providencia rettgeri DSM 1131 Proteobacteria >10 kDa Colicin A 
Yokenella regensburgei ATCC 43003 Proteobacteria Microcin Context 
Anaerobaculum hydrogeniformans ATCC BAA 1850 Synergistetes >10 kDa Linocin M18 
Synergistes sp. 3 1 syn1 Synergistetes >10 kDa Linocin M18 
 
Table 2. Additional information on PBGCs and whether the initial identification of 
the AOI by BAGEL3 was based on the presence of bacteriocin-associated genes 
(context) or a specific bacteriocin structural gene.
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Figure 1. Frequency of (A) bacteriocin class and (B) producing phylum among the 74 
PBGCs identified. 
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Further analysis of PBGCs of particular interest 
 
63 PBGCs are described in the supplementary text (available online at 
https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-015-0515-4) and 
depicted in Figures 2, 3, 4. 11 PBGCs from 3 different phyla were deemed of particular 
interest and were selected for further in silico analysis based on the relative rarity with 
which bacteriocin production has been associated with the corresponding genus 
(Bacteroides and Roseburia), or on the probiotic potential of strains from the genus 
(Bifidobacterium) or due to the importance/perceived importance of the genus in a gut 
environment (Bacteroides, Roseburia, Ruminococcus) (Figure 5).  
 
Identification of novel PBGCs in bifidobacteria 
 
Bifidobacteria are an important group of human gut commensal bacteria, accounting 
for between 3 and 7% of the gut microbiota in adults and up to 91% in newborns 
(Cheikhyoussef et al., 2009). Members of this genus have a long history of use as 
health-promoting/probiotic strains due to traits such as the regulation of intestinal 
microbial homeostasis, the inhibition of pathogens, the modulation of local and 
systemic immune responses, the maintenance of gastrointestinal barrier function, the 
production of vitamins and the bioconversion of a number of dietary compounds into 
bioactive molecules (Mayo and van Sinderen, 2010). Bifidobacteria have the potential 
to suppress the growth of both Gram-negative and Gram-positive bacteria but, to date, 
this activity has been more often attributed to the inhibitory action of organic acids 
rather than bacteriocin production (Martinez et al., 2013, Fukuda et al., 2011). For a 
review of the relatively rare examples of bacteriocin production by bifidobacteria see  
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Figure 2. Diagrammatic representation of remaining PBGCs identified in the 
Actinobacteria, Fusobacteria and Synergistetes phyla. 
  
Eggerthella sp. HGA1
Fusobacterium ulcerans ATCC 49185 
Fusobacterium varium ATCC 27725 
Anaerobaculum hyfrogeniformans ATCC BAA 1850 
Synergistes sp. 3_1_syn1 
Immunity / transport
Modification
Leader CleavageTransport and leader cleavage
Bacteriocin / modified pepitde Hypothetical protein / undefined 
association
Regulation
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
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Anaerofustis stercorihominis DSM 17244
Bacillus sp 7 6 55CFAA CT2
Dorea formicigenerans 4 6 53AFAA
Enterococcus faecalis PC1.1
Enterococcus faecalis TX1302
Enterococcus faecalis TX1341
Enterococcus faecalis TX1342
Enterococcus faecalis TX1467
Enterococcus faecalis TX2137
Enterococcus faecalis TX4244
Holdemania filiformis DSM 12042 
Listeria innocua ATCC 33091
Marvinbryantia formatexigens DSM 14469
> 10 kDa
> 10 kDa
Lantibiotic
Sactibiotic
> 10 kDa
> 10 kDa
Lantibiotic
> 10 kDa
> 10 kDa
Lantibiotic
Lantibiotic
> 10 kDa
> 10 kDa
Lantibiotic
> 10 kDa
> 10 kDa
> 10 kDa
LAP
Sactibiotic
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Figure 3. Diagrammatic representation of remaining PBGCs identified in the 
Firmicutes phylum. 
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Escherichia coli MS_110_3
Escherichia coli MS_117_3
Escherichia coli MS_119_7
Escherichia coli MS_124_1
Escherichia coli MS_146_1
Escherichia coli MS_153_1
Escherichia coli MS_16_3
Escherichia coli MS_185_1
Escherichia coli MS_196_1
Escherichia coli MS_200_1
Escherichia coli MS_21_1
Escherichia coli MS_45_1
Escherichia coli MS_57_2
> 10 kDa
Microcin
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
> 10 kDa
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Figure 4. Diagrammatic representation of remaining PBGCs identified in the 
Proteobacteria phylum 
  
Arcobacter butzleri JV22
Klebsiella sp. MS 92 3
Providencia rettgeri DSM 1131
Yokenella regensburgei ATCC 43003
Immunity / transport
Modification
Leader CleavageTransport and leader cleavage
Bacteriocin / modified pepitde Hypothetical protein / undefined 
association
Regulation
Escherichia coli MS_78_1
Escherichia coli MS_85_1
Escherichia coli SE11
Escherichia sp. 3_2_53FAA
> 10 kDa
> 10 kDa
> 10 kDa
Microcin
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Figure 5. Diagrammatic representation of PBGCs deemed of particular interest. 
  
Bifidobacterium longum
subsp. infantis ATCC 156997
Bifidobacterium sp. 
12_1_47BFAA 
Bacteroides dorei DSM 17855
Bacteroides fragilis 3_1_12 
Bacteroides sp. 2_1_16 
Bacteroides sp. 2_1_56FAA 
Bacteroides uniformis ATCC 8492 
Ruminococcus sp. 5 1 39B FAA
Ruminococcus obeum
ATCC 29174
Roseburia intestinalis L1-82
Immunity / transport
Modification
Leader CleavageTransport and leader cleavage
Bacteriocin / modified pepitde Hypothetical protein / undefined 
association
Regulation
Lantibiotic
Lantibiotic
Sactibiotic
Sactibiotic
Sactibiotic
Unmodified
Sactibiotic
Bacteroides sp. 9_1_42FAA 
Sactibiotic
Lantibiotic
Lantibiotic
Sactibiotic
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Martinez et al. (Martinez et al., 2013). Our in silico screen identified PBGCs of note 
in Bifidobacterium longum subsp. infantis ATCC 15697 and Bifidobacterium sp. 
12_1_47BFA (Figure 5). 
 
Bifidobacterium longum subsp. infantis ATCC 15697 was isolated from 
human infant faeces and sequenced by the Joint Genome Institute (JGI) (Sela et al., 
2008, Reuter, 1971). A previous study has shown that this strain has the ability to 
reduce the levels of plasma endotoxins via modulation of the gut microbiota. However 
the authors concluded that the effect was mediated by increased levels of faecal 
organic acids  (Rodes et al., 2014). The cluster of six genes identified are predicted to 
encode a LanL-type lantipeptide based on the presence of a LanL-type lanthionine 
synthetase gene. More specifically, the 8,139 bp cluster contains several lantibiotic-
related genes including a putative lanthionine synthetase (conserved domain 
pfam05147 3.10e-10), a putative oligopeptidase (conserved domain pfam00326 5.24e-
08) and a putative ABC transporter containing ATP-binding and permease subunits 
(conserved domains cd03255 and pfam02867 respectively). The cluster also contained 
a two-component regulatory system consisting of a putative histidine kinase 
(conserved domain CGO4585 6.70e-18) and a putative transcriptional response 
regulator (conserved domain COG2197 8.85e-57). 
 
Bifidobacterium sp. 12_1_47BFA was recovered from inflamed biopsy tissue 
from a 25-year-old female patient with Crohn's disease and its genome was found to 
contain a 7,996 bp lantibiotic cluster comprising six genes (Figure 5). A putative 
lantibiotic prepeptide LanA was found to be similar to BLD_1648 (BAGEL3 
bacteriocin I database 4e-43), a feature that was further supported by manual 
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annotation (conserved domain TIGR03893 6.47e-9). Also present in the area of 
interest was a putative LanM lantibiotic biosynthesis protein (conserved domain 
cd04792 0.0), a putative multidrug ABC transporter ATP-binding protein putatively 
involved in lantibiotic immunity (conserved domain cd03230 8.53e-42) and an ABC-
type bacteriocin/lantibiotic exporter (conserved domain COG2274 7.59e-145) 
significantly similar (BlastP 4e-117) to the crnT protein responsible for transport and 
leader cleavage of the bacteriocin carnolysin (Tulini et al., 2014). The area of interest 
also contained a FMN-dependent reductase (conserved domain pfam03358 5.13e-09) 
similar to that located within the carnolysin-associated crnJ protein (Tulini et al., 
2014). This family of proteins has been suggested to be an atypical lantibiotic post-
translational modification protein (Cotter et al., 2005b, Singh and Sareen, 2014). 
 
Identification of novel PBGCs in Bacteroides spp. 
 
Bacteroides are Gram-negative, non-spore-forming, obligate anaerobes and 
near universal constituents of the human gut microbiota, especially prevalent in those 
individuals whose long-term diets are rich in protein and animal fat (Wu et al., 2011). 
Translocation from the GIT can however result, in some cases, in bacteraemia and 
abscess formation (Wexler, 2007). Weight loss in obese humans subjected to dietary 
or surgical intervention has been associated with increased relative abundance in the 
phylum Bacteroidetes, with specific members including Bacteroides spp., 
Bacteroides-Prevotella spp. or the Bacteroides fragilis group bacteria having been 
associated with this phenomenon (Furet et al., 2010, Nadal et al., 2009, Santacruz et 
al., 2009, Santacruz et al., 2010). Despite their importance as a human gut commensal, 
there have been relatively few reports of bacteriocin production by members of the 
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Bacteroides to date (Avelar et al., 1999, Booth et al., 1977, Mossie et al., 1979, Nakano 
et al., 2006). In this study, six PBGCs were identified in Bacteroides strains that 
possessed features typical of sactipeptide (4), lantibiotic (1) or unmodified bacteriocin 
(1) clusters.  
 
Bacteroides dorei has been observed to be common in patients with active 
coeliac disease and it has also been proposed that the species be used as an indicator 
of water contamination by human faecal material (Shanks et al., 2014, Sánchez et al., 
2010). B. dorei DSM 17855 was isolated from a healthy, 23 year old, Japanese male 
(Bakir et al., 2006) and its genome was found to contain a five gene, 5,711 bp 
sactipeptide-like gene cluster (Figure 5). The cluster contained genes encoding a 
putative ABC-type transporter ATP-binding protein (BlastP 0.0, conserved domain 
COG2274 3.02e-34), a putative hemolysin secretion protein HlyD (BlastP 0.0), a 
structural gene belonging to pfam family pf10439 (Bacteriocin class II with double-
glycine leader peptide), a radical SAM domain-containing protein hypothesised to be 
involved in peptide modification (conserved domain TIGR03962 1.46e-06) and a 
putative bacteriocin-associated C39 family peptidase (conserved domain pfam03412 
1.13e-11). The latter may be involved in transport across the membrane in addition to 
leader cleavage, either alone or in conjunction with HlyD.  
 
Bacteroides fragilis-produced metabolites are important in the activation and 
regulation of the T-cell-dependent immune response (Mazmanian et al., 2008, Wexler, 
2007) and its administration as a therapeutic has been proposed for gastrointestinal 
and behavioural symptoms associated with human neurodevelopmental disorders 
(Hsiao et al., 2013). The genome of B. fragilis 3_1_12 found to contain a four gene, 
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4267 bp sactipeptide-like cluster (Figure 5). The putative structural gene belongs to 
pfam family PF14406 (Ribosomally synthesized peptide in Bacteroidetes) and BlastP 
identified it as a putative bacteriocin-type signal sequence containing a predicted 
leader sequence associated with peptide modification (conserved domain TIGR04149 
1.34e-12). Immediately downstream is a putative lipoprotein belong to pfam family 
PF08139 followed by a pair of putative radical SAM proteins, predicted to be involved 
in peptide modification. These radical SAM proteins, members of families 
TIGR04085 and TIGR04150, respectively, are known to occur in cassettes together 
with the bacteriocin signal sequence noted above (Haft and Basu, 2011). 
 
Bacteroides sp. 2_1_16 was isolated from a healthy biopsy of the descending 
colon of a 58-year old female patient undergoing colonoscopy its  genome was found 
to contain a 4,167 bp, three-gene cluster predicted to be sactipeptide-encoding based 
on the presence of a SacCD homolog (Figure 5). However, manual annotation also 
revealed a cluster of several genes with homology with those typically associated with 
lantibiotic production. Specifically, the cluster contained a putative LanC-like 
lanthionine synthetase (conserved domain cd04793 6.02e-08), a putative ABC 
transporter predicted to be a bacteriocin/lantibiotic transporter based on conserved 
domains (COG2274 0.0) and a putative ABC transporter secretion protein closely 
related to hemolysin secretors (conserved domain TIGR01843 1.86e-22). However, a 
putative structural peptide-encoding gene could not be identified in this gene cluster. 
 
The genome of Bacteroides sp. 2_1_56FAA was found to possess a 6,069 bp 
cluster containing five genes of note (Figure 5). Manual annotation revealed a gene 
predicted to encode a ribosomally synthesised peptide (pfam PF14406 0.00024 (Iyer 
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et al., 2009)), located immediately upstream of a putative CAAX protease self-
immunity family determinant (conserved domain pfam02517 8.17e-11). A gene 
encoding a putative ABC transporter containing a C39B peptidase domain (COG2274 
7.75e-159), predicted to be responsible for transport and leader cleavage, was also 
present. Two additional possible transport genes were identified immediately 
downstream, both putative hemolysin secretion proteins (conserved domain 
pfam13437 5.74e-09 and conserved domain pfam13437 5.37e-11, respectively). The 
lack of any bacteriocin-modification genes suggests that this cluster encodes an 
unmodified bacteriocin. 
 
Bacteroides sp. 9_1_42FAA was isolated from the duodenum of a 47 year old 
female patient and its genome contained a 5,714 bp area of interest comprised of five 
genes, This cluster was identified as a potential sactipeptide based on the presence of 
a SacCD homolog (Figure 5). The structural peptide putatively encoded within this 
cluster also possesses features associated with pfam family PF10439.4 i.e. unmodified 
subclass IIc bacteriocins. The area of interest also contains a putative ABC-type 
bacteriocin/lantibiotic exporter (contains conserved domain COG2274 0.0), a putative 
hemolysin secretion family protein (conserved domain TIGR01843 3.45e-06), a 
putative radical SAM peptide modification protein (conserved domain TIGR03962 
1.47e-17), and a putative bacteriocin transporter containing an endopeptidase C39 
domain (potentially involved in bacteriocin preprocessing; conserved domain 
pfam03412 1.13e-11) (Havarstein et al., 1995). This sequence exhibited very high 
(99%) nucleotide identity to the aforementioned gene cluster in B. dorei DSM 17855. 
This similarity includes structural genes with 100% amino acid sequence identity. 
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It has been previously documented that orally administering Bacteroides 
uniformis (strain CECT 7771) ameliorated high fat diet-induced metabolic and 
immune dysfunction associated with an altered gut microbiota in adult C57BL-6 mice 
(Gauffin Cano et al., 2012). Inspection of the genome of B. uniformis ATCC 8492 
revealed a 7,976 bp, five-gene sactipeptide-like cluster (Figure 5). Manual annotation 
identified a putative bacteriocin-type signal sequence containing a conserved 
TIGR04149 domain (7.43e-09). The area of interest also contained a pair of putative 
peptide-modifying radical SAM proteins (conserved domains TIGR04148 and 
TIGR04150 respectively) similar to those in B. fragilis 3_1_12 that were referred to 
above, a putative ABC-type bacteriocin exporter (conserved domain COG2274 0.0) 
and a putative hemolysin secretion protein (conserved domain pfam13437 1.02e-16). 
 
Identification of novel PBGCs in Ruminococcus spp. 
 
Ruminococci are Gram-positive anaerobes commonly found in the human gut, 
where they have been proposed to play a pivotal role in the fermentation of resistant 
starch (Ze et al., 2012). There have been several previous reports of bacteriocin 
production by members of the ruminococci, including a class IIa lantibiotic, 
ruminococcin A, produced by Ruminococcus gnavus E1 and two distinct class III 
bacteriocins produced by Ruminococcus albus 7 (Chen et al., 2004, Dabard et al., 
2001, Wang et al., 2012a). We identified two apparently novel Ruminococcus-
associated PBGCs, from among a total of 35 Firmicutes-associated clusters. 
 
The genome of Ruminococcus sp. 5_1_39_B_FAA contained a 13,553 bp 
lantibiotic-like cluster containing six genes (Figure 5). The cluster contained a putative 
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response regulator receiver protein (conserved domain COG3279 3.95e-24), a putative 
histidine kinase (conserved domain pfam14501 3.5e-20), a putative type 2 lantibiotic 
biosynthesis protein LanM (conserved domain TIGR03897 0.0), a putative UviB-like 
bacteriocin (BAGEL3 bacteriocin II database 3e-11), a putative ABC transporter 
ATP-binding protein (conserved domain COG1136 8.20e-111) and a putative efflux 
ABC transporter permease protein.  
 
Strains of Ruminococcus obeum have been shown to restrict Vibrio cholerae 
infection via a quorum-sensing-mediated mechanism (Hsiao et al., 2014). 
Ruminococcus obeum ATCC 29174 was isolated from human faeces and sequenced 
by the Washington University Genome Sequencing Centre. A 8,879 bp lantibiotic-like 
cluster comprising six genes was identified (Figure 5). The putative structural gene 
was found to resemble geobacillin I (BAGEL3 bacteriocin I database 5e-12), a nisin 
homolog isolated from Geobacillus thermodenitrificans (Garg et al., 2012). Also 
present in the area of interest were genes that appear to encode a two-component 
regulatory system, consisting of a putative histidine kinase (conserved domain 
COG0642 1.84e-24) and a putative NisR homolog containing signal receiver and 
effector domains (cd00156 and cd00383 respectively). Furthermore, genes potentially 
enoding a lantibiotic dehydratase similar to the entianin (lantibiotic) modification 
protein EtnB (BlastP 0.0) (Fuchs et al., 2011), an ABC transport protein similar to 
SpaT (transportation of the lantibiotic subtilin; BlastP 0.0) and a lanthionine 
synthetase protein similar to SpaC (modification of subtilin; BlastP 6e-117) were 
identified. 
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Identification of a novel PBGC in Roseburia spp. 
 
Roseburia is a genus of Gram positive, butyrate-producers found to be 
negatively associated with type 2 diabetes and ulcerative colitis (Machiels et al., 2014, 
Qin et al., 2012). It has also been linked with ameliorating high-fat diet induced 
metabolic alterations in mice (Neyrinck et al., 2012). The only  Roseburia-associated 
bacteriocin-producer to have been identified to date is Roseburia faecis M72/1 
(Hatziioanou et al., 2013). Roseburia intestinalis L1-82, the type strain, was found to 
contain a five gene, 6078 bp sactipeptide-like cluster (Figure 5). The area of interest 
contained a putative bacteriocin-associated radical SAM protein (conversed domain 
TIGR04068 0.0), a putative peptide maturation system protein (conserved domain 
TIGR04066 8.58e-165), a putative peptide maturation system acyl carrier-related 
protein (conserved domain TIGR04069 1.15e-29), a subtilase family serine protease 
(conserved domain cd07492 7.11e-40) and a putative ABC transporter (conserved 
domain cd03228 5.95e-65). However, there were no immediately obvious bacteriocin 
structural or immunity genes in the area of interest and so it is particularly unclear if 
this cluster has the potential to produce an antimicrobial. 
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Conclusions 
 
The large number of fully sequenced genomes available in public repositories 
means that genome-mining approaches are increasingly valuable with respect to the 
identification of novel genes and gene clusters (Eustaquio et al., 2011, Velásquez and 
van der Donk, 2011, Chen et al., 2014). As it has already been established that in silico 
approaches can be applied to the human microbiome for the purpose of identifying 
antimicrobial-producing microorganisms (Zheng et al., 2014, Donia et al., 2014), and 
that bacteriocins identified in this manner can be produced in vitro (Begley et al., 
2009), it is apparent that there are considerable potential benefits in screening for and 
harnessing putative bacteriocin gene clusters from such databases. 
It is commonly reported that between 30 and 99% of bacteria have the potential 
to produce at least one bacteriocin (Klaenhammer, 1988, Riley, 1998). It is thus 
notable that this in silico-based study identified just 59 genomes encoding probable 
PBGCs from 382 reference genomes, a frequency of just 15.4%. It is unclear whether 
this low number is representative of bacteriocin-production in the human GIT or an 
underestimation due to biases in identification of gene clusters. In support of the 
former of these theories, a recent study on the human microbiome by Zheng et al. 
reported that the gut contained the lowest density of putative bacteriocin genes of all 
body sites investigated (Zheng et al., 2014). That study identified 123 putative 
lantibiotic, 56 putative class II bacteriocin and 148 putative class III bacteriocin gene 
clusters in the gut environment. However sactipeptide-like clusters were not reported 
by Zheng et al. (Zheng et al., 2014).  The discrepancy between the results reported by 
this study and those reported by Zheng et al. can be explained by differences in 
methodology. This method used BAGEL3 for the initial analysis while Zheng et al. 
performed a PSI-BLAST-based approach using the amino acid sequences from the 
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BAGEL3 bacteriocin database as driver sequences. Furthermore, we manually 
annotated the potential clusters returned initially, resulting in a dramatic decrease in 
reported PBGCs. It is noteworthy that in silico screens are limited by their dependence 
on similarity to previously described bacteriocin-associated genes, meaning that is it 
possible to overlook completely novel bacteriocin clusters. 
The vast majority of known/characterised lantibiotics are produced by 
members of the Firmicutes (Li and O'Sullivan, 2012). Similarly, of the 11 lantibiotics 
PBGCs identified in this study, seven were found in the genomes of Firmicutes, with 
two associated with bifidobacteria (Actinobacteria) and two by Bacteroides spp. 
(Bacteroidetes). While these clusters typically contained features that are common to 
lantibiotic-associated gene clusters, two putative lantibiotic clusters (in 
Bifidobacterium sp. 12_1_47BFAA and Enterococcus faecalis TX1342 (Figures 5 and 
3 respectively)) contained predicted FMN reductase genes in addition to those more 
traditionally associated with lantibiotic modification.  
It is apparent that the in silico screen identified gene clusters representative of 
some classes of bacteriocin more frequently than others. Clusters resembling those 
associated with the production of bacteriolysins (formerly referred to as class III 
bacteriocins) were most common. The large numbers of colicin-like and enterolysin 
A-like clusters was possibly due to the overrepresentation of E. coli in the reference 
genome database and the relative ease of detection. It appears that enterolysin A does 
not possess a specific immunity gene; instead, resistance results from the absence of 
specific binding receptors (Mendez-Vilas and Antonio, 2011), making this single gene 
potentially easier to detect than a multi-gene operon. On the other hand, the relatively 
low frequency of class II bacteriocins (three unmodified and one class IIc) cannot be 
explained in a similar manner. It is unclear whether this paucity is due to the 
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methodology or an actual scarcity of class II bacteriocin producers in the gut 
microbiota. Comparatively, Zheng et al. identified 56 class II bacteriocin structural 
genes from gut-associated strains (Zheng et al., 2014) suggesting that either this is an 
overestimation due to the lack of manual annotation or the approach used in this study 
is not ideal for the identification of Class II bacteriocins. 
This comprehensive in silico study led to the identification of PBGCs in 
species that not previously associated with bacteriocin production, for example 
Bacteroides uniformis and Roseburia intestinalis. We also identified potential 
bacteriocin gene clusters in two Bifidobacterium species, a genus which has long been 
thought of as beneficial to the human host. It is not possible, by in silico methods 
alone, to state conclusively if these bacteriocins are produced in vitro. However, if 
even a portion of these gene clusters are responsible for bacteriocin production in the 
corresponding strain, it could greatly expand the arsenal of bacteriocins available for 
use in food and healthcare. Such investigations will be the focus of our future 
investigations. 
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A Profile Hidden Markov Model to investigate the 
distribution and frequency of LanB-encoding lantibiotic 
modification genes in the human oral and gut microbiome 
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Abstract 
 
The human microbiota plays a key role in health and disease, and bacteriocins, 
which are small, bacterially produced, antimicrobial peptides, are likely to have an 
important function in the stability and dynamics of this community. Here we examined 
the density and distribution of the subclass I lantibiotic modification protein, LanB, in 
human oral and stool microbiome datasets using a specially constructed profile Hidden 
Markov Model (HMM). 
The model was validated by correctly identifying known lanB genes in the 
genomes of known bacteriocin producers more effectively than other methods, while 
being sensitive enough to differentiate between different subclasses of lantibiotic 
modification proteins. This approach was compared with two existing methods to 
screen both genomic and metagenomic datasets obtained from the Human Microbiome 
Project (HMP). 
Of the methods evaluated, the new profile HMM identified the greatest number 
of putative LanB proteins in the stool and oral metagenome data while BlastP 
identified the fewest. In addition, the model identified more LanB proteins than a pre-
existing Pfam lanthionine dehydratase model. Searching the gastrointestinal tract 
subset of the HMP reference genome database with the new HMM identified seven 
putative subclass I lantibiotic producers, including two members of the Coprobacillus 
genus. 
These findings establish custom profile HMMs as a potentially powerful tool 
in the search for novel bioactive producers with the power to benefit human health, 
and reinforce the repertoire of apparent bacteriocin-encoding gene clusters that may 
have been overlooked by culture-dependent mining efforts to date. 
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Introduction 
 
Bacteriocins are ribosomally synthesised peptides produced by bacteria that 
inhibit the growth of other bacteria. Some classes of bacteriocins are post-
translationally modified to provide structures beyond those possible by ribosomal 
translation alone. These modifications are typically key to the peptide’s functionality, 
stability and target recognition (Arnison et al. 2013). Class I bacteriocins, also known 
as lantibiotics, are one such class of small (<5 kDa) modified bacteriocins, possessing 
the characteristic thioester amino acids lanthionine or methyllanthionine (Perez et al. 
2014). Lantibiotics form a subgroup within the larger lantipeptide family, which also 
includes peptides that lack antimicrobial activity. Lantipeptides can be divided into 
four different subclasses (I – IV) based on the distinct biosynthetic enzymes 
responsible for their posttranslational modification (Arnison et al. 2013). 
The most commonly studied lantibiotic, Nisin, is a subclass I lantibiotic, 
meaning that the linear prepeptide is processed by a LanBC modification system 
(Arnison et al. 2013). The core peptide undergoes a two-step posttranslational 
modification catalysed by two distinct enzymes - the dehydratase LanB and the 
cyclase LanC (Xie & van der Donk 2004). The leader sequence, necessary for 
recognition by the modification enzymes in the two previous steps, is then removed 
by the protease LanP to produce the active lantibiotic (Xie & van der Donk 2004). The 
operon-encoded nature of bacteriocins and bacteriocin-like peptides makes them ideal 
candidates for genome mining. In the case of modified bacteriocins, the structural 
prepeptide coding sequence often appears alongside the genes encoding proteins 
responsible for its modification and export from the cell. However, as more 
bacteriocins are discovered, the heterogeneous nature of these prepeptides is becoming 
ever more apparent. This diversity, coupled with their small sequence length, makes 
149 
 
bacteriocin prepeptides much more difficult to detect using sequence-homology based 
searches like BLAST (Altschul et al. 1990). In an effort to address these obstacles, 
shifting the focus to the detection of bacteriocin-associated proteins opens up more 
avenues of discovery than simply searching for prepeptide homologs. This provides 
opportunities to better determine the frequency with which specific types of 
bacteriocin gene clusters can be found in different environmental niches, such as the 
human microbiota, through the investigation of metagenomic data. 
It has been estimated that the human microbiota comprises approximately 100 
trillion bacterial cells, outnumbering our own cells by a factor of 10 or more (Bäckhed 
et al. 2005). A recent publication, however, has argued that the ratio is actually more 
likely to be one-to-one, with the numbers being similar enough that each defecation 
event may alter the ratio to favour human cells over bacteria (Sender et al. 2016). Of 
greater consequence than bacterial numbers, however, is the collection of genes 
encoded in this metagenome, thought to be approximately 150 times larger than that 
of the human genome, with a functional potential far broader than that of its host (Qin 
et al. 2010). Regardless of absolute numbers, this dynamic community is thought to 
contain 100-1000 phylotypes (Faith et al. 2013; Qin et al. 2010) and play an integral 
role in human health and disease (Clemente et al. 2012; Flint et al. 2012). The human 
microbiota exhibits robust temporal stability (Belstrøm et al. 2016; Jeffery et al. 2016) 
perhaps due, in part, to the protection against invading bacteria conferred by 
bacteriocins and other antimicrobials produced in situ (Corr et al. 2007; Moroni et al. 
2006; Rea et al. 2011a). As such, investigation of the density and diversity of 
bacteriocins produced in the microbiome of healthy individuals may shed light on 
beneficial and harmful members of this community, and key organisms for 
maintaining typical, i.e. health-associated, microbiota composition. 
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Mining the human microbiota, especially for antimicrobial compounds, has 
become a popular area of research in recent years (Donia et al. 2014; Walsh et al. 
2015). Due to the availability of metagenomic data generated by large public funding 
initiatives such as the Human Microbiome Project in the U.S. (The Human 
Microbiome Project Consortium 2012) and the European MetaHIT consortium 
(Dusko Ehrlich 2010), in silico mining of data has emerged as a new tool that has the 
potential to identify antimicrobial-producing probiotics that can modulate the gut 
microbiota (Erejuwa et al. 2014; Walsh et al. 2014), or address the increasingly serious 
threat to public health caused by antimicrobial resistance. There are many available 
tools for mining the microbiome for antimicrobials, including BAGEL3 (van Heel et 
al. 2013), antiSMASH (Weber et al. 2015), and traditional sequence-based approaches 
like BLAST (Altschul et al. 1990). A feature commonly integrated into these tools are 
Hidden Markov Models (HMM) (Morton et al. 2015; van Heel et al. 2013; Weber et 
al. 2015), a statistical method often used to model biological data such as speech 
recognition, disease interaction and changes in gene expression in cancer (Gales & 
Young 2007; Seifert et al. 2014; Sherlock et al. 2013). Profile HMMs, a specific subset 
of HMMs, represent the patterns, motifs and other properties of a multiple sequence 
alignment by applying a statistical model to estimate the true frequency of a nucleotide 
or amino acid at a given position in the alignment from its observed frequency (Yoon 
2009). Profile HMMs differ from general HMMs as they move strictly from left to 
right along the alignment and do not contain any cycles, a feature that makes them 
suitable for modelling nucleotide and protein sequence data, and have been notably 
utilized to detect viral protein sequences in metagenomic sequence data (Skewes-Cox 
et al. 2014). For each column in the multiple sequence alignment, the profile uses one 
of three types of hidden state -  a match state, an insert state, or a delete state, to 
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describe residue frequencies, insertions, and deletions, respectively (Yoon 2009). 
Profile HMMs are potentially more sensitive than sequence homology approaches for 
identifying more distantly related proteins as they focus on function-dependent 
conserved motifs that are theoretically slower-evolving, as opposed to focusing on 
overall sequence similarity. Indeed, profile HMMs are known to typically outperform 
pairwise sequence comparison methods (such as BLAST) in the detection of distant 
homologs (Park et al. 1998), at the cost of greater computational requirements – 
particularly in alignment scoring and E-value calculation (Madera & Gough 2002). 
Correspondingly, speed is the main advantage of BLAST over profile HMMs, 
however, as it is a heuristic algorithm it does not guarantee identification of the optimal 
alignment between query and database sequences. 
In this study we designed, validated and implemented a Profile HMM to search 
for putative subclass I lantibiotic gene clusters in the HMP metagenomes and 
compared its performance to some of the tools mentioned above. 
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Methods 
 
Data Collection 
 
HMASM (HMP Illumina WGS Assemblies) and HMRGD (HMP Reference 
Genomes Data) were downloaded from the Data Analysis and Coordination Centre 
for the HMP. 835 bacterial RefSeq protein sequences annotated as “lantibiotic 
dehydratase” were downloaded from NCBI Protein website (13 Apr 2015) in FASTA 
format (list available online at https://doi.org/10.7717/peerj.3254/supp-1). 
 
Building and Validating the new Profile Hidden Markov Model 
 
A global multiple sequence alignment was generated in the aligned-FASTA 
format using MUSCLE (v3.8.31) (Edgar 2004), and a profile HMM was built from 
the MSA aligned-FASTA file using the HMMER tool hmmbuild (v3.1b1 May 2013). 
For comparison of the new model’s performance, HMMER3’s hmmsearch tool was 
used, with default parameters, to search the Pfam lantibiotic dehydratase model 
PF04738 against the same stool and oral HMASM assemblies (the sequences used to 
build this model are available online at https://doi.org/10.7717/peerj.3254/supp-2). 
Positive and negative controls (listed in Table 1) were used to evaluate the model’s 
ability to 1) accurately identify LanB protein sequences, and 2) distinguish LanB 
protein sequences from other, related, lantibiotic modification proteins (i.e. LanM, 
LanKC, and LanL. The controls were also screened using the PF04738 model, the 
web-based bacteriocin genome mining tool BAGEL3 (van Heel et al. 2013), and a 
traditional BlastP using the nisin-associated lanthionine dehydratase, NisB, as the 
driver sequence (GenBank accession number CAA79468.1) to compare the sensitivity 
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and specificity of each approach. A flowchart of the steps involved in building, 
validating and applying a profile HMM is depicted in Figure 1. 
 
Target Sequence Translation 
 
The HMMER3 hmmsearch tool only accepts protein sequences as targets for 
comparison to protein profile HMMs so a python script was created to translate the 
nucleotide sequences of the assembled genomes and metagenomes to be screened into 
protein sequences. The DNA nucleotide sequences were translated in six frames using 
the standard genetic code. 
 
Metagenomic Screen 
 
The HMMER3 tool hmmsearch was used, with default parameters, to search both the 
new LanB profile HMM and the Pfam PF04738 profile HMM (Punta et al. 2012) 
against the stool and oral subsets of the Human Microbiome Project’s whole 
metagenomic shotgun sequencing assemblies (HMASM). 139 stool communities and 
382 communities from eight different body sites within the oral cavity were screened 
from the HMP database. These are listed in Table 2. As an additional comparison of 
performance, a traditional BlastP screen was performed on the same metagenomic 
samples using the previously mentioned nisin-associated lanthionine dehydratase, 
NisB, driver sequence. A significance cutoff of E ≤ 1x10-5 was chosen for both profile 
HMM and BlastP methods. 
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Strain Bacteriocin Control Subclass pHMM Pfam BlastP Bagel3 
Lactococcus lactis ssp. lactis S0 a,b,c,d Nisin Z Positive LanB + + + + 
Lactococcus  lactis ssp. lactis CV56 a,b,c,d Nisin A Positive LanB + + + + 
Lactococcus lactis ssp. lactis IO-1 a,b,c,d Nisin Z Positive LanB + + + + 
Bacillus subtilis subsp. spizizienii ATCC 6633 a,b,c,d Subtilin Positive LanB + + + + 
Staphylococcus aureus subsp. aureus USA300_FPR3757 a,c,d Bsa Positive LanB + - + + 
Streptococcus mutans CH43 a,b,d Mutacin I Positive LanB + + - + 
Streptococcus mutans UA787 a,b,d Mutacin III Positive LanB + + - + 
Streptococcus pyogenes a,b,c,d Streptin Positive LanB + + + + 
Staphylococcus epidermidis a,b,c,d Pep5 Positive LanB + + + + 
Lactococcus lactis subsp. lactis KF147 c None Negative - - - + - 
Streptococcus mutans GS-5  Mutacin GS-5 Negative LanM - - - - 
Lactococcus lactis subsp. lactis plasmid pES2  Lacticin 481 Negative LanM - - - - 
Streptomyces cinnamoneus cinnamoneus DSM 4005  Cinnamycin Negative LanM - - - - 
Bacillus paralichenformis APC 1576 Formicin Negative LanM - - - - 
Streptococcus salivarius plasmid pSsal-K12 Salivaricin B Negative LanM - - - - 
Streptomyces venezuelae ATCC 10712 d Venezuelin Negative LanL - - - + 
 
Table 1. Controls used in validation of the profile HMM, listing the lantibiotic produced, whether the strain was included as a positive or 
negative control, the subclass of modification protein responsible for lanthionine dehydration, and whether there was a significant hit identified 
by each method.
155 
 
 
 
 
Figure 1. Flowchart depicting the step involved in building and validation of, and 
screening using, a profile HMM 
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Site Number of Samples 
Attached Keratinized Gingiva 6 
Buccal Mucosa 107 
Palatine Tonsils 6 
Saliva 3 
Stool 139 
Subgingival Plaque 7 
Supragingival Plaque 118 
Throat 7 
Tongue Dorsum 128 
 
Table 2. Number of metagenomic samples per body site screened. 
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Manual Examination of Randomly Selected Gene Neighbourhoods 
 
A subset of sixty hits were randomly selected and the surrounding region examined to 
identify other proteins involved in lantibiotic biosynthesis. Open Reading Frames 
were identified using Glimmer v3.02 (Delcher et al. 1999), which were then visualised 
using Artemis (Carver et al. 2012) and blasted against the nr database using BlastP 
(significance accepted as E ≤ 10-5). 
 
Genomic Screen  
 
HMMER3’s hmmsearch tool was used, with default parameters, to search the new 
profile HMM against the draft genomes comprising the gastrointestinal tract subset of 
the Human Microbiome Project’s reference genome database. 
 
Taxonomic Classification of LanB-encoding contigs 
 
Taxonomy was assigned to LanB-encoding contigs, as assigned by our pHMM, using 
Kaiju (Menzel et al. 2016). Analysis was performed in MEM run mode using default 
parameters and the NCBI non-redundant protein database. 
 
Statistical Analysis 
 
Statistical analysis was performed in R (v. 3.1.3) (R Core Team 2015). 
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Results 
 
Validation of the Profile Hidden Markov Model 
 
The ability of the newly developed profile HMM and the Pfam lantibiotic 
dehydratase model PF04738 to detect LanB-encoding genes were compared using the 
positive and negative controls listed in Table 1. The positive controls were selected 
based on a relevant book chapter (Rea et al. 2011b) and all are previously characterised 
bacteriocin producers for which the sequence of the relevant biosynthetic gene cluster 
was available. None of the positive control sequences were used in the building of the 
model and a graphical representation of these clusters is presented in Figure 2. 
Lactococcus lactis subsp. lactis KF147 was chosen as a negative control because it is 
of the same subspecies as three of the positive controls (Lactococcus lactis subsp. 
lactis S0, Lactococcus lactis subsp. lactis CV56 and Lactococcus lactis subsp. lactis 
IO-1) but does not produce a bacteriocin. Streptococcus mutans GS-5, Streptomyces 
cinnamoneus cinnamoneus DSM 4005, the Lactococcus lactis subsp. lactis IL1835 
plasmid pES2, the Streptococcus salivarious plasmid pSsal-K12, and the newly 
characterised formicin producer Bacillus paralicheniformis APC 1576 were chosen as 
negative controls to evaluate the ability of the model to differentiate between LanB 
(subclass I) proteins and the LanM proteins-from these strains, which perform a 
similar, but distinct, function in the posttranslational modification of subclass II 
lantibiotics. Streptomyces venezuelae ATCC 10712 was chosen as the final negative 
control as it has been reported to produce a LanL-type lantipeptide (Goto et al. 2010). 
Examination of the ATCC 10712 genome using BAGEL3 identified several other 
orphan lantibiotic modification genes, including those encoding putative LanL, LanM, 
LanD and LanB proteins. The genome also appeared to encode a subclass III  
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Figure 2. BAGEL3 output of putative bacteriocin gene clusters identified in the 
positive controls used for validation of our new profile HMM. Each predicted open 
reading frame is colour-coded based on the role it plays in lantibiotic biosynthesis. 
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lantipeptide cluster comprised of genes potentially encoding a structural protein, two 
ABC-type transporters and a LanKC modification protein. Notably, there have been 
no reports of subclass I lantibiotic production by ATCC 10712 despite an in-depth 
investigation into the strain’s lantipeptide producing capability (Goto et al. 2010), and 
BAGEL3 identified no other lantibiotic-related genes in the area of interest leading us 
to determine that this was a false positive. 
The newly developed LanB profile HMM correctly identified the LanB protein 
in all nine positive controls, while the PF04738 profile HMM correctly identified the 
LanB protein in eight of the nine positive controls, failing to detect the Bsa-associated 
LanB protein in Staphylococcus aureus subsp. aureus USA300_FPR3757. Both the 
LanB and PF04738 profile HMMs returned no false positives when searched against 
the seven negative controls used in this study. 
The web version of BAGEL3 correctly identified the lantibiotic modification 
proteins in all positive and negative controls, excepting the aforementioned ATCC 
10712-encoded LanB concluded to be a false positive. Interestingly, examination of 
these controls with the BlastP method described previously, failed to correctly identify 
the LanB proteins encoded by Streptococcus mutans CH43 and Streptococcus mutans 
UA787, although the former (E = 3x10-4) fell just short of the significance cutoff (E ≤ 
1x10-5). BlastP also incorrectly identified a LanB protein in the negative control 
Lactococcus lactis subsp. lactis KF147. 
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Metagenomic Screen 
 
A search with the newly developed profile HMM against the HMASM 
database identified 399 hits from the stool metagenomes and 1169 hits from the oral 
metagenomes. In contrast, the PF04738 model identified 288 hits from the stool 
metagenomes and 686 from the oral metagenomes. Our model reported at least one 
putative lantibiotic gene cluster in 81% of oral metagenomes and 86% of stool 
metagenomes, compared to 73% and 76%, respectively, identified by the Pfam model. 
The distribution of hits per sample is presented in Figure 3. BlastP identified 231 hits 
from the stool metagenomes and 374 hits from the oral metagenomes. The results of 
these three approaches were compared to ascertain what proportion of significant hits 
was common to more than one search method. The results of this comparison are 
summarised in Figure 4 and show that the newly developed profile HMM identified 
the greatest number of lantibiotic modification genes in datasets from both body sites, 
while the BlastP approach identified the fewest. 
The overall results of these combined screening approaches, illustrated in 
Figure 5 and summarised in Table 3, show a higher number and density of hits in the 
oral metagenomes than in the stool metagenomes (Wilcoxon rank sum test, p = 
1.399e–05) and they also reveal a large variation in density of hits between the 
different sites within the oral metagenomes. This pattern was also reflected in four of 
the Oral subsites, namely Buccal Mucosa, Subgingival Plaque, Supragingival Plaque 
and Tongue Dorsum, all of which had a significantly higher LanB density than the 
Stool metagenomes (Wilcoxon rank sum test, (p = 0.0258,0.0014, 6.7e–09, and 9.4e–
06, respectively). Within the Oral samples, our model revealed a large variation in 
density of hits between different subsites. The throat metagenomes had the lowest 
LanB density, and exhibited significantly lower densities than Buccal Mucosa  
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Figure 3. Barchart depicting the distribution of lanthionine dehydratase protein 
numbers identified by our new profile HMM in metagenomic samples from the stool 
and oral microbiota. 
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Figure 4. Venn diagram illustrating the numbers of lanthionine dehydratase proteins 
reported in stool (A) and oral (B) metagenomic data by single and multiple methods.
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Figure 5. Comparison of lanthionine dehydratase density by body site reported by all three methods. Insert shows overall comparison between 
stool and oral environments. Significant differences in LanB density between subsites, as identified by our model, are highlighted. 
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pHMM Hits PF04738 Hits BlastP  Hits pHMM Hit/Mb PF04738 Hit/Mb BlastP Hit/Mb 
Attached Keratinized Gingiva 7 4 2 0.0244 0.0139 0.0070 
Buccal Mucosa 96 74 64 0.0326 0.0251 0.0217 
Palatine Tonsils 8 6 2 0.0204 0.0153 0.0051 
Saliva 6 5 7 0.0472 0.0393 0.0550 
Subgingival Plaque 33 22 9 0.0438 0.0292 0.0120 
Supragingival Plaque 528 306 148 0.0309 0.0179 0.0087 
Throat 5 2 0 0.0108 0.0043 0.0000 
Tongue Dorsum 486 267 142 0.0276 0.0151 0.0081 
Stool 399 288 231 0.0189 0.0136 0.0109 
  
Table 3. Comparison of lanthionine dehydratase proteins identified by each method and their density based on metagenome size. 
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 (Wilcoxon rank sum test, p = 0.0287), Subgingival Plaque (Wilcoxon rank sum test, 
p = 0.009), Supragingival Plaque (Wilcoxon rank sum test, p = 0.0016), and Tongue 
Dorsum (Wilcoxon rank sum test, p = 0.0031) subsites. 
 
Manual Examination of Selected Gene Neighbourhoods 
 
Sixty hits, listed in Table 4, were randomly selected from those identified by 
the new profile HMM, 45% (27/60) of which were identified by at least one of the 
other two methods, and manually examined to determine if a bacteriocin gene cluster 
could be identified. 42% (25/60) of these were not further analysed because the often 
relatively short regions assembled from the shotgun data prevented the identification 
of a full lantibiotic gene cluster. However, of the 35 remaining clusters, 28 (80%) 
appeared to encode multiple genes involved in the biosynthesis of bacteriocins and 
thiopeptides. These genes encode proteins involved in posttranslational modification, 
bacteriocin transport, leader cleavage and regulation (Figure 6). 
81 hits identified by BlastP were missed by both profile HMM approaches. 
50 of these originated in the stool metagenomes and were selected for manual 
annotation to determine if an overall structure or similarity could be observed. 29 of 
these 50 were part of clusters whose components showed relatively low sequence 
identity (39-50%) with proteins responsible for the biosynthesis of thiopeptides and 
lantibiotics, including a putative lanthionine dehydratase, a radical SAM/SPASM 
domain-containing protein, a thiopeptide-type bacteriocin biosynthesis domain-
containing protein, an S41 family peptidase, and a protein of unknown function 
(DUF4932)  
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Body 
Site Sample Contig 
Also 
Identified 
by Pfam 
Also 
Identified 
by BlastP 
Oral SRS011098 contig-100_15454.15454 No No 
Oral SRS013533 contig-100_13993.137974 No No 
Oral SRS013949 contig-100_16.127362 No No 
Oral SRS014476 contig-100_19698.19698 No No 
Oral SRS014476 contig-100_33982.33982 No No 
Oral SRS014578 contig-100_25195.25195 No No 
Oral SRS014684 15756 No No 
Oral SRS014691 contig-100_6081.124540 No No 
Oral SRS015040 629 Yes Yes 
Oral SRS015060 9087 No No 
Oral SRS015158 contig-100_15337.100130 No No 
Oral SRS015215 24967 No Yes 
Oral SRS015278 contig-100_10111.10111 No No 
Oral SRS015470 2052 No Yes 
Oral SRS016002 contig-100_476.158552 Yes No 
Oral SRS017080 contig-100_5941.5941 No No 
Oral SRS017439 contig-100_1672.143182.143182 Yes Yes 
Oral SRS018591 contig-100_9765.9765 No No 
Oral SRS019029 23866 No No 
Oral SRS019219 C2945900 No No 
Oral SRS019974 contig-100_20140.20140.20140 Yes No 
Oral SRS021960 contig-100_10619.10619 No No 
Oral SRS023358 contig-100_2141.2141 No No 
Oral SRS023938 5276 No No 
Oral SRS024081 SRS024081_LANL_scaffold_14492 Yes Yes 
Oral SRS042131 3502 Yes No 
Oral SRS045127 11735 No No 
Oral SRS056622 17271 Yes No 
Oral SRS058808 33685 No No 
Oral SRS063999 contig-100_1693.183379 No No 
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Body 
Site Sample Contig 
Also 
Identified 
by Pfam 
Also 
Identified 
by BlastP 
Stool SRS011271 contig-100_502.150577 Yes Yes 
Stool SRS013476 35183 No Yes 
Stool SRS014287 9924 Yes Yes 
Stool SRS015133 C3441160 No No 
Stool SRS015217 11881 Yes Yes 
Stool SRS015578 contig-100_12750.137163 No No 
Stool SRS015782 C3311357 No No 
Stool SRS016954 19735 No Yes 
Stool SRS017521 contig-100_1016.215526 Yes Yes 
Stool SRS018656 contig-100_2624.65167 No Yes 
Stool SRS018817 12490 Yes No 
Stool SRS019267 contig-100_30866.30866 No No 
Stool SRS019397 467 No No 
Stool SRS019910 contig-100_13822.36985 No Yes 
Stool SRS020233 53970 Yes Yes 
Stool SRS022071 5852 No Yes 
Stool SRS024625 contig-100_26018.53974 Yes No 
Stool SRS043411 11272 No No 
Stool SRS047014 contig-100_7652.187852 No No 
Stool SRS048164 2584 Yes Yes 
Stool SRS048870 contig-100_3433.99515 Yes Yes 
Stool SRS049712 contig-100_19642.88407 No No 
Stool SRS049995 22549 Yes Yes 
Stool SRS050925 contig-100_30127.70203 No No 
Stool SRS052697 contig-100_723.255260 Yes Yes 
Stool SRS054590 contig-100_344.344 No No 
Stool SRS062427 8699 Yes Yes 
Stool SRS065504 22874 No No 
Stool SRS065504 contig-100_509.193795 No No 
 
Table 4. Sample and contig identifiers of all randomly selected hits that underwent 
manual annotation. The table also states whether the hit was identified by Pfam and 
BlastP approaches. 
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Figure 6a. Graphical representation of stool hits randomly selected for manual 
examination. The full contig was analysed in each instance but only the area 
immediately surrounding the predicted LanB protein is illustrated. 
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Figure 6b. Graphical representation of oral hits randomly selected for manual 
examination. The full contig was analysed in each instance but only the area 
immediately surrounding the predicted LanB protein is illustrated. 
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predicted to be a putative metalloprotease. All 50 manually annotated gene clusters are 
available in GENBANK format (https://doi.org/10.6084/m9.figshare.4797790.v1) and 
an example of this cluster architecture is summarised in Table 5.  
 
Genomic Screen 
   
The draft genomes of the gastrointestinal tract subset of the HMRGD were also 
used as a database and searched using the new profile HMM. This resulted in the 
identification of seven hits, including two strains of Coprobacillus, a potentially 
probiotic genus (Stein et al. 2013; Yan et al. 2012) (Table 6). From these seven 
genomes, only three lantibiotic gene clusters were identified by BAGEL3, these are 
illustrated in Figure 7. Although this low frequency of lanthionine dehydratase proteins 
in the genomic dataset (0.006 hits/Mb) contrasts with the findings of the metagenome 
screen reported above, it is in agreement with previous reports of relatively low 
subclass I lantibiotic density within the human microbiota (Walsh et al. 2015; Zheng 
et al. 2014). A possible explanation for this significantly lower gene density (Welch’s 
two sample t-test, p = 1.232e-10) is that the subclass I lantibiotic clusters identified in 
the metagenomic data by the new profile HMM are present in the genomes of rarer 
members of the gut microbiota, which are not represented in the HMP reference 
genome database.  
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Taxonomic Classification of LanB-encoding contigs 
 
The MEM run mode of Kaiju works by searching for exact matches of given 
length between the query and database sequences, in the case of multiple hits of the 
same length in different taxa, a lowest common ancestor is inferred. Kaiju classified 
378 of 399 LanB-encoding contigs. Of these, 232 were classified to the species level - 
however 68 were removed as their exact species was ambiguous. Of the remaining 164 
classified contigs, 66 (40.2%) were represented at the species-level in the previously 
screened HMRGD database. The most abundant genus was Alistipes, accounting for 
14.03% of LanB-encoding contigs identified by our model, followed by Blautia 
(7.77%), Clostridium (4.51%), and Bacteroides (3.76%). Genus-level classification is 
summarised in Table 7. 
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Annotation Coverage (%) E-value Identitiy (%) 
lantibiotic dehydratase 98 4.00E-177 39 
thiopeptide-type bacteriocin biosynthesis domain-containing protein 93 6.00E-62 40 
lanthionine synthetase C-like protein 97 2.00E-75 39 
peptidase S41 97 5.00E-126 39 
ABC Transporter (COG2274) 99 0.00E+00 98 
hypothetical protein 77 6.00E-23 53 
DUF4932 domain-containing protein 95 2.00E-145 46 
radical SAM/SPASM domain-containing protein 96 6.00E-177 55 
HlyD family secretion protein 98 0.00E+00 65 
 
 
Table 5. Manual annotation of the putative BlastP-identified biosynthetic gene cluster on scaffold 39304 from stool metagenome SRS014923. 
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Accession Strain E Value 
JH414709 Bacillus sp. 7_6_55CFAA_CT2 9.0E-16 
GL636578 Coprobacillus sp. 29_1 3.7E-67 
AKCB01000002 Coprobacillus sp. D6 4.5E-68 
JH126516 Dorea formicigenerans 4_6_53AFAA 2.3E-81 
ACEP01000029 Eubacterium hallii DSM3353 9.4E-27 
KI391961 Fusobacterium nucleatum subsp. animalis 3_1_33 2.2E-09 
GG657999 Fusobacterium sp. 4_1_13 7.1E-09 
 
 
Table 6. Detailed information of all lanthionine dehydratase proteins identified in the 
gastrointestinal tract subset of the Human Microbiome Project’s reference genome 
database using our profile HMM. 
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Figure 7. BAGEL3 output of three putative bacteriocin gene clusters identified from 
the gastrointestinal tract subset of the Human Microbiome Project’s reference 
genome database by our new profile HMM. 
A – Coprobacillus sp. D6 
B – Coprobacillus sp. 29_1 
C – Dorea formicigenerans 4_6_53AFAA 
Each predicted open reading frame is colour-coded based on the role it plays in 
lantibiotic biosynthesis. 
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        %    Reads Genus 
14.03509 56 Alistipes 
7.769423 31 Blautia 
4.511278 18 Clostridium 
3.759398 15 Bacteroides 
2.506266 10 Ruminococcus 
2.506266 10 Parabacteroides 
2.255639 9 Coprobacillus 
1.503759 6 Bacillus 
1.503759 6 Eubacterium 
1.503759 6 Odoribacter 
1.253133 5 Chitinophaga 
1.002506 4 Streptococcus 
1.002506 4 Janibacter 
1.002506 4 Faecalibacterium 
0.75188 3 Prevotella 
0.75188 3 Paenibacillus 
0.75188 3 Chryseobacterium 
0.75188 3 Tenacibaculum 
0.75188 3 Leisingera 
0.75188 3 Pseudoflavonifractor 
0.75188 3 Erysipelatoclostridium 
0.75188 3 Lachnoclostridium 
0.75188 3 Tyzzerella 
0.501253 2 Dorea 
0.501253 2 Tannerella 
0.501253 2 Subdoligranulum 
0.501253 2 Lysinibacillus 
0.501253 2 Eisenbergiella 
0.250627 1 Nocardia 
0.250627 1 Saccharopolyspora 
0.250627 1 Streptomyces 
0.250627 1 Coprococcus 
0.250627 1 Eggerthella 
0.250627 1 Enterovibrio 
0.250627 1 Candidatus Accumulibacter 
0.250627 1 Oscillibacter 
0.250627 1 Celeribacter 
0.250627 1 Flavonifractor 
0.250627 1 Allokutzneria 
36.59148 146 Classified above rank Genus  
5.263158 21 Unclassified 
 
Table 7. Genus-level classification of putative LanB-encoding scaffolds identified 
by our model. 
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Discussion 
 
Bacteriocin production enhances the competitiveness of bacteria living in 
complex communities and has the potential to be harnessed for the benefit of human 
health. The goal of this study was to develop a profile HMM and to assess its ability, 
in comparison with several other approaches, to detect putative subclass I lantibiotic 
gene clusters in human metagenomic datasets. Through this process it was also 
possible to evaluate the potential frequency and distribution of these bacteriocin gene 
clusters in the human microbiota.  
To validate the model, nine positive controls and five negative controls were 
selected to evaluate its sensitivity and specificity. These controls were selected based 
on reported bacteriocin production; all positive controls were known producers of 
subclass I lantibiotics while the negative controls produced either different subclasses 
of lantibiotics or none at all. Following validation, genomic and metagenomic data 
corresponding to two niches within the human microbiome were chosen as the focus 
of this study. The first of these niches was human stool and was selected as the 
corresponding samples were most likely to yield bacteriocin producers with the 
potential to modulate undesirable microbiota profiles associated with obesity, 
colorectal cancer, type 2 diabetes or inflammatory bowel diseases due to their ability 
to survive and colonise this environment. Secondly, human oral communities were 
examined as a previous study showed that they contained, by far, the greatest 
proportion of bacteriocin structural genes across a number of human metagenome 
samples (Zheng et al. 2014). Zheng et al. reported that 80% of class I bacteriocins 
(lantibiotics) and 89% of all bacteriocins identified using their method originated in 
the oral metagenomes, while the stool metagenomes contained just 15% and 7%, 
respectively. The same study reported that 88% of samples from the oral cavity and 
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73% of samples from the gut contained at least one bacteriocin (regardless of class), 
while the new profile HMM reported these statistics as 81% and 83%, respectively for 
subclass I lantibiotics alone. The in silico screen carried out with the profile HMM is 
consistent with the observation by Zheng et al. (Zheng et al. 2014) by yielding a higher 
number and density of hits from the oral, compared to the stool, metagenomic data. 
Furthermore, the large variation in density of hits between sites within the oral 
environment suggests that lantibiotic production confers a greater advantage in buccal 
musoca, subgingival plaque, supragingival plaque, and tongue dorsum communities 
compared to communities from the throat. This may be due to the direct benefits of 
antimicrobial activity but could also involve the intra- and interspecies signalling roles 
attributed to lantibiotic peptides (Upton et al. 2001), particularly in the intensely 
competitive microbial biofilm environment of dental plaque. 
One of the most interesting observations from the study was the large variation 
in the numbers of lanB genes reported by the three different approaches. The BlastP 
approach identified, by far, the lowest number of significant hits overall and the lowest 
in every body site examined, except for the saliva microbiome. Our model identified 
more than double the number of hits provided by the BlastP-based approach, in line 
with the aforementioned knowledge that profile HMMs can detect as much as three 
times as many distant homologs than pairwise methods (Park et al. 1998). Our model 
also identified a greater number of LanB proteins than the Pfam PF04738 model when 
used to search the same data using the same parameters. While the PF04738 model 
relates to the C-terminus of the lanthionine dehydratase protein, responsible for the 
glutamate elimination step of lantibiotic modification (Ortega et al. 2015), the newly 
developed profile HMM takes the full length of the LanB protein into consideration, 
thereby providing greater predictive power. The BlastP approach used here utilizes a 
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single driver sequence while both profile HMMs are representative of a much larger 
number of sequences – 835 and 573 protein sequences were used to build our model 
and the Pfam model respectively - perhaps explaining the differing number of hits 
reported by each approach. It is possible that an altered BlastP approach, pooling the 
unique hits reported by a standard BlastP search using each of the 835 driver sequences 
used to build our profile HMM, would result in a comparable number of proteins 
identified. 
Our model, in addition to identifying more potential LanB proteins, was the 
only method evaluated that did not identify any false positive or false negative in the 
control dataset. As stated above, profile HMMs are already known to be particularly 
sensitive, the validation step, however, also suggests that they are more specific than 
the other methods evaluated as they were the only approach which did not return any 
false positives.  When selecting the controls used to examine the performance of the 
different approaches, greater consideration was given to the quality of these controls 
than their quantity. Only controls with experimentally characterised lantibiotic 
production were included in the validation dataset. This relatively small control group 
means that, although the results of the validation step may explain the contrasting 
numbers of LanB proteins reported by our model and the PF04738 model, it cannot be 
said for certain that our model performed better.  
Zheng et al., using the same metagenomic data that was the focus of this study, 
identified 17 potential subclass I lantibiotics from stool samples and 76 from oral 
samples, a much lower frequency of detection than in this study, probably due to the 
different methodologies used. That study focused on searching for proteins similar to 
those in BAGEL3’s manually curated database, an approach which likely lost 
sensitivity because bacteriocin precursor peptides can differ considerably at primary 
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sequence level. Furthermore, the screen employed a BLAST-based approach which, 
as demonstrated here, exhibited the lowest number of significant hits reported. 
To investigate the areas surrounding the LanB-encoding genes identified by our model 
we randomly selected thirty positive hits from the oral and stool metagenome screens 
for manual examination. This approach revealed that several of the hits were on 
scaffolds that were either too small to contain a full gene or did not contain the gene’s 
start codon. This was most likely as a consequence of the fragmented nature of the 
metagenomic data, as opposed the identification of true false positives by the model 
and would probably occur regardless of the method employed. 42% (25/60) of hits 
selected for manual examination were discarded based on these criteria. It also 
revealed that a considerable number of hits exhibited low (~30%) similarity to putative 
thioesterases in the nr protein sequence database, highlighting that lanthionine 
dehydratases are relatively-closely related to proteins involved in the posttranslational 
modification of thiopeptides, most likely those responsible for dehydration of serine 
and threonine residues (Garg et al. 2013). The similarity between these dehydratase 
proteins suggests a possible common ancestor protein (Kelly et al. 2009). Another 
possible explanation relates to the fact that all of the proteins annotated as thiopeptide 
modification proteins are putative annotations and none, to our knowledge, have been 
confirmed as such in vitro. It is possible, therefore, that these may simply be 
lanthionine dehydratases which have been incorrectly annotated due to automatic 
software and incomplete/under-curated databases. The majority of clusters identified 
contained genes encoding both LanB and LanC modification proteins, while many also 
contained a leader cleavage and activation peptidase and/or ABC transporter proteins 
for export of the mature peptide, suggesting that these have the potential to encode a 
functional lantibiotic. 
181 
 
To evaluate the model’s performance in a genomic context we applied it to 
the gastrointestinal tract subset of the HMP’s reference genome database and 
compared the results to our previously published study which used the online 
bacteriocin genome mining tool BAGEL3 to screen this same database (Walsh et al. 
2015). The results of the two screens were startlingly different and served to 
highlight the variation in results that can arise from applying different methods to the 
same data. Interestingly, the gastrointestinal tract reference genomes encoded a 
significantly lower frequency of LanB hits than the stool metagenomic samples. 
Taxonomic classification of the 399 LanB-encoding contigs identified by our new 
model from the stool metagenomes revealed that only 40.2% of these potential 
lantibiotic producing strains were represented in the reference genome database, 
suggesting that the majority of these lantibiotics were encoded by rarer members of 
the gut microbiota or those that have not previously been identified as important. 
Taxonomic classification of these LanB-encoding contigs also served to highlight 
patterns in the results of the three approaches used (Figure 8), for example our model 
identified Allokutzneria, Coprococcus, Enterovibrio, Paenibacillus, and 
Tenicibaculum-encoded LanB proteins that were completely missed by the Pfram 
and BlastP approaches. 
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Figure 8. Proportion of hits identified in metagenomic stool samples by our model that were also identified by other methods. Illustrates that the 
proportion also identified by A) Pfam and B) BlastP approaches varies by producing genus. The black line shows the overall proportion of hits 
identified by each method. 
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Conclusions 
 
Across the oral and stool communities examined, this study identified 2007 
unique putative subclass I lantibiotic biosynthetic gene clusters by three different 
methods, further emphasising the tremendous potential that the human microbiota has 
as a source of therapeutic compounds. As this study was performed entirely in silico, 
the next challenge lies in experimentally identifying and characterising these putative 
bacteriocins to identify those with the ability to desirably modulate the microbiota for 
the treatment of disease.  
  
184 
 
 
References 
 
ALTSCHUL SF, GISH W, MILLER W, MYERS EW, AND LIPMAN DJ. 1990. 
Basic local alignment search tool. J Mol Biol 215:403-410. 10.1016/s0022-
2836(05)80360-2 
ARNISON PG, BIBB MJ, BIERBAUM G, BOWERS AA, BUGNI TS, BULAJ G, 
CAMARERO JA, CAMPOPIANO DJ, CHALLIS GL, CLARDY J, COTTER 
PD, CRAIK DJ, DAWSON M, DITTMANN E, DONADIO S, DORRESTEIN 
PC, ENTIAN K-D, FISCHBACH MA, GARAVELLI JS, GORANSSON U, 
GRUBER CW, HAFT DH, HEMSCHEIDT TK, HERTWECK C, HILL C, 
HORSWILL AR, JASPARS M, KELLY WL, KLINMAN JP, KUIPERS OP, 
LINK AJ, LIU W, MARAHIEL MA, MITCHELL DA, MOLL GN, MOORE 
BS, MULLER R, NAIR SK, NES IF, NORRIS GE, OLIVERA BM, ONAKA 
H, PATCHETT ML, PIEL J, REANEY MJT, REBUFFAT S, ROSS RP, 
SAHL H-G, SCHMIDT EW, SELSTED ME, SEVERINOV K, SHEN B, 
SIVONEN K, SMITH L, STEIN T, SUSSMUTH RD, TAGG JR, TANG G-
L, TRUMAN AW, VEDERAS JC, WALSH CT, WALTON JD, WENZEL 
SC, WILLEY JM, AND VAN DER DONK WA. 2013. Ribosomally 
synthesized and post-translationally modified peptide natural products: 
overview and recommendations for a universal nomenclature. Natural Product 
Reports 30:108-160. 10.1039/C2NP20085F 
BÄCKHED F, LEY RE, SONNENBURG JL, PETERSON DA, AND GORDON JI. 
2005. Host-Bacterial Mutualism in the Human Intestine. Science 307:1915-
1920. 10.1126/science.1104816 
185 
 
BELSTRØM D, HOLMSTRUP P, BARDOW A, KOKARAS A, FIEHN N-E, AND 
PASTER BJ. 2016. Temporal Stability of the Salivary Microbiota in Oral 
Health. PLoS ONE 11:e0147472. 10.1371/journal.pone.0147472 
CARVER T, HARRIS SR, BERRIMAN M, PARKHILL J, AND MCQUILLAN JA. 
2012. Artemis: an integrated platform for visualization and analysis of high-
throughput sequence-based experimental data. Bioinformatics 28:464-469. 
10.1093/bioinformatics/btr703 
CLEMENTE JOSE C, URSELL LUKE K, PARFREY LAURA W, AND KNIGHT 
R. 2012. The Impact of the Gut Microbiota on Human Health: An Integrative 
View. Cell 148:1258-1270. http://dx.doi.org/10.1016/j.cell.2012.01.035 
CORR SC, LI Y, RIEDEL CU, O'TOOLE PW, HILL C, AND GAHAN CGM. 2007. 
Bacteriocin production as a mechanism for the antiinfective activity of 
Lactobacillus salivarius UCC118. Proceedings of the National Academy of 
Sciences 104:7617-7621. 10.1073/pnas.0700440104 
DELCHER AL, HARMON D, KASIF S, WHITE O, AND SALZBERG SL. 1999. 
Improved microbial gene identification with GLIMMER. Nucleic Acids Res 
27:4636-4641.  
DONIA MOHAMED S, CIMERMANCIC P, SCHULZE CHRISTOPHER J, 
WIELAND BROWN LAURA C, MARTIN J, MITREVA M, CLARDY J, 
LININGTON ROGER G, AND FISCHBACH MICHAEL A. 2014. A 
Systematic Analysis of Biosynthetic Gene Clusters in the Human Microbiome 
Reveals a Common Family of Antibiotics. Cell 158:1402-1414. 
10.1016/j.cell.2014.08.032 
186 
 
DUSKO EHRLICH S. 2010. [Metagenomics of the intestinal microbiota: potential 
applications]. Gastroenterol Clin Biol 34 Suppl 1:S23-28. 10.1016/s0399-
8320(10)70017-8 
EDGAR RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and 
high throughput. Nucleic Acids Res 32:1792-1797. 10.1093/nar/gkh340 
EREJUWA OO, SULAIMAN SA, AND AB WAHAB MS. 2014. Modulation of gut 
microbiota in the management of metabolic disorders: the prospects and 
challenges. Int J Mol Sci 15:4158-4188. 10.3390/ijms15034158 
FAITH JJ, GURUGE JL, CHARBONNEAU M, SUBRAMANIAN S, SEEDORF H, 
GOODMAN AL, CLEMENTE JC, KNIGHT R, HEATH AC, LEIBEL RL, 
ROSENBAUM M, AND GORDON JI. 2013. The Long-Term Stability of the 
Human Gut Microbiota. Science 341. 10.1126/science.1237439 
FLINT HJ, SCOTT KP, LOUIS P, AND DUNCAN SH. 2012. The role of the gut 
microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol 9:577-589.  
GALES M, AND YOUNG S. 2007. The application of hidden Markov models in 
speech recognition. Found Trends Signal Process 1:195-304. 
10.1561/2000000004 
GARG N, SALAZAR-OCAMPO LMA, AND VAN DER DONK WA. 2013. In vitro 
activity of the nisin dehydratase NisB. Proceedings of the National Academy 
of Sciences of the United States of America 110:7258-7263. 
10.1073/pnas.1222488110 
GOTO Y, LI B, CLAESEN J, SHI Y, BIBB MJ, AND VAN DER DONK WA. 2010. 
Discovery of Unique Lanthionine Synthetases Reveals New Mechanistic and 
Evolutionary Insights. PLoS Biol 8:e1000339. 10.1371/journal.pbio.1000339 
187 
 
JEFFERY IB, LYNCH DB, AND O'TOOLE PW. 2016. Composition and temporal 
stability of the gut microbiota in older persons. ISME J 10:170-182. 
10.1038/ismej.2015.88 
KELLY WL, PAN L, AND LI C. 2009. Thiostrepton biosynthesis: prototype for a 
new family of bacteriocins. J Am Chem Soc 131:4327-4334. 
10.1021/ja807890a 
MADERA M, AND GOUGH J. 2002. A comparison of profile hidden Markov model 
procedures for remote homology detection. Nucleic Acids Res 30:4321-4328.  
MENZEL P, NG KL, AND KROGH A. 2016. Fast and sensitive taxonomic 
classification for metagenomics with Kaiju. Nature Communications 7:11257. 
10.1038/ncomms11257 
http://www.nature.com/articles/ncomms11257#supplementary-information 
MORONI O, KHEADR E, BOUTIN Y, LACROIX C, AND FLISS I. 2006. 
Inactivation of Adhesion and Invasion of Food-Borne Listeria monocytogenes 
by Bacteriocin-Producing Bifidobacterium Strains of Human Origin. Applied 
and Environmental Microbiology 72:6894-6901. 10.1128/aem.00928-06 
MORTON JT, FREED SD, LEE SW, AND FRIEDBERG I. 2015. A large scale 
prediction of bacteriocin gene blocks suggests a wide functional spectrum for 
bacteriocins. BMC Bioinformatics 16:1-9. 10.1186/s12859-015-0792-9 
ORTEGA MA, HAO Y, ZHANG Q, WALKER MC, VAN DER DONK WA, AND 
NAIR SK. 2015. Structure and mechanism of the tRNA-dependent lantibiotic 
dehydratase NisB. Nature 517:509-512. 10.1038/nature13888 
PARK J, KARPLUS K, BARRETT C, HUGHEY R, HAUSSLER D, HUBBARD T, 
AND CHOTHIA C. 1998. Sequence comparisons using multiple sequences 
188 
 
detect three times as many remote homologues as pairwise methods. J Mol 
Biol 284:1201-1210. 10.1006/jmbi.1998.2221 
PEREZ RH, ZENDO T, AND SONOMOTO K. 2014. Novel bacteriocins from lactic 
acid bacteria (LAB): various structures and applications. Microbial Cell 
Factories 13:S3-S3. 10.1186/1475-2859-13-S1-S3 
PUNTA M, COGGILL PC, EBERHARDT RY, MISTRY J, TATE J, BOURSNELL 
C, PANG N, FORSLUND K, CERIC G, CLEMENTS J, HEGER A, HOLM 
L, SONNHAMMER ELL, EDDY SR, BATEMAN A, AND FINN RD. 2012. 
The Pfam protein families database. Nucleic Acids Res 40:D290-D301. 
10.1093/nar/gkr1065 
QIN J, LI R, RAES J, ARUMUGAM M, BURGDORF KS, MANICHANH C, 
NIELSEN T, PONS N, LEVENEZ F, YAMADA T, MENDE DR, LI J, XU J, 
LI S, LI D, CAO J, WANG B, LIANG H, ZHENG H, XIE Y, TAP J, LEPAGE 
P, BERTALAN M, BATTO J-M, HANSEN T, LE PASLIER D, 
LINNEBERG A, NIELSEN HB, PELLETIER E, RENAULT P, SICHERITZ-
PONTEN T, TURNER K, ZHU H, YU C, LI S, JIAN M, ZHOU Y, LI Y, 
ZHANG X, LI S, QIN N, YANG H, WANG J, BRUNAK S, DORE J, 
GUARNER F, KRISTIANSEN K, PEDERSEN O, PARKHILL J, 
WEISSENBACH J, BORK P, EHRLICH SD, AND WANG J. 2010. A human 
gut microbial gene catalogue established by metagenomic sequencing. Nature 
464:59-65. 
http://www.nature.com/nature/journal/v464/n7285/suppinfo/nature08821_S1.ht
ml 
R CORE TEAM. 2015. R: A Language and Environment for Statistical Computing.  
189 
 
REA MC, DOBSON A, O'SULLIVAN O, CRISPIE F, FOUHY F, COTTER PD, 
SHANAHAN F, KIELY B, HILL C, AND ROSS RP. 2011a. Effect of broad- 
and narrow-spectrum antimicrobials on Clostridium difficile and microbial 
diversity in a model of the distal colon. Proceedings of the National Academy 
of Sciences 108:4639-4644. 10.1073/pnas.1001224107 
REA MC, ROSS RP, COTTER PD, AND HILL C. 2011b. Classification of 
Bacteriocins from Gram-Positive Bacteria. In: Drider D, and Rebuffat S, eds. 
Prokaryotic Antimicrobial Peptides: From Genes to Applications. New York, 
NY: Springer New York, 29-53. 
SEIFERT M, ABOU-EL-ARDAT K, FRIEDRICH B, KLINK B, AND DEUTSCH 
A. 2014. Autoregressive Higher-Order Hidden Markov Models: Exploiting 
Local Chromosomal Dependencies in the Analysis of Tumor Expression 
Profiles. PLoS ONE 9:e100295. 10.1371/journal.pone.0100295 
SENDER R, FUCHS S, AND MILO R. 2016. Revised estimates for the number of 
human and bacteria cells in the body. bioRxiv. 10.1101/036103 
SHERLOCK C, XIFARA T, TELFER S, AND BEGON M. 2013. A coupled hidden 
Markov model for disease interactions. Journal of the Royal Statistical Society 
Series C, Applied Statistics 62:609-627. 10.1111/rssc.12015 
SKEWES-COX P, SHARPTON TJ, POLLARD KS, AND DERISI JL. 2014. Profile 
Hidden Markov Models for the Detection of Viruses within Metagenomic 
Sequence Data. PLoS ONE 9:e105067. 10.1371/journal.pone.0105067 
STEIN RR, BUCCI V, TOUSSAINT NC, BUFFIE CG, RÄTSCH G, PAMER EG, 
SANDER C, AND XAVIER JB. 2013. Ecological Modeling from Time-Series 
Inference: Insight into Dynamics and Stability of Intestinal Microbiota. PLoS 
Comput Biol 9:e1003388. 10.1371/journal.pcbi.1003388 
190 
 
THE HUMAN MICROBIOME PROJECT CONSORTIUM. 2012. Structure, function 
and diversity of the healthy human microbiome. Nature 486:207-214. 
10.1038/nature11234 
UPTON M, TAGG JR, WESCOMBE P, AND JENKINSON HF. 2001. Intra- and 
Interspecies Signaling between Streptococcus salivarius and Streptococcus 
pyogenes Mediated by SalA and SalA1 Lantibiotic Peptides. J Bacteriol 
183:3931-3938. 10.1128/JB.183.13.3931-3938.2001 
VAN HEEL AJ, DE JONG A, MONTALBAN-LOPEZ M, KOK J, AND KUIPERS 
OP. 2013. BAGEL3: Automated identification of genes encoding bacteriocins 
and (non-)bactericidal posttranslationally modified peptides. Nucleic Acids 
Res 41:W448-453. 10.1093/nar/gkt391 
WALSH CJ, GUINANE CM, HILL C, ROSS RP, O’TOOLE PW, AND COTTER 
PD. 2015. In silico identification of bacteriocin gene clusters in the 
gastrointestinal tract, based on the Human Microbiome Project’s reference 
genome database. BMC Microbiol 15:183. 10.1186/s12866-015-0515-4 
WALSH CJ, GUINANE CM, O'TOOLE PW, AND COTTER PD. 2014. Beneficial 
modulation of the gut microbiota. FEBS Lett 588:4120-4130. 
10.1016/j.febslet.2014.03.035 
WEBER T, BLIN K, DUDDELA S, KRUG D, KIM HU, BRUCCOLERI R, LEE SY, 
FISCHBACH MA, MÜLLER R, WOHLLEBEN W, BREITLING R, 
TAKANO E, AND MEDEMA MH. 2015. antiSMASH 3.0—a comprehensive 
resource for the genome mining of biosynthetic gene clusters. Nucleic Acids 
Res 43:W237-W243. 10.1093/nar/gkv437 
191 
 
XIE L, AND VAN DER DONK WA. 2004. Post-translational modifications during 
lantibiotic biosynthesis. Curr Opin Chem Biol 8:498-507. 
10.1016/j.cbpa.2004.08.005 
YAN X, GURTLER JB, FRATAMICO PM, HU J, AND JUNEJA VK. 2012. 
Phylogenetic identification of bacterial MazF toxin protein motifs among 
probiotic strains and foodborne pathogens and potential implications of 
engineered probiotic intervention in food. Cell & Bioscience 2:1-13. 
10.1186/2045-3701-2-39 
YOON B-J. 2009. Hidden Markov Models and their Applications in Biological 
Sequence Analysis. Current Genomics 10:402-415. 
10.2174/138920209789177575 
ZHENG J, GÄNZLE MG, LIN XB, RUAN L, AND SUN M. 2014. Diversity and 
dynamics of bacteriocins from human microbiome. Environ Microbiol:n/a-n/a. 
10.1111/1462-2920.12662 
192 
 
Chapter 4 
The relationship between subclass I lantibiotic gene density and 
the composition and functional potential of the gut microbiota 
 
Identification of lantibiotic modification proteins and subsequent analysis was performed by 
the candidate 
DNA extraction, sequencing and preliminary analysis was performed by Wiley Barton of 
Teagasc Moorepark, Cork. 
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Abstract 
 
 
The gut microbiota of elite-athletes has been shown to be more compositionally 
diverse than that of controls. This dissimilarity is even more pronounced at the functional 
level. Given the considerable differences between the athlete and control microbiota, and the 
hypothesised influence of bacteriocin production on the composition and function of the gut 
microbial community, this data was selected to determine the extent to which the distribution 
of antimicrobial peptides can vary across different individuals. The profile Hidden Markov 
Model (HMM) developed in Chapter 3 of this thesis was used to search these data for LanB 
proteins, which are responsible for the posttranslational modifications characteristic of 
subclass I lantibiotics – a well-studied type of bacteriocin with potent antimicrobial activity. 
The sensitive nature of this profile HMM means it is ideally suited to searching cohorts, such 
as those studied here, which are quite different in respects to their microbiota. Ultimately, 
eighty-one shotgun-sequenced metagenomes, accompanied by collected metadata, were 
examined and it was revealed that class I lantibiotic gene cluster levels differed in the 
microbiota of athletes compared to high BMI sedentary controls. Also apparent was a 
relationship between the presence of these gene clusters and lean mass. Further investigation 
revealed that diet and overall functional capacity of the microbiota exhibited the strongest 
relationship with subclass I lantibiotic gene cluster density and some interesting relationships 
with the gut microbiota were highlighted for future examination, particularly a seemingly 
counterintuitive correlation with peptidoglycan biosynthesis. 
These results also established that the relationship between subclass I lantibiotics and 
the host is very different between elite athletes and the sedentary population, most likely due 
to their extreme diet and exercise regimen.  
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Introduction 
 
 
Bacteriocins are a class of ribosomally-synthesised antimicrobial peptides produced by 
many bacteria. Lantibiotics are a group of post-translationally modified bacteriocins that are 
distinguished by the modifications they contain, and the proteins responsible for these 
modifications. The profile Hidden Markov Model (HMM) developed in chapter 3 of this thesis 
identifies lanthionine dehydratase, LanB, proteins that contribute to the production of subclass 
I lantibiotics (Arnison et al., 2013). In this study we use LanB proteins as an indicator of the 
number of unique bacteriocin-producing bacteria in each metagenome. This profile HMM is 
suited to searching metagenomic data as the increased sensitivity of profile HMMs over 
sequence homology approaches, such as BLAST, allows detection of more distantly related 
proteins in relatively under-characterised members of the gut microbiota while also 
overcoming the limitation of tools tailored to genomic data, such as BAGEL3, which struggle 
with the fragmented nature of metagenomic assemblies as they rely on identifying multiple 
proteins related to biosynthesis within a set genomic region.  
To assess distribution of LanB proteins across different human gut samples we utilised 
data obtained from elite-athletes (members of the Irish national rugby team) which, through 
two previous publications (Barton et al., 2017, Clarke et al., 2014), form part of a growing body 
of evidence suggesting part of the benefit of exercise is affected through modulation of the gut 
microbiota (Estaki et al., 2016, Bressa et al., 2017). In addition to high levels of exercise, these 
elite-athletes have previously been shown to have a significantly different diet to the sedentary 
populations (Clarke et al., 2014) which, as highlighted previously in this thesis, has tremendous 
potential to influence the gut microbiota. The elite athlete microbiota differed with respect its 
compositional and functional diversity from that of control cohorts (Barton et al., 2017, Clarke 
et al., 2014). The shotgun metagenomic data, and accompanying metadata, generated as part 
of these previous studies (Barton et al., 2017, Clarke et al., 2014) are ideally suited to 
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examining whether subclass I lantibiotic production differs between the gut microbiota of 
athletes and non-athletes using the developed profile HMM, and investigating potential 
relationships between subclass I lantibiotic production, diet, host physiology, and microbiota 
composition and function. 
 
Methods 
 
Study population 
 
Elite professional male athletes (the Irish national rugby team; n=40) and healthy 
controls (n=46) matched for age and gender were enrolled in 2011 (Barton et al., 2017, Clarke 
et al., 2014). Due to the range of physiques within a rugby team (player position dictates need 
for a variety of physical constitutions, i.e., forward players tend to have larger BMI values than 
backs, often in the overweight/ obese range) the recruited control cohort included two groups 
of low (BMI ≤25.2) and high (BMI ≥26.5) BMI, respectively. Approval for this study was 
granted by the Cork Clinical Research Ethics Committee. 
Acquisition of clinical, exercise and dietary data 
 
Self-reported dietary intake information was accommodated by a research nutritionist 
within the parameters of a food frequency questionnaire in conjunction with a photographic 
food atlas as per the initial investigation (Clarke et al., 2014). Fasting blood samples were 
collected and analysed at the Mercy University Hospital clinical laboratories, Cork. 
Commercial multispot microplates (Meso Scale Diagnostics) were used to measure cytokines. 
Preparation of metagenomic libraries 
 
Upon initial collection, stool and urine samples were stored on ice prior to DNA 
extraction and purification from the fresh stool using the QIAmp DNA Stool Mini Kit (cat. no. 
51504 Qiagen, Crawley, West Sussex, UK), after which samples were stored securely at -80°C. 
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DNA extraction was carried out in accordance with the manufacturer’s protocol with the 
addition of a zirconia bead (11079101z-BSP, 11079110z-BSP, 11079125z-BSP Stratech 
Scientific) cell disruption bead-beating step (30s X 3).  
Metagenomic library preparation was performed with the Illumina Nextera XT DNA 
Library Preparation Kit (cat# FC-131-1096, Illumina Inc., USA) in accordance with the 
manufacturer’s protocol (15031942, Illumina). Normalisation of samples to the recommended 
0.2 ng/μL per individual library was carried out with the ThermoFisher Qubit 2.0 Flurometric 
Quantitation system (Q32854, ThermoFisher). Tagmentation and amplification carried out 
with G-STORM GS1 thermal cycler system. Following the combined enzymatic fragmentation 
and adapter sequence tagging—tagmentation—and the subsequent amplification of the 
tagmented DNA, libraries were purified with the AMPure magnetic bead system at a ratio of 
1:1.8 (DNA:AMPure) (9A63880, Beckman Coulter). Subsequently, libraries were assessed for 
appropriate fragment size (~500bp) on the Agilent 2100 Bioanalyzer system. With the libraries 
passing quality and fragment length requirements, the library preparation was continued on 
through library normalization, which was met with an additional assessment of suitable molar 
concentrations (~2 nM) with the KAPA Library Quantification Kit (KK4824, Kapabiosystems) 
run on a Roche LightCycler 480 (Roche Applied Science). Samples were combined into 8 final 
pools prior to being shipped on dry ice for sequencing. 
 
Statistical and bioinformatics analysis 
 
Delivered raw FASTQ sequence ﬁles (EMBL Nucleotide Sequence Database (ENA) 
(http://www.ebi.ac.uk/ena/data/), accession number PRJEB15388) were quality checked as 
follows: contaminating sequences of human origin were ﬁrst removed through the NCBI Best 
Match Tagger (BMTagger). Poor-quality and duplicate read removal, as well as trimming was 
implemented using a combination of SAM (sequence alignment map) and Picard tools. 
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Processing of raw sequence data produced a total of 2,803,449,392 ﬁltered reads with a mean 
read count of 32,598,248.74 (±10,639,447 SD) per each of the 86 samples. These reﬁned reads 
were then subjected to functional proﬁling by the Human Microbiome Project Uniﬁed 
Metabolic Analysis Network (HUMAnN2 V.0.5.0) pipeline. The functional proﬁling 
performed by HUMAnN2 composed tabulated ﬁles of microbial metabolic pathway abundance 
and coverage derived from the Metacyc database, and gene family abundance (reported in reads 
per kilobase (RPK) to normalize for gene length) derived from the ChocoPhlan and UniRef50 
databases. Metagenome assembly was performed by the Iterative de Bruijn Graph de novo 
assembler IDBA. 
The HMMER3 tool hmmsearch was used, with default parameters, to search the profile 
HMM created in chapter 3 of this thesis against the 81 assembled metagenomes. An identified 
sequence was deemed to be valid if its associated E-value was less than, or equal to, 1×10−5. 
All statistical analyses were performed in R (v. 3.2.3). Correlations were performed using the 
‘psych’ package (v. 1.7.21.3). Spearman correlations were calculated and adjusted by FDR. 
Diversity measures and non-metric multidimensional scaling (NMDS) were calculated using 
the ‘vegan’ package (v. 2.3-1) and illustrated with ggplot2. NMDS was performed by the 
‘metaMDS’ function in 2 dimensions using Wisconsin Double Standardised, square-root 
transformed, Bray-Curtis dissimilarities calculated by ‘vegdist’. Random Forests was used to 
predict LanB density based on diet and microbiota data using the default parameters of the 
‘randomForest’ package in R (v. 4.6-12) with “ntree” set to 2000. The Boruta package for R 
(v. 5.1) was used with default parameters to identify variables in these data with predictive 
power. 
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Results 
 
LanB density differs between athletes and high BMI controls 
 
LanB density was calculated as the number of significant (E < 1e-05) hits identified by 
the profile HMM divided by the size of the assembled metagenome. In theory, each sequenced 
region is present exactly once in these assembled metagenomes. As such, LanB density, as 
used here, represents the number of unique subclass I lantibiotic gene clusters per megabase. 
The number and density of LanB proteins identified in each metagenome are summarized in 
Table 1. 
No difference in LanB density was observed between athletes and non-athletes 
(Wilcoxon rank sum test, p = 0.09768), athletes and low BMI controls (Wilcoxon rank sum 
test, p = 0.56), or low BMI controls and high BMI controls (Wilcoxon rank sum test, p = 
0.07914). There was, however, a significantly higher LanB density in high BMI controls 
relative to athletes (Wilcox rank sum test, p = 0.03178). The distribution of LanB density is 
illustrated in Figure 1. 
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Sample Group LanB Number LanB Density (Hits/Mb) 
APC025-001 Athlete 0 0 
APC025-002 Athlete 1 0.033913378 
APC025-003 Athlete 1 0.007273414 
APC025-004 Athlete 0 0 
APC025-005 Athlete 2 0.019967118 
APC025-006 Athlete 1 0.011080495 
APC025-009 Athlete 1 0.005600408 
APC025-012 Athlete 4 0.032608909 
APC025-013 Athlete 2 0.013897774 
APC025-014 Athlete 2 0.016430241 
APC025-015 Athlete 0 0 
APC025-016 Athlete 0 0 
APC025-017 Athlete 0 0 
APC025-018 Athlete 4 0.019281996 
APC025-019 Athlete 2 0.01001908 
APC025-020 Athlete 2 0.0135753 
APC025-021 Athlete 2 0.009669501 
APC025-022 Athlete 0 0 
APC025-023 Athlete 1 0.007373666 
APC025-024 Athlete 0 0 
APC025-025 Athlete 4 0.026913032 
APC025-026 Athlete 0 0 
APC025-027 Athlete 0 0 
APC025-028 Athlete 0 0 
APC025-029 Athlete 1 0.009199093 
APC025-030 Athlete 1 0.006742014 
APC025-031 Athlete 0 0 
APC025-032 Athlete 0 0 
APC025-033 Athlete 2 0.015286124 
APC025-034 Athlete 4 0.033107776 
APC025-035 Athlete 1 0.007273414 
APC025-036 Athlete 0 0 
APC025-037 Athlete 0 0 
APC025-038 Athlete 2 0.019967118 
APC025-039 Athlete 1 0.011080495 
APC025-042 Athlete 0 0 
APC025-102 Low BMI Control 2 0.012051089 
APC025-104 Low BMI Control 1 0.006101681 
APC025-105 High BMI Control 8 0.049778401 
APC025-106 Low BMI Control 0 0 
APC025-107 Low BMI Control 1 0.009217572 
APC025-108 High BMI Control 1 0.013442144 
APC025-109 High BMI Control 4 0.022023952 
APC025-110 Low BMI Control 1 0.006145777 
APC025-111 Low BMI Control 2 0.00955504 
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APC025-112 High BMI Control 6 0.049471412 
APC025-113 Low BMI Control 2 0.011476498 
APC025-114 High BMI Control 3 0.014647225 
APC025-117 Low BMI Control 0 0 
APC025-118 Low BMI Control 1 0.010244197 
APC025-119 Low BMI Control 1 0.007594878 
APC025-120 High BMI Control 4 0.021555498 
APC025-121 Low BMI Control 3 0.018519849 
APC025-122 Low BMI Control 0 0 
APC025-123 Low BMI Control 0 0 
APC025-124 High BMI Control 0 0 
APC025-125 Low BMI Control 4 0.030515023 
APC025-127 High BMI Control 2 0.021437921 
APC025-128 Low BMI Control 0 0 
APC025-129 Low BMI Control 4 0.035066908 
APC025-130 Low BMI Control 1 0.007724202 
APC025-131 Low BMI Control 2 0.011663179 
APC025-132 Low BMI Control 1 0.007655815 
APC025-133 Low BMI Control 0 0 
APC025-134 Low BMI Control 2 0.018684523 
APC025-136 Low BMI Control 3 0.016121732 
APC025-137 High BMI Control 0 0 
APC025-138 High BMI Control 1 0.009080728 
APC025-139 High BMI Control 0 0 
APC025-140 High BMI Control 6 0.086164261 
APC025-142 High BMI Control 2 0.014719434 
APC025-143 High BMI Control 1 0.007886491 
APC025-144 High BMI Control 2 0.019296602 
APC025-146 High BMI Control 0 0 
APC025-147 High BMI Control 3 0.015211851 
APC025-148 High BMI Control 3 0.023917107 
APC025-149 High BMI Control 2 0.016430241 
APC025-150 High BMI Control 0 0 
APC025-151 High BMI Control 3 0.020230598 
APC025-152 High BMI Control 3 0.020230598 
APC025-154 High BMI Control 0 0 
 
Table 1. Number and density of LanB proteins identified in each metagenome. 
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Figure 1. Density plots illustrating the distribution of LanB density when separated into: A) 
athletes and non-athletes; and B) athletes, Low BMI Controls, and High BMI controls. 
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Taxonomic classification of LanB-encoding assemblies 
 
MetaPhlAn2 only accepts sequencing reads as input so taxonomy was assigned to the 
LanB-encoding scaffolds using Kaiju in MEM mode with default parameters. The phylum- and 
genus-level classifications are listed in Table 1 and illustrated in Figure 2. Interestingly, there 
was a considerably larger proportion of putative Bacteroidetes producers in athlete samples 
compared to non-athletes (36.6% vs 22.3%), even though the two groups had comparable 
Bacteroidetes levels (Wilcoxon rank sum test, p = 0.2475). At genus-level, athletes showed a 
much larger proportion of putative Chryseobacterium lantibiotic producers than non-athletes 
although this genus was not detected by MetaPhlAn2. Athletes also possessed a number of 
apparent lantibiotic-producing Robseburia species which were absent in non-athletes. This 
genus is known for butyrate-production in the gut microbiota, a function previously highlighted 
as increased in the microbiota and faecal metabolite profile of athletes (Barton et al., 2017). 
Finally, athletes also contained a higher proportion of putatively lantibiotic-producing Dorea, 
a genus previously negatively associated with markers for insulin resistance 
(10.1038/nutd.2015.9). The genus-level classification of putative LanB-encoding scaffolds are 
described in Table 2 and the relative proportions of the highlighted subclass I lantibiotic 
producers are illustrated in Figure 3. 
An inverse relationship with LanB density becomes apparent as lean mass increases 
 
Linear regression reported a negative relationship between lean mass and LanB 
density in athletes (p = 0.005647) that was not present in non-athletes (p = 0.8904). This was 
most likely due to athletes possessing a higher lean mass than non-athletes (Welch Two 
Sample T-test, p = 1.898e-14) as a local polynomial regression model (LOESS), illustrated in 
Figure 4, shows this negative relationship begins to appear as the lean mass of non-athletes 
increases. There was no observed relationship between LanB density and either BMI or 
waist-hip ratio. 
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Group Athlete Non-athlete Total 
 LanB hits assigned to taxon 
Phylum 
   
Actinobacteria 3 7 10 
Bacteroidetes 15 19 34 
Euryarchaeota 0 1 1 
Firmicutes 19 45 64 
Proteobacteria 2 2 4 
Unassigned 0 3 3 
Unassigned at Rank 2 8 10 
Genus 
   
Agrobacterium 1 0 1 
Alistipes 6 9 15 
Bacillus 1 2 3 
Bacteroides 2 3 5 
Blautia 3 7 10 
Chitinophaga 0 1 1 
Chryseobacterium 6 1 7 
Clostridioides 0 1 1 
Clostridium 1 2 3 
Desulfomicrobium 1 0 1 
Dorea 3 1 4 
Erysipelatoclostridium 0 1 1 
Eubacterium 0 2 2 
Faecalibacterium 0 2 2 
Flavonifractor 0 1 1 
Frankia 1 1 2 
Janibacter 1 1 2 
Methanosarcina 0 1 1 
Niabella 0 1 1 
Paenibacillus 0 2 2 
Prevotella 1 0 1 
Ralstonia 0 2 2 
Roseburia 2 0 2 
Ruminococcus 1 1 2 
Tyzzerella 2 5 7 
Unassigned 0 3 3 
Unassigned at Rank 5 32 37 
Unclassified Clostridiales 0 1 1 
Unclassified 
Lachnospiraceae 
4 2 6 
 
Table 2. Number of LanB producers classified by Kaiju at Phylum and Genus levels in athletes 
and non-athletes.
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Figure 2. Pie charts depicting taxonomy of LanB producers classified by Kaiju at Phylum (A) and Genus (B) levels in athletes and non-athletes. 
All sequences ‘unclassified at rank’ are removed. 
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 Figure 3. Proportion of LanB-producing scaffolds classified as selected taxa by Kaiju 
in athletes and non-athletes.
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Figure 4. Scatterplot of lean mass versus LanB density. Each point represents a sample and is coloured by group. Lines are local regression 
(LOESS) lines and are coloured by group. The main plots shows the data when divided into athletes and non-athletes. The insert shows the data 
when separated into athletes, low BMI controls and high BMI controls. 
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LanB density is associated with the functional capacity of the gut microbiota in 
athletes 
A negative relationship was observed between LanB density and microbial 
gene family alpha diversity in athletes (p = 0.03737) but not in non-athletes (p = 
0.8943). Interestingly, this was the sole aspect of the overall function and composition 
of the microbiota, as established by HUMAnN2, where athletes could be separated 
from non-athletes by alpha diversity (Simpson index increased in non-athletes, 
Wilcoxon rank sum test, p = 0.0176), beta diversity (PERMANOVA, R2 = 0.12603, p 
= 0.001), and within-group variance of beta diversity (increased in athletes, ANOVA, 
p = 0.0004132). These diversity measures are illustrated in Figure 5. Neither 
microbiota composition nor microbiota-encoded pathways data significantly separated 
the groups by the above diversity measures. 
Similarly, microbial gene family data possessed the only discriminatory power 
when the samples were divided into three groups. The negative relationship between 
LanB density and microbial gene family alpha diversity observed in athletes was not 
present in either high or low BMI control groups, while low BMI controls had a higher 
microbial gene family alpha diversity compared to athletes (Simpson index, Wilcoxon 
rank sum test, p = 0.036). Again, within-group variance of beta diversity was higher 
in athletes compared to both low BMI and high BMI control groups (Tukey multiple 
comparisons of means, adjusted p = 0.0038949 and 0.0155110, respectively). These 
diversity measures are illustrated in Figure 6.  
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Figure 5. Illustration of diversity measures used to compare athletes to non-athletes based on gene families data. A) NMDS plot with 95% 
confidence ellipses. B) Within-group variance of beta diversity calculated by distance of each point to the centroid of the group. C) Alpha diversity 
measured by Simpson’s index. 
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Figure 6. Illustration of diversity measures used to compare athletes, low BMI controls, and high BMI controls based on gene families data. A) 
NMDS plot with 95% confidence ellipses. B) Within-group variance of beta diversity calculated by distance of each point to the centroid of the 
group. C) Alpha diversity measured by Simpson’s index. 
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LanB density was observed to have a relationship with the overall function of the gut 
microbiota in athletes (ANOVA, p = 0.03896) but not in non-athletes (ANOVA, p = 
0.9468). This relationship was identified using the first principal component generated 
from Bray-Curtis dissimilarities of microbial gene families (Figure 5A). 
LanB density shows distinct relationships with host diet and gut microbiota 
function in athletes and non-athletes 
 
Correlating 2367 variables describing host physiology, diet, microbiota 
composition and microbiota function with LanB density identified four significant 
(FDR < 0.1) correlations in athletes and one in non-athletes. Across all samples, ten 
variables were significantly correlated with LanB density, the subject’s height, daily 
intake of cholesterol, fibre, energy, starch, fat, carbohydrate, protein and sugar, and a 
microbial pathway involved in cell wall biosynthesis (MetaCyc pathway 6386). All of 
these correlations are negative with the exception of pathway 6386 and are listed in 
Table 3 and illustrated in Figure 7. 
Cholesterol intake data was not available for non-athletes so it cannot be said for 
certain that is has no relationship with LanB density in that cohort. 
A machine learning-based approach identified variables with the ability to 
predict LanB density 
 
Random Forests classification and the feature selection algorithm Boruta 
identified two microbiota-encoded functions and two dietary variables as possessing 
significant power to predict LanB density across all samples - MetaCyc pathway 6386, 
involved in cell wall biosynthesis and shown above to be correlated with LanB density 
in athletes, gene family GO:0000776, responsible for kinetochore structure, daily 
carbohydrate intake, and daily fibre intake. Multiple linear regression using these four 
variables to predict LanB density identified a significant relationship (R2 = 0.1939, p  
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Variable correlated with LanB Density (Hit/Mb) 
Correlation 
Coefficient 
FDR-
adjusted p 
All Samples 
Cholesterol (g/day) -0.418670754 0.020509335 
PWY 6386 - UDP N-acetylmuramoyl pentapeptide biosynthesis II (lysine containing) 0.411994762 0.093108528 
Height -0.382731731 0.016012188 
Fibre (g/day) -0.373864145 0.010531227 
Energy (KJ/day) -0.338875963 0.0129467 
Starch (g/day) -0.334036601 0.0129467 
Fat (g/day) -0.315403048 0.016915465 
Carbohydrate (g/day) -0.304987026 0.017568527 
Protein (g/day) -0.29964693 0.017568527 
Sugars (g/day) -0.228857567 0.073583226 
Athlete Only 
PWY 6386 - UDP N-acetylmuramoyl pentapeptide biosynthesis II (lysine containing) 0.623529441 0.03349097 
Height -0.496343064 0.078961767 
Starch (g/day) -0.430163152 0.071782674 
Cholesterol (g/day) -0.418670754 0.071782674 
Non-athlete Only 
Fibre (g/day) -0.407337063 0.057472077 
 
Table 3. Variables that significantly correlated with LanB density across all samples, athlete samples only, and non-athlete samples only.
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Figure 7. Dotplot of variables that significantly correlated with LanB density across all samples, athlete samples only, and non-athlete samples 
only. Each dot is position according to the absolute value of the correction coefficient and coloured by direction of the correlation. 
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= 0.0005796). The individual relationships between these variables and LanB density 
are illustrated in Figure 8. 
GO:0000776 was increased in non-athletes compared to athletes (Wilcoxon 
rank sum test, p = 0.005326) and the non-athlete group appeared to be responsible for 
driving the association as the relationship found in that group (p = 0.006237) was 
absent in athletes (p = 0.6092). Carbohydrate intake and Fibre intake were both 
increased in athletes compared to non-athletes (Wilcoxon rank sum test, p = 6.026e-
05 and 0.006865, respectively). There was no observable difference in MetaCyc 
pathway 6386 abundance between the two groups. 
 
Discussion 
 
 
The previously developed profile HMM was employed in this study to assess 
the distribution of lanB-containing gene clusters across individuals known to differ 
with respect to gut microbiota composition and function. 
The main driving force behind this study was to investigate if the extreme diet 
and exercise regimen of these elite-athletes, two factors known to have a significant 
impact on the function and composition of the gut microbiota, was reflected in altered 
subclass I lantibiotic production within this intestinal community. One strategy often 
employed in identifying potential probiotics is associating the presence or absence of 
a particular taxa with a desirable phenotype, so any bacteriocin-producers unique to 
the athlete group could be theorised as playing a role in maintaining this microbiota 
profile and be highlighted for further investigation. The profile HMM developed 
previously in this thesis was employed to identify putative subclass I lantibiotic 
biosynthetic clusters. The profile HMM was used to screen assembled metagenomes 
as the lanthionine dehydratase protein is 993 amino acids in length (Uniprot ID  
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Figure 8. Scatterplot of the four variables identified by Boruta as possessing power to predict LanB density across all samples. Each point 
represents a sample and is coloured by group. Lines are linear regression lines to show direction of the relationship, and the R-squared value 
denotes the proportion of variation explained by the linear model, both are coloured by group. 
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P20103), meaning that only the unique number of LanB proteins in each sample are 
reported as metagenome assembly results in the loss of quantitative information. In 
theory, lantibiotic-producers in less diverse samples may be present at a higher 
relative abundance than would be reported, even after normalization for metagenome 
size, than producers in more diverse samples. However, as there was no measurable 
difference in compositional alpha diversity between any of the groups, this was 
deemed to be of no concern. 
While there was no overall difference in LanB density between athletes and 
non-athletes, it was interesting to note the relationship between subclass I lantibiotic 
production and lean mass, particularly as this relationship was not present with BMI 
and waist-hip ratio, two of the most widely used indicators of health. BMI was 
expected to be of limited use in athletes as it often overestimates body fat in heavily 
muscled individuals 
(https://www.cdc.gov/obesity/downloads/bmiforpactitioners.pdf). However, 
investigation of BMI in non-athletes, and waist-hip ratio in both groups, suggests that 
there is indeed no relationship between subclass I lantibiotic production and body fat. 
The plotting of a local regression model (Figure 4) suggests that there is a minimum 
lean mass below which there is no relationship with LanB density. 
The previously published article examining this dataset reported that athletes 
had the highest mean abundance across 29 of 34 differentially expressed metabolic 
categories described by MetaCyc pathways (Barton et al., 2017). These pathways (e.g. 
amino acid and antibiotic biosynthesis, and carbohydrate metabolism), in combination 
with faecal metabolite data, pointed towards enrichment of microbiota-encoded 
functions resulting in enhanced muscle turnover and overall health (Barton et al., 
2017). A potential explanation for reduced alpha diversity of athletes compared to 
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non-athletes in microbial gene families data could be specialisation of the microbiota 
to manage such extreme levels of physical activity. 
Correlations showed that diet and microbiota function have the greatest 
relationship with subclass I lantibiotic production in the human gastrointestinal tract. 
As mentioned in chapter 1 of this thesis, diet has a substantial impact on the gut 
microbiota and this is most likely the driving factor behind the observed relationship. 
In addition, these results mirror repeated observations that the functionality of the 
microbiota is more important than its composition.  An interesting observation taken 
from these correlations is that there is no overlap in the reported relationships between 
the two groups, suggesting that athletes possess a different relationship with subclass 
I lantibiotic production than the rest of the population. There was also some evidence 
of different taxa of bacteriocin-producers between the two groups. The microbiota of 
athletes appeared to contain some taxa which have previously been associated with 
functions beneficial to human health such as short-chain fatty acid biosynthesis and 
reduced insulin resistance, a feature which may give them a competitive advantage in 
this population, allowing them to survive and confer these benefits to the host. 
It is also interesting to note such a small proportion of the 2367 tested variables 
were significantly correlated with LanB frequency, a trend also identified by the 
machine-learning-based approach which identified just four variables with predictive 
power, implying that the association between subclass I lantibiotic production and the 
microbiota is relatively subtle but that host diet has the strongest influence on this 
relationship. 
The positive relationship between LanB density and MetaCyc pathway 6386, 
identified by both correlation and machine learning approaches, is particularly 
intriguing. This pathway is involved in biosynthesis of cell wall peptidoglycan, 
218 
 
specifically the conversion of UDP-N-acetyl-glucosamine to UDP-MurNAc-
pentapeptide (UDPMurNAc) (Munch and Sahl, 2015). UDPMurNAc is a precursor to 
Lipid II, the target of many antimicrobial peptides, including the subclass I lantibiotics 
under investigation here. One would expect that increased subclass I lantibiotic density 
would accompany lower lipid II biosynthesis; however the opposite is evident here. 
Microbiotas with higher LanB density also tended to contain increased levels of this 
pathway. A possible explanation could be increased peptidoglycan biosynthesis in the 
microbiota as a defensive or compensatory response to subclass I lantibiotic 
production, although metatranscriptomics would be needed to investigate this further. 
Another possible explanation is that, as this pathway is associated with Gram-positive 
bacteria (Firmicutes and Actinobacteria) and the largest proportion of identified 
bacteriocin producers belonged to the Firmicutes phylum, subclass I lantibiotic 
production may be conferring a competitive advantage to these producers who are 
intrinsically resistant to their own bacteriocin. Although a definitive mechanism 
cannot be confirmed, this is an intriguing observation that warrants further 
investigation to better understand the bacteriocin-production dynamic in the intestinal 
microbiota. 
The work here highlights a potential relationship between subclass I lantibiotic 
production within the gut microbiota and the host. It also suggests that production of 
these antimicrobial compounds may affect overall microbiota function as well as 
individual functions. It is most likely, however, that these observations are a result of 
specialisation of the gut microbiota by the extreme diet and exercise regime of elite-
athletes. 
  
219 
 
References 
 
 
 
 
 
ARNISON, P. G., BIBB, M. J., BIERBAUM, G., BOWERS, A. A., BUGNI, T. S., 
BULAJ, G., CAMARERO, J. A., CAMPOPIANO, D. J., CHALLIS, G. L., 
CLARDY, J., COTTER, P. D., CRAIK, D. J., DAWSON, M., DITTMANN, 
E., DONADIO, S., DORRESTEIN, P. C., ENTIAN, K.-D., FISCHBACH, M. 
A., GARAVELLI, J. S., GORANSSON, U., GRUBER, C. W., HAFT, D. H., 
HEMSCHEIDT, T. K., HERTWECK, C., HILL, C., HORSWILL, A. R., 
JASPARS, M., KELLY, W. L., KLINMAN, J. P., KUIPERS, O. P., LINK, A. 
J., LIU, W., MARAHIEL, M. A., MITCHELL, D. A., MOLL, G. N., MOORE, 
B. S., MULLER, R., NAIR, S. K., NES, I. F., NORRIS, G. E., OLIVERA, B. 
M., ONAKA, H., PATCHETT, M. L., PIEL, J., REANEY, M. J. T., 
REBUFFAT, S., ROSS, R. P., SAHL, H.-G., SCHMIDT, E. W., SELSTED, 
M. E., SEVERINOV, K., SHEN, B., SIVONEN, K., SMITH, L., STEIN, T., 
SUSSMUTH, R. D., TAGG, J. R., TANG, G.-L., TRUMAN, A. W., 
VEDERAS, J. C., WALSH, C. T., WALTON, J. D., WENZEL, S. C., 
WILLEY, J. M. & VAN DER DONK, W. A. 2013. Ribosomally synthesized 
and post-translationally modified peptide natural products: overview and 
recommendations for a universal nomenclature. Natural Product Reports, 30, 
108-160. 
BARTON, W., PENNEY, N. C., CRONIN, O., GARCIA-PEREZ, I., MOLLOY, M. 
G., HOLMES, E., SHANAHAN, F., COTTER, P. D. & O'SULLIVAN, O. 
2017. The microbiome of professional athletes differs from that of more 
sedentary subjects in composition and particularly at the functional metabolic 
level. Gut. 
220 
 
BRESSA, C., BAILÉN-ANDRINO, M., PÉREZ-SANTIAGO, J., GONZÁLEZ-
SOLTERO, R., PÉREZ, M., MONTALVO-LOMINCHAR, M. G., MATÉ-
MUÑOZ, J. L., DOMÍNGUEZ, R., MORENO, D. & LARROSA, M. 2017. 
Differences in gut microbiota profile between women with active lifestyle and 
sedentary women. PLOS ONE, 12, e0171352. 
CLARKE, S. F., MURPHY, E. F., O'SULLIVAN, O., LUCEY, A. J., HUMPHREYS, 
M., HOGAN, A., HAYES, P., O'REILLY, M., JEFFERY, I. B., WOOD-
MARTIN, R., KERINS, D. M., QUIGLEY, E., ROSS, R. P., O'TOOLE, P. 
W., MOLLOY, M. G., FALVEY, E., SHANAHAN, F. & COTTER, P. D. 
2014. Exercise and associated dietary extremes impact on gut microbial 
diversity. Gut. 
ESTAKI, M., PITHER, J., BAUMEISTER, P., LITTLE, J. P., GILL, S. K., GHOSH, 
S., AHMADI-VAND, Z., MARSDEN, K. R. & GIBSON, D. L. 2016. 
Cardiorespiratory fitness as a predictor of intestinal microbial diversity and 
distinct metagenomic functions. Microbiome, 4, 42. 
KNOLL, R. L., FORSLUND, K., KULTIMA, J. R., MEYER, C. U., KULLMER, U., 
SUNAGAWA, S., BORK, P. & GEHRING, S. 2016. Gut microbiota differs 
between children with Inflammatory Bowel Disease and healthy siblings in 
taxonomic and functional composition - a metagenomic analysis. American 
Journal of Physiology - Gastrointestinal and Liver Physiology. 
MARCHESI, J. R., ADAMS, D. H., FAVA, F., HERMES, G. D. A., HIRSCHFIELD, 
G. M., HOLD, G., QURAISHI, M. N., KINROSS, J., SMIDT, H., TUOHY, 
K. M., THOMAS, L. V., ZOETENDAL, E. G. & HART, A. 2015. The gut 
microbiota and host health: a new clinical frontier. Gut. 
221 
 
MUNCH, D. & SAHL, H. G. 2015. Structural variations of the cell wall precursor 
lipid II in Gram-positive bacteria - Impact on binding and efficacy of 
antimicrobial peptides. Biochim Biophys Acta, 1848, 3062-71. 
QIN, J., LI, R., RAES, J., ARUMUGAM, M., BURGDORF, K. S., MANICHANH, 
C., NIELSEN, T., PONS, N., LEVENEZ, F., YAMADA, T., MENDE, D. R., 
LI, J., XU, J., LI, S., LI, D., CAO, J., WANG, B., LIANG, H., ZHENG, H., 
XIE, Y., TAP, J., LEPAGE, P., BERTALAN, M., BATTO, J.-M., HANSEN, 
T., LE PASLIER, D., LINNEBERG, A., NIELSEN, H. B., PELLETIER, E., 
RENAULT, P., SICHERITZ-PONTEN, T., TURNER, K., ZHU, H., YU, C., 
LI, S., JIAN, M., ZHOU, Y., LI, Y., ZHANG, X., LI, S., QIN, N., YANG, H., 
WANG, J., BRUNAK, S., DORE, J., GUARNER, F., KRISTIANSEN, K., 
PEDERSEN, O., PARKHILL, J., WEISSENBACH, J., BORK, P., EHRLICH, 
S. D. & WANG, J. 2010. A human gut microbial gene catalogue established 
by metagenomic sequencing. Nature, 464, 59-65. 
REA, M. C., DOBSON, A., O'SULLIVAN, O., CRISPIE, F., FOUHY, F., COTTER, 
P. D., SHANAHAN, F., KIELY, B., HILL, C. & ROSS, R. P. 2011. Effect of 
broad- and narrow-spectrum antimicrobials on Clostridium difficile and 
microbial diversity in a model of the distal colon. Proceedings of the National 
Academy of Sciences, 108, 4639-4644. 
RICHARDS, J. L., YAP, Y. A., MCLEOD, K. H., MACKAY, C. R. & MARINO, E. 
2016. Dietary metabolites and the gut microbiota: an alternative approach to 
control inflammatory and autoimmune diseases. Clin Trans Immunol, 5, e82. 
SUBIRATS BAYEGO, E., SUBIRATS VILA, G. & SOTERAS MARTINEZ, I. 2012. 
[Exercise prescription: indications, dosage and side effects]. Med Clin (Barc), 
138, 18-24. 
 
  
 
 
Walsh, C. 2017. An in silico analysis of bacteriocin production in the human 
microbiota and its relationship with health. PhD Thesis, University College 
Cork. 
 
Please note that Chapter 5 (pp.222-269) is unavailable due to a restriction 
requested by the author.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CORA Cork Open Research Archive http://cora.ucc.ie  
 
270 
 
General Discussion 
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As discussed in Chapter 1 of this thesis, many human diseases can be traced to the 
disrupted function of the gut microbiota, thereby making targeted manipulation of this 
community, through diet, probiotics, or antimicrobials, a logical intervention for treatment of 
these conditions. The initial challenge relates to identifying the particular dietary 
interventions, probiotic species, or antimicrobial compounds that can bring about the desired 
alterations. With this in mind, chapters 2 and 3 of this thesis focus on the in silico analysis of 
the gut microbiota with a view to identifying bacteriocins, or bacteriocin-producers, within 
the intestinal community that may have this potential. Regardless of whether the microbiota 
is regarded as a ‘hidden organ’ or a co-evolving symbiont, it is in its interest to protect the 
host, and itself, from individual pathogenic organisms and detrimental shifts in microbiota 
profile. Therefore, the bacteriocin-producing component of this community is the logical 
place to search for biotherapeutics to ensure gut health. 
The initial, genomics-focused, approach in Chapter 2 employed the widely-used 
BAGEL3 software to search genomic data, representative of the human gastrointestinal 
microbiota, which was collected by the Human Microbiome Project. This screen identified 74 
putative bacteriocin-encoding gene clusters (PBGCs) from 382 sequenced genomes following 
manual examination. The study identified potential next-generation probiotics by detecting 
PBGCs in taxa not classically associated with bacteriocin production such as Bacteroides 
spp. and Roseburia spp. Of particular note were putative sactibiotic gene clusters identified in 
three Bacteroides species with members currently under early stages of therapeutic 
investigation. Preclinical in vitro work has suggested that strains of B. dorei and B. fragilis 
isolated from the human microbiota have potential applications in cholesterol reduction 
(Gerard et al. 2007) and regulation of the immune system (Deng et al. 2016), respectively. A 
sactibiotic gene cluster was also identified in a B. uniformis strain, a species which has 
recently showed promise in treatment of metabolic and immunological dysfunction in mice 
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with high-fat-diet inducted obesity (Cano et al., 2012). There have been no reports of 
bacteriocin production by any of these three strains. 
Chapter 3 focused on another in silico approach centred on designing, validating and 
implementing a profile HMM to investigate a specific category of bacteriocins, subclass I 
lantibiotics, in metagenomic data, again using data collected by the Human Microbiome 
Project. The profile HMM was sensitive enough to identify all positive controls during the 
validation step while also being specific enough to not return any false positives from similar 
proteins involved in modification of other lantibiotic subclasses. The model showed that 
subclass I lantibiotic production is not equal across body sites, implying that bacteriocin 
production may confer a greater competitive advantage in some microbial niches compared to 
others. Once taxonomy was assigned to those LanB-encoding scaffolds, it was apparent that 
the reference genome database searched previously was not fully representative of the human 
gut microbiota. Just 40% of the putative bacteriocin-producers found through the HMM 
analysis were present in the genomic database, suggesting that rarer members of the 
microbiota, or those not previously perceived as important, may be influencing it’s 
functionality, thus highlighting more novel candidates for further therapeutic assessment.  
The main motivation for designing a custom profile HMM was that this approach is 
ideally suited to searching metagenomic data, thereby facilitating a wider search for novel 
bacteriocin clusters. The increased sensitivity of profile HMMs over sequence-homology 
approaches, such as a BLAST-based approach, allowed detection of more distantly related 
proteins in relatively under-characterised members of the gut microbiota, while also 
overcoming the limitation of tools tailored to genomic data, such as BAGEL3, which struggle 
with the fragmented nature of metagenomic assemblies as they rely on identifying multiple 
proteins related to biosynthesis within a set genomic region. These advantages meant that the 
model was suited to comparing the density and distribution of putative bacteriocin gene 
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clusters in elite athletes, investigated in chapter 4 of this thesis, with that of a sedentary 
population, and investigating the factors influencing bacteriocin production in both cohorts. 
Perhaps unsurprisingly, diet showed the strongest relationship with putative subclass I 
lantibiotic production within in the gut microbiota. More interesting, however, was the 
relationship between bacteriocin gene density and the lean mass of the host. Across all 
subjects, individuals with a higher lean mass tended to have a lower density of unique 
bacteriocin producers than their lighter counterparts. This was particularly evident in the 
athletes whose extreme diet and exercise regimens appeared to have focussed their 
microbiota to support muscle turnover and overall fitness. 
The final chapter of this thesis investigated how metabolic health could be altered in a 
diet-induced obesity mouse model by probiotic feeding, with a particular focus on the gut 
microbiota through extensive bioinformatics approaches. The outcomes of feeding the two 
strains under investigation, both members of the Lactobacillus genera, were startlingly 
different. L. plantarum AH0315 had a profound impact on the overall composition and 
function of the gut microbiota without any accompanying change in host metabolic 
phenotype, while L. casei AH0077 significantly improved several metabolic markers without 
an overall impact on the gut microbiota’s overall composition and function. In addition to 
these observations made from the overall profile of the gut microbiota, there were some 
alterations by both probiotics of specific taxa and microbial-encoded pathways. The current 
hypothesised mechanism by which AH0077 brings about these changes is thought to involve 
EPS-production and lipid-binding but further work is needed to confirm this. Correlation 
analysis between individual features (both compositional and functional) of the population 
and metabolic measurements taken from the host supported the current thinking that the 
function of the gut microbiota is of greater importance to health and disease than its 
composition. Biomarker discovery using the LEFSe algorithm on the lean control group also 
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provided further evidence to some taxa gaining attention as next-generation probiotics for the 
treatment of obesity such as Akkermansia and members of the Christensenellaceae (Derrien 
et al., 2016, Goodrich et al., 2014). 
Taken together, this thesis identifies many potential bacteriocin producers from the 
human microbiota with the potential to influence the structure of this population in the 
treatment of disease and improvement of overall gastrointestinal and indeed possibly 
metabolic health. Further work will be needed to confirm functionality and characterise these 
putative bacteriocin-producers and select those with the desired target spectrum. This work 
also shows how probiotic feeding can influence the metabolic health of an obese host in a 
strain-specific manner either independent of the gut microbiota or in a targeted manner – 
altering specific functions without influencing its overall composition and function. 
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